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COPD (Chronic Obstructive Pulmonary Disease) and lung cancer are related 
conditions associated with inflammation. Relatively little focus has been given to the 
endothelium, through which inflammatory cells transmigrate to reach the lung. We 
sought to determine if coding and non-coding alterations in pulmonary endothelium 
exist in COPD and lung cancer. 
Methods 
Patients with and without COPD undergoing thoracic surgery were recruited. 
Pulmonary Endothelial Cells were isolated from lung and tumour and extracted RNA 
(ribonucleic acid) used for miRNA (micro-RNA) and mRNA (messenger RNA) 
microarrays. Ingenuity pathway analysis (IPA) was also carried out. 
Results 
2071 genes and 43 miRNAs were significantly upregulated in COPD. 4 targets were 
validated by quantitative polymerase chain reaction, of which miR-181b-3p was 
chosen for functional validation. Another target, miR-429, was also increased in lung 
tumour. Several cancer-related pathways such as transforming growth factor- β were 
altered in the IPA. There was significantly reduced tube formation and endothelial 
sprouting in Human umbilical vein endothelial cells transfected with miR-181b-3p, 





Upregulation of miR-181b-3p reduces tube formation and sprouting by endothelial 
cells. This might be significant in the development of emphysema as lung vasculature 
is important in the structural maintenance of alveoli.  
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Chronic obstructive pulmonary disease (COPD) and lung cancer are two important 
smoking related conditions. COPD has 10.1% prevalence (with Forced expiratory 
volume in one second (FEV1) < 80%) in adults over 40 years worldwide (3) and is 
also an important cause of morbidity and mortality, resulting in over 29 000 deaths in 
the UK in 2012.(4) Lung cancer is the leading cause of cancer morbidity in North 
America, and is amongst the top 5 cancers ranked by disability adjusted life years 
lost (DALYs) in all regions of the world, except Sub-Saharan Africa.(5) It is the most 
common cause of cancer death accounting for 35 895 deaths in the UK in 2014.(6) 
Survival rates have changed little despite improvements in screening (7), surgery (8) 
and chemotherapy(9, 10). Focussing screening to high-risk groups could identify 
patients early, and thus raise cure rates. Patients with COPD are one such group; 
lung cancer incidence in COPD patients is high, even after adjustment for smoke 
exposure (11) suggesting possible shared pathogenesis. By understanding the 
pathogenesis of COPD and lung cancer in detail it is possible that new treatments 
may be developed and the risk of lung cancer in COPD may be reduced. 
1.1 Chronic Obstructive Pulmonary Disease (COPD) 
 
COPD is a condition characterized by airflow obstruction which is not normally fully 
reversible with the use of bronchodilators, and is generally thought to be progressive 
over time.(12) Damage in both the airways and lung parenchyma contribute to the 
airway obstruction.(12, 13) An abnormal chronic inflammatory response to noxious 
particles or gases also occurs.(12) Spirometry is used to diagnose airway obstruction 
which is defined as a ratio of Forced Expiratory Volume in one second (FEV1) to 
Forced Vital Capacity (FVC; the total volume expired) of less than 0.7.(14) The 
 3 
airflow obstruction usually occurs as a result of smoking but genetic factors (e.g., 
alpha 1 antitrypsin deficiency), the burning of biomass fuels in developing countries 
and occupational factors also play a role.(12, 15) In fact only 20%-30% of smokers 
develop COPD suggesting an important role for other factors in the development of 
the disease.(16) 
1.1.1 Clinical Features 
 
COPD patients are typically aged over 35 at presentation with a history of a known 
risk factor (usually smoking). (17) Common presenting symptoms include exertional 
breathlessness, chronic cough, sputum production and wheeze.(17) Occasionally 
systemic symptoms such as weight loss may also feature.(17) British and 
American/European guidelines classify COPD by means of severity ranging from mild 
(FEV1 > 80% predicted) to very severe (FEV1 < 30% predicted) (see Table 1.1).(17, 
18) However, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
have suggested that a patient’s symptoms and exacerbation history should also be 
taken into consideration in determining severity.(12) GOLD classifies patients into 4 
classes using airway obstruction, exacerbation history and results from symptom 
scoring systems for breathlessness (Modified British Medical Research Council 
Questionnaire; mMRC) and health status impairment (COPD Assessment Test; CAT) 
(see Figure 1.1).(12) In theory by using patient symptoms and history as part of the 
severity assessment one should be able to identify patients at higher risk of disease 
progression who may not initially look high risk based on FEV1 alone. This should 
allow the assessing clinician to start relevant treatment to reduce risk earlier. 
However, the GOLD classification does have its limitations. For example, the cut-offs 
chosen for mMRC and CAT scoring were not evidence based and the presumed 
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equivalence of a CAT score of 10 and mMRC of 1 is not always correct.(19) For 
example, one study found that a CAT score of 13 was more comparable to a mMRC 
of 1 in their patient group.(19) Other groups have also shown that the GOLD 
classification substantially varies depending on which health assessment is used.(20) 
Increasing treatment based on GOLD severity has not been shown to improve health 
outcomes and a large cohort (N=15 632) from seven countries found FEV1 
thresholds were more effective at staging COPD severity for mortality compared to 
the GOLD criteria.(21) Severity assessment based on FEV1 has also been more 
successful at identifying patients with a worse health status in comparison to GOLD 
staging.(22) Therefore, for these reasons in addition to the fact this was a UK-based 
study the GOLD criteria were not used in this thesis. 
The cause of airway obstruction seen in COPD varies between patients, but is 
primarily the result of a mixture of airways disease (chronic bronchiolitis) and 
destruction of the parenchyma (emphysema). (12) The contribution of airways and 
parenchymal disease varies between COPD patients and this is reflected in a range 
of clinical presentations including chronic bronchitis, emphysema and bronchiectasis. 
(12, 18) A combination of these conditions may be present in a single patient. (18) 
Chronic bronchitis is defined as a productive cough occurring on most days for a 
period of at least three months in two consecutive years.(23) Emphysema is a 
pathological diagnosis of permanent enlargement of the airspaces distal to the 
terminal bronchioles resulting from destruction of the lung parenchyma. (24) 
Bronchiectasis is also defined pathologically as the persistent and progressive 
development of dilated and thick-walled bronchi.(25) 
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Spirometry (including reversibility testing using bronchodilators) should be performed 
in all patients to confirm the diagnosis of COPD.(17, 18) Although most patients will 
demonstrate fixed airway obstruction a degree of reversibility may be seen. (18) 
However, a large increase in FEV1 in response to bronchodilation should prompt 
consideration of a diagnosis of asthma.(18) Lung function tests may also 
demonstrate reduced maximal expiratory flows in the mid-volume range suggesting 
small airway obstruction. (26) These changes can sometimes be seen in early COPD 
before a change in FEV1/FVC.(26) However, these values vary highly between 
individuals and consequently are not used routinely in the diagnosis of COPD. (26, 
27) Patients with advanced COPD may also show an increase in static lung volumes 
(Total Lung Capacity, TLC and Residual Volume, RV).(18) Increased static lung 
volumes in combination with a reduced transfer factor (relative to lung volume, KCO) 
is suggestive of emphysema in these patients. (28) However, emphysema is more 
accurately diagnosed using computed tomography (CT).(29) In classical COPD 
emphysema commonly has a centrilobular appearance and is primarily distributed in 
the upper zones. (30) It is characterized by enlargement of the centrilobular airspace 
and primarily effects the proximal respiratory bronchioles.(31) Another distribution of 
emphysema, panlobular emphysema, consists of a uniformly dilated airspace from 
the respiratory bronchioles to the alveoli and is typical of emphysema occurring in 
alpha-1-antitrypsin deficiency (A1ATD; section 1.1.3).(31) Emphysema in this group 
of patients is also typically in the lower zones in contrast to usual COPD patients.(32) 
Finally, paraseptal emphysema is characterized by enlarged airspaces in the 
periphery of the lobules and is commonly associated with fibrosis or other types of 
emphysema.(31)  
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CT can be used to measure the density of the lungs and CT densitometry has been 
demonstrated as a useful measure of the severity of emphysema in vivo.(33) Various 
measures of density can be used but the 15th percentile point (Perc15) (the cut-off 
value in Hounsfield Units below which 15% of lung voxels are distributed) is a true 
measure of density and decreases as the severity of emphysema worsens.(33) For 
this reason Perc15 is the most commonly used measure of CT density and has been 
demonstrated to be the most robust at measuring emphysema progression.(33) This 
has led to the use of Perc15 as an outcome measure in COPD clinical trials such as 
alpha-1-antitrypsin augmentation therapy.(34) Appearances of emphysema on CT 
are shown in figure 1.2. 
High Resolution CT (HRCT) is the investigation of choice to diagnose bronchiectasis. 
(25) Classically bronchial wall dilatation (lumen greater than accompanying 
pulmonary artery or lack of tapering) is seen. (25, 35) This can be classified 
according to the shape of the bronchi into cylindrical, varicose and cystic forms. (36) 
Bronchial wall thickening and mucous plugging of smaller airways (‘tree-in-bud’ 
pattern) may also be visualised.  (35, 37) Patients typically present with a daily 
productive cough. (38) The colour of the sputum produced is related to purulence 
(release of neutrophil myeloperoxidase) (39) which relates to changes seen on 
HRCT. (40) Cystic and varicose variants of bronchiectasis are associated with 
greater sputum purulence.(40) Typical images of bronchiectasis on HRCT are seen 


















Table 1.1: Severity of COPD by spirometry 
Severity FEV1 % predicted 
Mild > 80 
Moderate 50-80 
Severe 30-50 
Very Severe <30 
 
This table outlines how the severity of COPD is graded according to results recorded 
by spirometry. This classification is used in both British and American/European 















Figure 1.1: GOLD classification of COPD: Severity of COPD according to the 
international GOLD classification. Patients are placed into one of four groups (A-D) 
based on their severity of airflow obstruction on spirometry (table 1.1), symptoms 
(according to one of two symptom-severity scores, mMRC or CAT) and history of 
exacerbations over the past 12 months. mMRC = Modified British Medical Research 
Council Questionnaire. CAT = COPD Assessment Test. 
CAT< 10   CAT > 10 
Symptoms 










































Figure 1.2: Appearances of emphysema on CT.  This is a scan of the thorax at the 
level of the heart. It represents a cross-sectional slice of tissue viewed as if you are 
looking towards the patient’s head. There is enlargement of airspaces and tissue 
destruction throughout both lungs (highlighted). 
 
Figure 1.3: Appearances of bronchiectasis on CT. This is a scan of the thorax at the 
level of the heart. It represents a cross-sectional slice of tissue viewed as if you are 
looking towards the patient’s head. Thickened and enlarged bronchioles can be 





Management of COPD can be divided into non-pharmacological and 
pharmacological aspects. The most important treatment intervention is smoking 
cessation that both slows the decline of FEV1 and improves patient symptoms and 
overall survival. (17, 41-43) Therefore, current NICE guidance recommends all 
COPD patients should be given encouragement to help stop smoking regardless of 
age. (17) Patients should be offered attendance at a support programme for smoking 
cessation which may also include smoking cessation therapy: nicotine replacement 
therapy (NRT), bupropion or varenicline.(17) 
Pulmonary rehabilitation, an individualised programme of care including education 
and exercise, has been shown to improve quality of life and symptoms. (44) It is 
recommended in patients who are functionally disabled by their COPD.(17) 
Pharmacological treatment in COPD primarily consists of inhaled therapy targeting 
airflow obstruction and inflammation.(17) Short acting bronchodilators (beta2 
agonists and muscarinic antagonists) are recommended in the first instance to 
relieve symptoms. (17) NICE recommend treatment is then increased in a stepwise 
fashion in patients who continue to have symptoms. If FEV1 >50% long-acting 
bronchodilators are recommended (long-acting beta2 agonists (LABA) or long acting 
muscarinic antagonists (LAMA)).(17) If FEV1 < 50% combined therapy with inhaled 
steroids (ICS) (LABA+ICS) or LAMA alone is recommended.(17) Finally, LABA, 
LAMA and ICS can be used at once in patients with ongoing symptoms or 
exacerbations. (17)  
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Recently, several combination inhalers of LABA/LAMA have been licensed for the 
management of COPD. These have been shown to improve lung function and 
symptoms in comparison with monotherapies. (45) A meta-analysis of 6 studies 
comparing LABA/LAMA to LABA/ICS have also shown that these two combinations 
appear to be equivalent at preventing exacerbations.(46) However, evidence that 
LABA/LAMAs are more effective at preventing exacerbations compared to LAMAs 
alone is lacking.(45, 47) This class of medications is not recommended by NICE, but 
is recommended by GOLD for patients with breathlessness without a history of 
exacerbations. (12) 
Other treatments used in the management of stable COPD include oral theophylline 
(another bronchodilator with potential anti-inflammatory properties (48)) which can be 
trialled after inhaled therapy has been optimized and oral mucolytics (in patients with 
a productive cough).(17) Long term oxygen therapy has also been shown to improve 
prognosis in patients with an arterial partial pressure of oxygen of less than 7.3 or 8 
with co-morbidities (such as pulmonary hypertension).(17, 49) 
Exacerbations of COPD (defined as a worsening of a patient’s symptoms) may be 
infective or non-infective. (17) Similarly the main focus of treatment is bronchodilation 
and anti-inflammatory treatment with steroids. Antibiotics may also be required if a 
patient is producing purulent sputum.(12, 17) A summary of interventions in COPD 
and their cost is presented in figure 1.4. 
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Figure 1.4: COPD value pyramid. The cost in quality-adjusted life years (QALYs) for 
common COPD interventions.(50, 51) Interventions at the top of the pyramid are 
more expensive and have a higher QALY than interventions in the bottom part of the 
pyramid. Simple interventions such as smoking cessation represent better value (in 













Numerous mechanisms have been proposed in the pathogenesis of COPD. One of 
the key mechanisms is the balance between anti-proteases and proteases.(52) 
Different proteases break down connective tissue in the lung such as elastin; (53) 
this enzyme release is prevented from doing tissue damage in healthy patients by 
protective antiproteases .(52, 54) A good clinical example of the importance of 
protease balance is alpha1-antitrypsin deficiency (A1ATD); a genetically determined 
anti-protease deficiency which predisposes to COPD.(55) A1AT (alpha-1-antitrypsin) 
is an anti-protease that inhibits the actions of serine proteases such as neutrophil 
elastase (NE).(54) Cysteine proteases (cathepsins) which are found in lysosomes 
may also be involved in the pathogenesis of COPD.(53) For example, cathepsin 
inhibitors reduce the development of emphysema in transgenic mice.(56) The third 
class of proteases implicated in the development of COPD are matrix 
metalloproteases (MMPs).(57) Several MMPs are found in increased amounts in 
patients with COPD (58, 59) and transgenic MMP-12-/- mice are also resistant to 
emphysema induced by chronic smoke exposure.(60) 
As well as increased protease activity, reduced anti-protease activity may also play a 
role in the development of usual COPD. For example, oxidative stress in COPD 
patients (discussed below) may inactivate both A1AT and secretory leukocyte 
protease inhibitor (SLPI); the other major serine protease inhibitor in the airways.(53, 
61) MMPs are inhibited by tissue inhibitors of MMPs (TIMPs) of which there are 4 
types.(62) Although there is evidence that 2 of the TIMPs are up-regulated in 
smokers there is also an increase in the frequency of loss-of-function mutations in 
TIMP-2 in COPD patients suggesting that TIMP activity may be reduced.(62, 63) 
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There is a wealth of evidence demonstrating systemic inflammation in COPD, as 
shown by increased levels of chemokines, cytokines and acute phase reactants.(64) 
Smoking can cause inflammation, but the degree seen in COPD is higher than in 
smokers alone and persists despite smoking cessation.(65) Inflammation in COPD 
also appears to be greater in severe disease(66), although its variability over time 
and with exacerbations has thwarted attempts to find biomarkers in the blood that 
relate consistently to clinical features.(67) Interleukin-6 (IL-6), C reactive protein 
(CRP), IL-8 and surfactant protein D (SP-D) (68, 69) levels are typically high in 
COPD and are important in the recruitment of inflammatory cells, although fibrinogen 
seems the most reliable biomarker to date.(64, 67) Fibrinogen levels are associated 
with increased exacerbation rates and poorer outcomes (70, 71), however it is a non-
specific marker and as such has inherent weaknesses. More specific related 
markers, such as Aa-Val360 may prove more useful in the future.(72) There is an 
accumulation of inflammatory cells in COPD lungs, including macrophages, 
neutrophils, B cells and CD4+ and CD8+ T cells.(73) Macrophages release multiple 
inflammatory mediators including reactive oxygen species, cytokines, chemokines, 
extracellular matrix proteins and MMPs.(74) In COPD their function may be impaired, 
for instance they show impaired phagocytosis of bacteria, which may result in an 
increased inflammatory response to bacteria in the lower airways.(74) Neutrophils 
also produce reactive oxygen species, elastase and cytokines, which play a role in 
emphysema and COPD development.(54) Lymphocytes, including both B and T 
cells, are also found in high numbers in COPD lung and may be involved in immune 
activation, leading to perpetuation of inflammation and on-going parenchymal 
destruction. (75) Such a reaction is typical of autoimmune disease, and 
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characteristics of autoimmunity have been reported in COPD (76) although whether 
they are cause or effect is a matter of debate.(77) 
Oxidative stress has also been proposed as a causative factor in COPD. The normal 
metabolism of oxygen results in the development of reactive oxygen species (ROS) - 
these are usually removed from the cell by enzymes or anti-oxidants such as 
superoxide dismutase.(53, 78) If the balance between the formation and removal of 
ROS is disturbed oxidative stress can occur.(78) Oxidative stress is well recognized 
in COPD and is particularly elevated during exacerbations.(79) Cigarette smoke is a 
key driver of oxidative stress.(80) It contains noxious chemicals which are 
metabolized to benign and/or toxic metabolites, the latter of which can damage tissue 
and predispose to disease.(80) Other oxidants such as ozone may also play a role in 
oxidative stress in these patients.(80) Inflammatory cells which are activated in 
COPD such as neutrophils also provide an endogenous source of oxidative stress by 
producing ROS.(81) Oxidative stress may play a role in the development of COPD 
via different mechanisms. For example, oxidants activate intracellular pathways by 
upregulating the expression of multiple inflammatory genes resulting in damage to 
the lung. (53) Oxidative stress also damages cells in the lung directly resulting in cell 
lysis and increased epithelial permeability. Increased oxidants cause mucous 
hypersecretion and impaired mucociliary clearance further contributing to the disease 
process.(82) 




Figure 1.5: Pathogenesis of COPD: Inflammatory cells release reactive oxygen 
species causing oxidative stress. Inflammatory cells also release proteases 
disrupting protease/antiprotease balance. Inflammation results in parenchymal 
destruction and COPD. Pollutants such as cigarette smoke cause inflammation 
directly and indirectly by producing oxidative stress. Oxidative stress also results in 
lung damage directly. Oxidative stress reduces antiprotease activity further disrupting 









1.2 Lung Cancer 
 
Lung cancer is common: Over 39 000 patients are diagnosed with lung cancer each 
year in the UK and it is now the leading cause of female cancer death.(83) 90% of 
lung cancers are caused by smoking, although other environmental factors such as 
asbestos exposure also play a role.(84) Lung cancers are classified by histology into 
small cell and non-small cell cancers (NSCLC); the latter are the more common and 
include squamous and adenocarcinomas.(85) Generally small cell tumours have the 
poorest prognosis, with overall survival being 9 months when managed by 
chemotherapy.(86) Even in NSCLC prognosis is generally poor unless surgery can 
be offered, and a systematic review reported mean survival of just over 7 months if 
left untreated.(87) 
1.2.1 Clinical Features 
The incidence of lung cancer is related to age; patients are at increased risk of lung 
cancer if they are over 40 years old.(88) In 2012 43% of all patients diagnosed in the 
UK were over 75 years old.(6) NICE recommend that people should be referred 
urgently for suspected lung cancer via a 2 week wait referral to hospital if they are 
over 40 and present with unexplained haemoptysis.(88) An urgent chest x-ray to look 
for lung cancer should be performed in people over 40 with 2 or more symptoms 
suggestive of lung cancer (or one symptom if they previously smoked).(88) 
Symptoms can be non-specific such as cough, weight loss and breathlessness such 
that clinical suspicion is key to making the diagnosis.(88) A chest x-ray is also 
required in people over 40 with possible signs of lung cancer on clinical examination 
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(such as finger clubbing), recurrent chest infections, lymphadenopathy or 
thrombocytosis.(88) 
Once a patient has been referred to a specialist for suspected lung cancer the initial 
investigation of choice is a CT scan of the chest, lower neck and upper abdomen.(83, 
89) If the CT confirms the presence of a likely lung cancer the next investigations 
should be tailored to the individual patient depending on the location of the tumour. 
Investigations commonly used include biopsy (via CT or ultrasound guidance) and 
Positron emission tomography (PET)-CT scanning.(83, 89)  
Once imaging and biopsy results are available the lung cancer is further defined in 
two ways: histological type and stage. Both of these play a role in the management of 
the lung cancer. The International Association for the Study of Lung Cancer (IASLC), 
American Thoracic Society (ATS) and the European Respiratory Society (ERS) 
released guidelines on the classification of lung cancer in 2011.(90) A summary of 
this can be found in table 1.2. 
Approximately 85% of all lung cancers diagnosed are non-small cell lung carcinoma 
(NSCLC), the majority of which are adenocarcinoma.(91, 92) Squamous cell 
carcinoma is most strongly associated with smoking; over 90% of cases are smoking 
related.(91) Adenocarcinoma is more common in never-smokers than smokers and is 
the most common type of lung cancer in young patients.(92, 93) Small cell lung 
carcinoma (SCLC) is distinct from other subgroups as it has a rapid doubling time 
and tends to metastasize early. SCLC is therefore particularly sensitive to 
chemotherapy, but the prognosis is poor and most patients die from recurrent 
disease.(94, 95) 
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Table 1.2: Histological classifications of lung cancer(90) 
Small Cell Carcinoma (SCLC) 
Non-small cell carcinoma (NSCLC) 
Divisions of 
NSCLC 
Adenocarcinoma, further divisions: 
Patterns present: acinar, papillary, micropapillary, lepidic, 
mucinous, fetal, colloid 
Signet ring features 
Clear cell features 
Adenosquamous carcinoma 
Squamous cell carcinoma 
Large cell neuroendocrine carcinoma (LNEC) 
Poorly differentiated NSCLC with spindle and/or giant cell 
carcinoma (previously sarcomatoid) 
NSCLC, not otherwise specified (previously included large cell 
carcinoma) 
 
This table outlines the classification of lung cancer according to the International 
Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS) 
and the European Respiratory Society (ERS). Lung cancer is divided into 2 main 
groups: Small cell lung carcinoma (SCLC) and Non-small cell lung carcinoma 








Lung cancer can be further divided into stages according to the ‘Tumour, Node, 
Metastases’ (TNM) staging from the International Union against cancer.(96) This has 
been used by NICE in the UK since 2010.(83) In this staging system the tumour, 
lymph nodes and presence/absence of metastases are rated and these ratings are 
combined to give an overall stage.(96) In general, patients with stage I cancer have 
the best prognosis and those with stage IV the worst.(96) This has now been 
validated in different centres.(97)  
1.2.2 Management 
Lung cancer is managed by groups of different specialists in lung cancer multi-
disciplinary teams (MDTs). NICE recommend that all patients with lung cancer are 
discussed in such MDTs, which are considered quorate when they include 
respiratory physicians, lung cancer specialist nurses, oncologists, pathologists, 
radiologists and thoracic surgeons.(83)  
Treatment is generally determined by cancer stage, histological subtype and patient 
fitness.(83, 89) It can be divided into treatment with and without curative intent (table 
1.3).(83, 89) 
As SCLC behaves differently to NSCLC treatment is considered differently by 
NICE.(83) Patients with limited disease (T1-4N0-3M0) should be offered platinum 
based chemotherapy and concurrent radiotherapy if their disease can be 
encompassed within a radical thoracic radiotherapy volume and their performance 
status is good.(83, 98) In a very small proportion of patients (T1-2aN0M0) surgery 
should be considered.(83, 99) However, due to the aggressive nature of the disease  
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Table 1.3: Treatments used in the management of NSCLC 









T1a-3N0-1M0 with poor 
patient fitness 










Stage III or IV No (83) 
This table outlines common forms of treatment for NSCLC. The second column lists 
when these treatments would be used according to TMN staging criteria. The final 
column lists whether or not the treatment is curative. CHART: Continuous 
hyperfractionated accelerated chemotherapy; SABR: Stereotactic ablative 
radiotherapy. 
Table 1.4: Palliative therapies used in the management of lung cancer 
Reason for treatment Intervention Reference 
Hypercalcaemia Bisphosphonates (103) 
Pain or cough Opioids (83) 
Symptoms arising from primary 
cancer eg breathlessness, 
haemoptysis, chest pain 
Palliative thoracic radiotherapy (104) 
Brain metastases Dexamethasone and cranial 
radiotherapy 
(105) 
Superior vena cava (SVC) 
obstruction 
Stenting +/- chemotherapy and 
radiotherapy 
(106) 
Bony metastases Radiotherapy (107) 
Metastatic spinal cord compression Spinal radiotherapy (108) 
Breathlessness due to malignant 
pleural effusion 
Pleural aspiration/pleurodesis (83, 109) 






This table outlines common palliative treatments used in all types of lung cancer and 
reasons why these treatments might be considered. 
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it is likely that chemotherapy and/or radiotherapy will still be required in these 
patients.(89)  
In addition to surgery/radiotherapy/chemotherapy patients may require symptomatic 
or palliative treatment. Palliative treatments are summarized in table 1.4. 
New treatments designed to target particular mutations in lung cancer have also 
been developed. It is possible these treatments will allow clinicians to tailor specific 
treatments to certain patients rather than treating patients as a homogenous group. 
Examples of new treatments in development are outlined in table 1.5. 
1.2.3 Pathogenesis 
Smoking, occupational toxins and air pollution may result in damaging mutations 
which have potential to induce dysplastic and neoplastic changes in the lung 
parenchyma due to alterations in cell differentiation, growth and death.(111) 
Cigarette smoke contains over 60 carcinogens (112) which can be activated by 
cytochrome P450 (CYP) enzymes; inhalation of these, pollutants and micro-
organisms can cause damage directly or due to oxidative stress.(111) This results in 
DNA adducts which in turn may cause mutations if they are not repaired.(113) 
Commonly these mutations are in oncogenes (such as p53), but they may also affect 
inflammatory pathways.(114, 115) Mostly these mutations are repaired, but when 
there is a high rate of damage due to ROS cells are likely to be transformed to a 
malignant phenotype.(114) Table 1.6 outlines several of the genes known to be 
mutated in lung cancer. As shown in table 1.5 several of these now have specific 
drugs targeting them. 
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Table 1.5: New therapies in lung cancer 
Treatment Target mutation Stage of 
testing(116) 
Licensed Reference 
AZD4547 Fibroblast growth factor Phase II/III No (117) 
AZD2014 Mechanistic target of 
rapamycin (mTOR)  
Phase II No (118) 
Palbociclib Cyclin-dependent kinase-
4/6 (CDK- 4/6) 
Phase II/III No (119) 
Crizotinib Anaplastic lymphoma 
kinase (ALK) 
Phase III Adenocarcinoma (120) 
Selumetinib Mitogen-activated protein 
kinase kinase (MEK) 
Phase II No (121) 
AZD5363 Protein kinase B (AKT) Phase II No (122) 
AZD9291 Epidermal growth factor 
receptor (EGFR) T790M 
Phase II No (123) 
Durvalumab Programmed death-
ligand 1 (PDL-1) 
Phase III No (124) 
This table outlines new treatments for lung cancer based on specific mutations within 
cancer cells. The third column lists what phase of testing the treatment is at and the 












Table 1.6: Examples of genes commonly mutated in lung cancer 




EGFR Proliferation, cell survival Licensed (125) 
ALK Proliferation, cell survival Licensed (126) 
CDK4 Proliferation, migration II/III (127) 
FGF EMT II/III (128) 
AKT Proliferation, cell survival, migration II (129) 
MEK Proliferation, cell survival, uncontrolled cell 
differentiation, angiogenesis 
II (130) 
mTOR Proliferation, migration II (131) 
c-Kit Proliferation  (132) 
FHIT Proliferation, cell survival  (133) 
FUS1 Proliferation, cell survival  (134) 
MYC Proliferation, cell survival, uncontrolled cell 
differentiation, angiogenesis, migration 
 (135) 
p16INK Proliferation  (136) 
p53 Cell survival  (137) 
    
PI3K Proliferation, cell survival, migration  (138) 
PTEN Proliferation, cell survival, migration  (139) 
RAS Proliferation, cell survival, angiogenesis  (140) 
RASSF1A Proliferation, cell survival, microtubule 
instability, EMT 
 (141) 
RB Proliferation  (142) 
SEMA3B Cell survival  (143) 
SEMA3F Cell survival  (144) 
STAT Proliferation, cell survival, migration, 
angiogenesis 
 (145) 
TGFβ EMT, migration  (146) 
This table outlines genes commonly mutated in lung cancer and the effect of the 
mutation. EGFR= Epidermal growth factor receptor. ALK = Anaplastic lymphoma 
kinase. CDK4 = Cyclin-dependent kinase-4. FGF = Fibroblast growth factor. AKT = 
Protein kinase B. MEK = Mitogen-activated protein kinase kinase. mTOR = 
Mechanistic target of rapamycin. c-Kit = stem cell factor receptor. FHIT = Fragile 
histidine triad protein. FUS1 = FUS RNA binding protein. MYC = MYC proto-
oncogene. bHLH transcription factor. p16INK = cyclin-dependent kinase inhibitor 2A. 
multiple tumor suppressor 1. P53 = tumour protein 53. PI3K = Phosphatidylinositol-
4,5-bisphosphate 3-kinase. PTEN = phosphatase and tensin homolog. RASSF1A = 
Ras association domain family member 1. SEMA3B = Semaphorin 3B. SEMA3F = 
Semaphorin 3F. STAT = Signal transducer and activator of transcription. TGFβ = 
Transforming growth factor-β. 
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There is evidence that carcinogenesis occurs at sites of chronic inflammation.(147) 
For example, hepatocellular carcinoma can occur in patients with chronic hepatitis 
and colon cancer in the setting of colitis.(148) There is some evidence that increased 
inflammation may also be associated with the development of lung cancer. 
Epidemiologically, a cohort study of 7081 patients showed an increased risk of lung 
cancer in patients with a CRP of > 3 mg/dL.(149) Furthermore, a mouse model of 
chronic inflammation showed increased lung tumourigenesis.(150) However, clinical 
studies of anti-inflammatory drugs, such as inhaled corticosteroids, have shown 
inconsistent results. A cohort study has shown lower rates of lung cancer compared 
to patients not taking inhaled corticosteroids(151), whilst a randomized controlled trial 
(RCT) did not.(152) Whether targeting pulmonary inflammation to prevent lung 
cancer will be beneficial therefore remains uncertain. One way inflammation may 
lead to the development of lung cancer is by activation of the epithelial growth factor 
(EGFR) cascade. This is activated in response to oxidative stress, neutrophil 
elastase and other proteases.(153) Overexpression of EGFR has been associated 
with a high risk of developing lung cancer and can occur years after smoking 
cessation.(154) The arachidonic acid metabolic pathway may also be related to lung 
cancer development. Inflammatory cells release arachidonic acid metabolites 
including prostaglandins - this is mediated by cyclooxygenase enzymes (COX) 
including COX-2.(147) Prostaglandin E2, the product of COX-2, regulates the 
inflammatory response, but also has effects on cell proliferation, apoptosis and 
angiogenesis(147) and therefore may have a role in cancer development. Raised 
COX-2 levels relate to survival in NSCLC(155), inhibition of COX-2 reduces lung 
cancer in animal models(155) and patients who regularly take COX-2 inhibitors have 
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reduced rates of lung cancer.(156) Finally, carriers of a polymorphism of the COX-2 
gene have an increased risk of lung cancer.(157) 
Epithelial-mesenchymal transition (EMT), a process where epithelial cells gradually 
acquire a mesenchymal phenotype may have an important role in the development of 
lung cancer.(158) During this process epithelial cells undergo multiple changes in 
transcription, motility and cell adhesion properties.(158) Epithelial cells typically have 
tight cell-cell interactions and lack of mobility whereas mesenchymal cells are mobile 
with only loose cell-cell interactions.(159) During EMT key transcription factors (such 
as Snail) (160) are upregulated resulting in expression of different cytoskeletal 
proteins and cellular junctional components.(158) Typically the expression of E-
cadherin reduces and N-cadherin (expressed on mesenchymal cells) increases. This 
phenomenon can be used to monitor the development of EMT.(161) This change to a 
mesenchymal cell type is thought to allow the malignant cells to migrate contributing 
to cancer invasion and metastasis and may also play a role in resistance to 
chemotherapeutic drugs.(162) Different signalling factors can induce EMT including 
fibroblast growth factor and Notch although transforming growth factor-β (TGF-β) has 
been the most commonly studied.(162) TGF-β directly activates known EMT 
transcription factors thus repressing the expression of E-cadherin.(163) TGF-β may 
be particularly important in lung cancer as expression of TGF-β is upregulated by 
smoking.(159) Increased expression of TGF-β has also been shown to be related to 
increased metastatic potential of NSCLC tissues.(164) 
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1.3 Evidence for the shared pathogenesis of COPD and lung cancer  
The relative risk of lung cancer in COPD is over twice that of the general 
population.(11) As both diseases are related to smoking it could be assumed that the 
relationship between COPD and lung cancer might be related to smoking alone. 
However, in recent years it has been shown that patients with COPD, or CT 
diagnosed emphysema, have a higher risk for lung cancer even when adjusting for 
smoking history.(165, 166) Furthermore, increased severity of airway obstruction is 
associated with a correspondingly elevated risk of lung cancer.(167) Emphysema in 
non-smokers is also a risk for lung cancer further reinforcing that smoking, alone, 
cannot explain the relationship between COPD and lung cancer.(111) Taken together 
this evidence suggests that there is a link between COPD and lung cancer other than 
smoking. 
Only 20%-30% of smokers develop COPD and 10%-15% develop lung cancer.(16) 
Familial linkage studies and genome-wide association studies (GWAS) have been 
performed for COPD, lung function and lung cancer and there is overlap in the 
chromosomal areas identified, which demonstrates shared genetic risk. (104) For 
example, Wang et al looked at the gene expression pattern in lung samples from 
COPD patients and demonstrated that genes involved in extracellular membrane 
synthesis and apoptosis were up-regulated, whilst genes involved in the anti-
inflammatory response were down-regulated.(168) Another study looking at gene 
expression in squamous cell carcinoma found that in patients with co-existing COPD 
there was a more frequent loss of 5q or a low expression of genes on 5q than in 
patients without co-existing COPD.(169)  
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There is impairment in DNA repair in COPD due to low levels of Ku 86, a protein 
involved in DNA repair.(170) This suggests that oxidant induced damage in COPD 
patients is more likely to result in carcinogenesis. It is also possible that processes 
which control DNA repair may influence a patient’s risk of developing lung cancer 
and that such processes may be altered in COPD.(171) For example, there is 
evidence that acetylation of histone H3 on lysine 56 (H3K56) is important in DNA 
repair.(172) Deacetylation of H3K56 is controlled by histone deactylases (HDACs) 1 
and 2 and sirtuin (SIRT) 1.(173) As there are low levels of HDAC2 and SIRT1 in 
COPD this may reduce the protection against DNA breakage caused by 
environmental factors further increasing lung cancer risk.(174) 
Epigenetics is the regulation of gene expression by heritable mechanisms that do not 
make direct changes to DNA itself.(111) Examples of epigenetic mechanisms include 
histone acetylation and methylation.(111) Tumour suppressor genes, including p53, 
may be rendered inactive in patients with low SIRT1 levels, including COPD 
patients.(175, 176) Methylation of the promoter of p16 (a tumour suppressor gene) is 
seen in the sputum of COPD patients and aberrant methylation of p16 can be also 
seen in the sputum of patients with NSCLC suggesting this too may be a shared 
mechanism of disease.(177)  
It is likely that mechanisms underlying COPD development increase the risk of lung 
cancer development. For example, inflammation in COPD might predispose to the 
development of malignancy.(64, 147) Oxidative stress in COPD may also increase 
cancer risk. Nuclear factor erythroid 2-related factor 2 (Nrf2) is the main transcription 
factor that regulates phase II detoxifying antioxidant enzymes.(178) Low Nrf2 
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expression occurs in COPD and this may also predispose patients with COPD to lung 
cancer due to increased oxidative stress.(179) Oxidative stress also increases p21 
expression, a cyclin-dependent kinase inhibitor whose levels are raised in patients 
with COPD and lung cancer.(180) Elevation of p21 results in hyperproliferation and 
carcinogenesis.(181) As above, the balance between anti-proteinases and 
proteinases is an important determinant of emphysema that occurs in COPD.(52) 
Proteinases are also important in lung cancer development as they release growth 
factors such as transforming growth factor-β (TGF-β) which can lead to 
tumorigenesis.(111) TGF-β also drives epithelial cell mesenchymal transition (EMT), 
which is regulated by galectin 3. (163) There are raised levels of galectin 3 in COPD 
lung and increased levels are also associated with poor prognosis in NSCLC.(182, 
183) A summary of the relationship between COPD and lung cancer is presented in 
figure 1.6 
1.4 The role of the endothelium in the lung  
 
The pulmonary vasculature is critical to gas exchange in the lung, with a total 
pulmonary vascular surface area of 90 m2.(184) The entire vascular system is lined 
by endothelial cells, which form a continuous monolayer.(184) Endothelial cells are 
encased by a basement membrane, a thin protein sheet (50 nm thick) that consists of 
laminins, collagen and proteoglycans.(185) Endothelial cells are also covered on the 
luminal side by the glycocalyx, a network of proteoglycans and glycoproteins involved 
in multiple processes such as cell-cell signalling and haemostasis.(186) Finally, 
embedded in the basement membrane are a non-continuous layer of pericytes, 
which are key mediators of several microvascular processes such as endothelial cell  
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Figure 1.6: A summary of the relationship between COPD and lung cancer (1). The 
figure shows some of the key pathways leading to both chronic obstructive 
pulmonary disease (COPD) and cancer, and demonstrates the complexity of the 
interactions between the diseases. Cigarette smoke causes oxidative stress which 
can both drive inflammation and occur due to inflammation; both processes lead to 
COPD. Inflammation may in turn lead to activation of matrix metalloproteases 
(MMPs) and the transforming growth factor-β (TGF-β) pathway, which by way of 
epithelial mesenchymal transition can promote lung cancer growth. Oxidative stress 
may also directly activate the epidermal growth factor receptor pathway, which is 
involved in lung cancer growth. Cigarette smoke also interacts with pre-existing 
genetic predisposition and causes changes in DNA and miRNA, which lead to 
processes relevant to cancer growth, such as cell proliferation and apoptosis, as well 
as to COPD. Finally, COPD may cause hypoxia that may augment angiogenesis, 
thereby interacting with prostaglandin based pathways to influence cell proliferation 
further, with the potential to influence cancer risk. EGFR: epithelial growth factor. 





proliferation and angiogenesis. (187, 188) A diagram of the structure of the 
endothelium is shown in figure 1.7. 
The endothelium does not represent a passive lining of the vasculature, but a 
dynamic tissue involved in vessel homeostasis, response to pathological stimuli and 
cell-cell interactions.(184)  
One particular important function of the pulmonary endothelium is maintenance of 
pulmonary vascular tone by the production of mediators such as nitric oxide 
(NO).(189) There is evidence that NO production is important in maintaining the low 
resistance seen in pulmonary vasculature as systemic delivery of NO synthase 
inhibitors increases pulmonary vascular resistance.(189) Prostacyclin (PGI2), an 
eicosanoid, is another potent vasodilator produced by the endothelium.(190) In fact, 
systemic delivery of PGI2 has been used as a treatment of primary pulmonary 
hypertension (PPH); a condition characterised by pulmonary vascular 
constriction.(190) However, endothelial cells can also produce potent 
vasoconstrictors in addition to vasodilators. For example, endothelin-1 (ET-1), which 
is produced by endothelial cells in response to several stimuli such as hypoxia, sheer 
stress, angiotensin and growth factors.(191) Interestingly, ET-1 production appears 
to be reduced by NO and may therefore partly explain the vasodilatory response to 
NO.(192) Targeting ET-1 has also been exploited in the treatment of PPH.(191) 
Another eicosanoid, thromboxane A2 (TXA2), is a potent vasoconstrictor and acts in 
opposition to PGI2.(193) TXA2 acts via a G protein coupled receptor to increase 
calcium influx into smooth muscle cells resulting in constriction.(193) Reactive 
oxygen species (ROS) produced in response to oxidative stress may also act via NO 
to cause vasoconstriction by reducing NO bioavailability.(194) Therefore, mediators 
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produced by the endothelium may result in pulmonary vasoconstriction and 
vasodilation and so perhaps it is the overall balance of these mediators that 
determines the overall vascular response. 
Neutrophil transendothelial migration (TEM) is an important mechanism by which the 
endothelium plays a role in the lung. As previously discussed (section 1.1.3) 
neutrophils play an important role in the inflammatory response. (54) In order to 
reach the lung tissue neutrophils must bind to, and migrate through, the endothelium. 
(188) Initially neutrophils extend part of themselves (a pseudopod) to invaginate the 
apical endothelial cell membrane. The neutrophil binds to the endothelial cell through 
a variety of cell surface proteins before migrating between the endothelial cells. (188) 
This is illustrated in figure 1.8. 
Endothelial mediators may also be important in the pulmonary inflammatory 
response. For example, increased cellular levels of calcium secondary to acute 
inflammation activate NO synthase.(184) This results in the production of proteins, 
which produce a scaffold for inflammatory cells.(195, 196) TXA2 is also important in 
the inflammatory response and appears to upregulate TEM by enhancing the 
production of adhesion molecules such as intercellular adhesion molecule 
(ICAM).(197) In addition, release of ROS may also upregulate TEM through a similar 
mechanism.(198) Finally, another important endothelial inflammatory mediator is von 
Willebrand Factor (vWF). This factor is important in the clotting cascade, but platelets 
bound to vWF express P-selectin, which binds to and recruits leucocytes resulting in 




Figure 1.7: The endothelium. The endothelium consists of a layer of endothelial cells 
encased in a basal membrane. The endothelial cells are covered on the luminal side 
by the glycocalyx, a network of proteoglycans and glycoproteins. Finally, pericytes 
are also embedded in the basal membrane and are important in some endothelium 
functions such as angiogenesis. 
 
 
Figure 1.8: Transendothelial migration: The neutrophil passes along the endothelium 
before binding to an endothelial cell via adhesion molecules (eg MAC-1, illustrated as 
red bars). The neutrophil invaginates the endothelial cell membrane before migrating 







Conversely, endothelial cells may also result in the production of anti-inflammatory 
mediators. For example, NO may act in an anti-inflammatory manner through the 
reduction of adhesion molecules, which would reduce inflammatory cell infiltration via 
TEM.(200) Similarly, PGI2 also has anti-inflammatory actions resulting in the reduced 
vascular permeability and therefore oedema formation, in response to acute 
inflammatory stimuli.(201) Thus, in a similar fashion to vasomotor tone control, it is 
likely that the overall balance of these different mediators controls whether the 
endothelium does or does not promote inflammation. 
Finally, another important role of the pulmonary endothelium is its part in the renin-
angiotensin system (RAS). Renin (which is produced by the kidney) converts 
angiotensinogen from the liver into angiotensin I.(202) This in turn is converted to 
angiotensin II by angiotensin converting enzyme (ACE), which is predominantly 
expressed in the pulmonary endothelium.(202) Angiotensin II stimulates the adrenal 
cortex to produce aldosterone resulting in increased salt and water retention from the 
kidney thus increasing systemic blood pressure.(202) This is important in the 
response to acute hypotension.(202) In addition to these systemic effects, 
angiotensin II acts locally in the lung via its receptor AT1R (Angiotensin receptor 1) 
resulting in vasoconstriction, increased ROS production and vascular 
remodelling.(203) The effects of angiotensin binding on its other receptor AT2R 
(Angiotensin receptor 2) appear to oppose AT1R effects in other organ systems but 
current research into pulmonary AT2R effects is conflicting and therefore 
controversial at present.(204) 
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1.4.1 The role of the endothelium in COPD 
In the 1950s Liebow demonstrated that alveolar septa in COPD patients were almost 
avascular.(205) This led to the hypothesis that vascular atrophy resulted in the 
destruction of alveoli.(205) Supporting this concept, increased levels of apoptotic 
endothelial cells have been identified in the lungs of patients with COPD.(206) It is 
also possible to induce emphysema in rodents by deliberately causing endothelial 
apoptosis.(207) A reduction in endothelium in patients with emphysema may be 
caused by reduced levels of Vascular Endothelial Growth Factor (VEGF).(208) VEGF 
is a highly specific growth factor for endothelial cells that is produced in response to 
hypoxia.(209) It induces both cell proliferation and migration and prevents endothelial 
cell apoptosis.(209) VEGF levels might be reduced in such patients as Hypoxia 
Inducible Factor-1α (HIF-1α), a major transcription factor for VEGF, is also reduced in 
patients with emphysema.(210) Levels of HIF-1α and VEGF may be related to 
disease severity: both are correlated with FEV1 percentage predicted in patients with 
emphysema.(210) Interestingly, similar studies looking at the expression of HIF-1α 
and VEGF in patients with chronic bronchitis (rather than emphysema) have shown 
HIF-1α and VEGF are increased in this patient group.(211) This suggests that the 
endothelium might be involved in different ways depending on the clinical 
presentation of COPD. There is also evidence that vasculature may be altered in the 
airways of patients with COPD, in addition to their peripheral lung tissue – several 
groups have shown an increased vascular area in the airways of patients with 
COPD.(212, 213) It is possible that this might contribute to airway narrowing.(213) 
In addition to altered levels of endothelium in patients with COPD, the endothelium 
appears to behave in a dysfunctional manner. Endothelial dysfunction is defined as 
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disturbed endothelial dependent vasodilatation.(214) It results in a breakdown of the 
microvascular endothelial barrier and loss of the anti-adhesive and anti-thrombotic 
functions of the endothelium.(214) Endothelial dysfunction is associated with severity 
of COPD and is related to FEV1. (215, 216) Dysfunction is also related to clinical 
outcomes: patients with increased endothelial dysfunction have reduced 6 minute 
walk test results and a worse overall prognosis.(217, 218) Endothelial dysfunction is 
also increased in patients with exacerbations of COPD.(219) Therefore it has been 
postulated that increased endothelial dysfunction may induce the development of 
systemic atherosclerosis and therefore the increased cardiac events seen in these 
patients.(218) 
Endothelial dysfunction was previously measured by arterial catheterization to 
identify the response of the artery to acetylcholine.(220) Patients with endothelial 
dysfunction respond with vasoconstriction rather than vasodilatation as 
expected.(220) However, due to the invasive nature of this technique flow mediated 
dilation (FMD) of the brachial artery was developed as an alternative measurement of 
endothelial dysfunction.(221) FMD looks at the response of the brachial artery to 
reactive hyperaemia using Doppler ultrasound and can be used as a surrogate 
measure of more central endothelial dysfunction.(221) It is reproducible both within 
and between days when repeated measures are made in COPD patients (222) and 
associated with FEV1 and percentage of emphysema on CT scan.(216) These 
associations were independent of smoking and other major causes of endothelial 
dysfunction.(216) The relationship between FMD and FEV1 was explained by the 
percentage of emphysema.(216) This suggests that endothelial dysfunction might be 
involved in emphysema pathogenesis and COPD.(216) Alternatively, one can look at 
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the blood level of von Willebrand factor (vWF) as an indication of endothelial 
dysfunction.(223) This is a glycoprotein synthesized by endothelial cells, with 
increased levels being related to worsening endothelial dysfunction.(223) Exhaled 
nitric oxide (NO) is another measure of endothelial dysfunction. NO is reduced in 
endothelial dysfunction due to a reduction in production and/or inactivation of NO 
synthase by ROS.(223) Maricic et al demonstrated both increased vWF and reduced 
exhaled NO levels in patients with COPD (223). Finally, the level of endothelial 
microparticles (EMPs) in blood can be used as a measurement of endothelial 
dysfunction. EMPs are membrane vesicles which are shed by activated or apoptotic 
endothelial cells.(219) EMP levels are increased in patients with COPD who have 
frequent exacerbations compared to those who do not have frequent 
exacerbations.(219) EMPs are also positively correlated with the severity of 
emphysema in patients with COPD.(224) Endothelial dysfunction may be a result of 
the increased levels of oxidative stress seen in COPD. Patients with COPD and low 
levels of FMD show improvements in FMD when given anti-oxidants.(225)  
The RhoA/Rho-kinase pathway which is upregulated in patients with COPD may also 
result in endothelial dysfunction.(226) RhoA is a small G-protein and Rho-kinase is 
its’ downstream effector.(226) This pathway is important in a variety of cell functions 
including migration and proliferation.(226) Levels of RhoA and Rho-Kinase are 
associated with the level of endothelial dysfunction in patients with COPD.(226) 
Angiotensin-converting enzyme (ACE), a regulatory protein with both vascular and 
collagenolitic effects has different variants.(227) The D variant is associated with both 
endothelial dysfunction and number of exacerbations in patients with COPD and thus 
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may also play a role in the development of endothelial dysfunction.(227) A summary 
of the different ways endothelial dysfunction can be measured is in table 1.7. 
Although there have not been specific treatment trials for endothelial dysfunction in 
COPD, many of the above pathways have potential treatments associated with them 
such as anti-oxidants mentioned above. Patients on long-term ICS have both lower 
levels of VEGF in pulmonary tissue (228) and reduced endothelial dysfunction 
compared to patients not on ICS.(229) Therefore, targeting inflammation may be 
important to improve endothelial dysfunction in these patients.(229) The ACE D 
variant is associated with increased production of ACE suggesting that perhaps ACE 
inhibitor drugs (already available for other conditions such as hypertension) may 
provide another treatment option for this subgroup of patients.(227) Rho-kinase 
inhibitors have also improved NO release from endothelial cells in vitro suggesting 
that blocking this pathway may provide another means to improve endothelial 
dysfunction.(230)  
TEM appears to be upregulated in COPD and macrophage-1 antigen (MAC-1), a 
protein involved in TEM is upregulated in neutrophils from COPD patients.(231) 
MAC-1 binds to Intracellular adhesion molecule-1 (ICAM-1) on the surface of 
endothelial cells. Serum levels of ICAM-1 are inversely related to lung function and 
are also associated with increased percentages of emphysema on CT scan 
suggesting that this mechanism may be clinically relevant. (232, 233) Blocking the 
action of ICAM-1 in rodent models has also reduced pulmonary inflammation, further 
supporting the possibility that ICAM-1 might be related to inflammation in 
COPD.(234) 
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Table 1.7: Methods of measuring endothelial dysfunction in COPD. 
Measurement Alteration in COPD Associated changes in 
COPD 
Reference 
FMD of brachial 
artery 






Increased  (223) 
Exhaled NO levels Reduced  (223) 
Peripheral blood 
EMP levels 




RhoA / Rho-kinase 
pulmonary artery 
levels 
Increased  (226) 
ACE levels D variant associated 





This table summarizes different methods of how to assess endothelial dysfunction in 
patients and how the measurement is altered in COPD. The third column lists any 
other associated changes seen in COPD with endothelial dysfunction such as 
exacerbation rate. FMD: Flow-mediated dilatation; vWF: vWillebrand Factor; NO: 











1.4.2 The role of the endothelium in lung cancer  
Pathologists identified that tumours were vascular in the 1800s suggesting that 
vessels might be necessary for tumour growth.(235) By the 1970s it was suggested 
that inhibiting angiogenesis could treat cancer which led to the search for several 
angiogenic factors in the 1980s.(236, 237) Angiogenesis is defined as the growth of 
new blood vessels and is required for larger tumours to obtain nutrients and 
oxygen.(238, 239) This is essential for tumour growth, progression and 
metastasis.(240) Hypoxia is a key driver and stimulates the production of 
proangiogenic factors such as HIF-1α.(241) Angiogenesis involves the proliferation, 
migration and invasion of endothelial cells.(242) 
VEGF is involved in one of the major pathways in angiogenesis and has been 
extensively studied.(242) Activation of VEGF results in endothelial survival, migration 
and differentiation.(240) VEGF also mobilises endothelial progenitor cells (EPCs) 
from the bone marrow.(240) There are 6 versions of VEGF and 3 VEGF 
receptors.(240) Importantly, in NSCLC, VEGF has been shown to be a negative 
prognostic marker.(243) VEGF is predominantly upregulated in response to HIF-1α 
expression which is increased in hypoxic cells.(244) However, other growth factor 
receptors such as EGFR and insulin-like growth factor have also been shown to 
upregulate VEGF expression. (245, 246) As above, COX-2 plays a role in 
angiogenesis – this effect is partially mediated through upregulation of VEGF.(247) 
Finally, mutations in oncogenes and tumour suppressor genes can also increase 
VEGF expression.(248, 249) 
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Eventually, in the 2000s drugs were developed to target VEGF in cancer. 
Bevacizumab, a monoclonal antibody to VEGF, was given to patients with non-
operable, non-squamous NSCLC in a phase III study in 2006.(250) Patients with 
squamous cell lung cancer were excluded due to increased rates of haemorrhage 
seen in this subgroup during previous phase II trials.(251) Patients were randomised 
to traditional chemotherapy with and without bevacizumab. Patients in the 
bevacizumab group had significantly improved progression-free and overall 
survival.(250) However, benefits of treatment with bevacizumab are limited and 
eventually patients develop resistance.(240) This may be due to the role of other 
growth factors in the angiogenesis pathway including fibroblast growth factor (FGF) 
and platelet derived growth factor (PDGF).(252) 
There are 22 ligands in the FGF family, 5 of which have a role in angiogenesis.(252) 
Endothelial cells express FGF receptors (FGFR-1 and FGFR-2) that upregulate 
pathways involved in angiogenesis once stimulated.(252) For example, 
phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) 
pathways.(240) This results in endothelial cell proliferation and migration and pericyte 
recruitment.(253) Mutations in FGFRs are some of the most prevalent mutations in 
human cancer, which has resulted in the development of FGF targeted therapy.(254) 
For example, the multi-targeted antiangiogenic drug Cediranib.(255) However, phase 
III studies have not been promising so far; addition of Cediranib did not improve 
survival in advanced NSCLC compared to carboplatin/paclitaxel alone.(255) In 
addition, there was increased toxicity in the Cediranib arm resulting in an early 
termination of the trial.(255)  
 41 
PDGF is released from platelets in response to vascular damage.(252) There are 5 
PDGF ligands, which bind to PDGFRs on endothelial cells.(240, 256) Activation of 
these receptors results in angiogenesis.(257) There is also evidence that PDGF 
activation results in increased cell proliferation and consequently may also directly 
result in tumourigenesis.(258) In NSCLC increased PDGF expression in tumour 
tissue is associated with increased lymph node metastases and poor survival.(259) 
PDGF is also targeted by some of the multi-targeted antiangiogenic therapies in 
development including Cediranib.(255) Similarly, phase III trials have not been 
successful. For example Sorafenib and Motesanib have been shown to improve 
progression free survival in combination with chemotherapy compared to 
chemotherapy alone.(260, 261) However, these drugs have not improved overall 
survival and use of Motesanib results in increased adverse effects.(260, 261) 
Therefore, these agents are not used for lung cancer treatment presently. 
1.5 The study of micro-RNA and messenger RNA expression in 
the pathogenesis of lung disease  
1.5.1 The study of micro-RNAs in lung disease 
Micro-RNAs (miRNAs) are small (around 20 nucleotides) non-coding ribonucleic 
acids (RNAs) that act to regulate gene expression.(262) They do this via direct 
interaction between their 5’ region (seed sequence) and the 3’ region of their target 
messenger RNA (mRNA).(262) The processing of miRNAs is outlined in figure 1.9.  
 42 
 
Figure 1.9: miRNA processing: RNA polymerase II transcribes the miRNA gene to 
form pri-miRNA. Pri-miRNA is cleaved to pre-miRNA by Drosha/DGCR8 and 
exported to the cytoplasm by Exportin 5/RAN GTP. Dicer cleaves pre-miRNA to a 









MiRNAs are initially transcribed in the nucleus by RNA polymerase II to form pri-
miRNA (100-1000 nucleotides).(263) These are cleaved to form pre-miRNA (50-60 
nucleotides) by the Drosha/DGCR8 enzymes in the nucleus.(263) The pre-miRNAs 
are transported to the cytoplasm by Exportin 5/Ran GTP complex and are cleaved 
again by the Dicer protein to produce a mature miRNA duplex consisting of an active 
and passenger strand.(263) The active strand associates with Ago proteins to form a 
miRNA-induced-silencing-complex (RISC) which can interact with target mRNA.(263) 
miRNAs can suppress mRNA targets by either suppressing translation or causing 
mRNA degradation.(264) However, more recently it has been shown that some 
miRNA/Ago complexes are transported into the nucleus and can bind to DNA 
promoter regions activating transcription and therefore can be positive regulators of 
gene expression as well as negative.(263)  
There is evidence that miRNAs are important in lung development. For example, 
Dicer-null mice have abnormal lung epithelium and airway branching.(265) miRNAs 
may also be important in the regulation of inflammation in the lung and have been 
shown to alter expression in response to exogenous lipopolysaccharide (LPS) in 
animal models.(266) Animal studies have also demonstrated altered lung miRNA 
expression in rats exposed to heavy smoke and those with emphysema in 
comparison to controls suggesting that miRNAs might influence the development of 
COPD.(267) 
Human studies also suggest a role for miRNAs in COPD pathogenesis. For example, 
let-7c is significantly suppressed in the sputum of patients with COPD compared to 
those without.(268) Whole lung miRNA studies have shown that the miRNA 
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expression appears to differ between patients with and without COPD.(269, 270) For 
example, Ezzie et al demonstrated key differences in miRNA expression in pathways 
important to the development of COPD such as transforming growth factor-β and 
focal adhesion pathways.(269) However, very few studies have looked at the miRNA 
expression in COPD in individual cell types in the lung; this is important for two main 
reasons. Firstly, one cannot assume that miRNA changes in whole lung apply to 
each cell type, which makes it difficult to identify potential cellular pathogenic 
pathways in COPD. Secondly, miRNA signals from different cells might cancel each 
other out resulting in important miRNA targets being missed. Examples of miRNA 
studies focusing on single cell types include Schembri et al who demonstrated that 
28 miRNAs were differentially expressed between smokers and non-smokers in 
bronchial epithelium.(271) This suggests that miRNA expression may become altered 
prior to the development of COPD. (271) Sato et al also showed that fibroblasts from 
patients with COPD have downregulated expression of miR-146a, which increased 
the COX-2 response and may therefore be important in the altered inflammation 
seen in COPD patients.(272) A third study demonstrated a low miR-218-5p level in 
lung tissue of COPD patients which was validated in Human Bronchial Epithelial 
Cells (HBECs) and related to airway obstruction.(273) This suggests that miR-218-5p 
may have a role in COPD pathogenesis.(273) However, as yet there are no reported 
studies on miRNA expression in pulmonary endothelial cells in COPD. 
miRNA changes in COPD patients may precede the development of lung cancer. 
One study demonstrated significant differences in miRNA expression (in blood) in 
COPD and lung cancer patients compared to controls.(274) The miRNA signatures of 
COPD and lung cancer patients were more similar to each other than to controls 
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suggesting that some miRNA changes in lung cancer are already present in COPD 
patients before cancer develops.(274) Similarly, another study demonstrated that 
bronchoalveolar lavage (BAL) samples from people with COPD shared 5 deregulated 
miRNAs with samples from patients with adenocarcinoma and COPD.(275) (These 5 
miRNAs were not deregulated in patients with adenocarcinoma only suggesting they 
might be specific to adenocarcinoma development in COPD rather than normal lung.) 
It is possible that these deregulated miRNAs may have had a role in the development 
of cancer in the COPD patients because they represent epigenetic changes prior to 
the development of malignancy that persist in the setting of cancer. For example, 
miR-15b which was identified as upregulated in COPD and adenocarcinoma has 
previously been shown to be upregulated in NSCLC and is associated with a poor 
prognosis.(276) Similarly, miR-365 which was identified as downregulated in COPD 
and cancer has been shown to target epithelial-mesenchymal transition.(277)  
In conclusion there is evidence that miRNA expression is altered in COPD patients 
and shares some similarity with miRNA changes in lung cancer. However, the 
evidence for this in specific cell types is lacking. Importantly there is no published 
data on the miRNA expression in pulmonary endothelial cells. 
Despite a lack of studies looking at miRNA expression in pulmonary endothelial cells 
there are some studies suggesting miRNAs are involved in angiogenesis. This 
initially stemmed from murine model studies in which investigators produced Dicer 
knockout mice.(278) Mouse embryos without Dicer demonstrated stunted growth and 
developmental defects.(278) All Dicer knockout mice retarded phenotype died within 
15 days of gestation suggesting this phenotype was not viable.(278) Blood vessel 
formation in the embryos and yolk sacs was also severely compromised suggesting 
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Dicer (and thus miRNAs) could be key in angiogenesis.(278) This was supported by 
in vitro studies that used knockdowns of Dicer in Human umbilical vein endothelial 
cells (HUVECs).(279) Knockdown of Dicer resulted in the alteration of key endothelial 
related genes such as VEGFR2 (Vascular Endothelial Growth Factor Receptor 
2).(279) Knockdown of Dicer also resulted in reduction of sprouting, tube forming 
ability and migration of endothelial cells suggesting a reduction in angiogenesis 
capability.(280) Finally, mouse models with cell-specific inactivation of endothelial 
Dicer demonstrated reduced postnatal angiogenesis to several responses such as 
VEGF, tumours and wound healing.(281) 
There is also evidence that specific miRNAs directly affect angiogenesis. For 
example, Poliseno et al demonstrated that miR-221 and -222 were upregulated in 
HUVECs and appeared to reduce c-Kit protein levels which resulted in reduction of 
wound healing and tube formation in HUVECs.(282) Interestingly, some miRNAs 
have been directly linked to angiogenesis in hypoxia. This may be particularly 
relevant in the setting of lung cancer and COPD, especially as inflamed tissues can 
become hypoxic.(283) For example, miR-20a is downregulated by hypoxia and 
directly targets HIF-1α.(284) Thus, reduction in miR-20a would increase HIF-1α and 
its’ target VEGF resulting in increased angiogenesis. MiR-424 has also been shown 
to be increased in response to hypoxia.(285) This targets cullin-2 (CUL2), a 
scaffolding protein which is important in the assembly of the ubiquitin ligase 
system.(285) This consequently stabilises HIF-1α and therefore promotes 
angiogenesis.(285) This could perhaps be relevant to the increase in angiogenesis 
seen in cancer, but less so in the reduction of the vascular bed apparent in 
emphysema. However, other miRNAs induced in hypoxia might reduce HIF-1α 
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activity. For example, miR-20b is induced in hypoxia and targets HIF-1α 
consequently leading to a reduction of VEGF.(286) Therefore, perhaps endothelial 
function depends on the balance of expression of different miRNAs and their 
cumulative effect on HIF-1α in hypoxia. 
Mizuno et al also demonstrated that 2 other miRNAs (miR-199a-5p and -34a) might 
be involved in pulmonary endothelial function in COPD.(287) Both miRNAs were 
increased in lung tissue from COPD patients and negatively correlated with FEV1 
percentage predicted.(287) Transfection of these miRNAs into human pulmonary 
endothelial cells (HPECs) resulted in reduced HIF-1α levels.(287) This suggests that 
increased levels of these miRNAs might reduce HIF-1α in the setting of COPD 
resulting in impairment of lung vessel homeostasis and loss of blood vessels. 
Consequently, these miRNAs could be important in the development of emphysema.  
There is greater evidence that miRNAs are important in angiogenesis in lung cancer. 
For example, miR-494 enhances wound closure, migration and tube formation in 
HUVECS in vitro.(288) This is relevant in lung cancer as A549 (lung cancer cell line 
cells) can secrete and deliver miR-494 to HUVECs in vitro suggesting that a similar 
process could occur within the lung cancer microenvironment.(288) Similarly, miR-
378 is upregulated in patients with NSCLC, which has metastasized.(289) In addition 
to contributing to tumour cell migration and invasion, miR-378 increases 
angiogenesis in implanted tumours in mouse models thereby suggesting that it may 
play a role in lung cancer metastasis formation.(289) Other studies have 
demonstrated certain miRNAs are suppressed in lung cancer, which has an effect on 
angiogenesis through lack of suppression of their targets. For example, miR-128 is 
reduced in the NSCLC tissues and appears to target VEGF-C.(290) Overexpression 
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of miR-128 leads to reduction of endothelial tube formation in vitro consequently 
suggesting that upregulation of VEGF and increased angiogenesis might occur in 
lung cancer through suppression of miR-128.(290) Another example of a similar 
mechanism is the downregulation of miR-206 in NSCLC.(291) This miRNA targets 
the protein 14-3-3ζ which, in turn, interacts with phosphorylated-signal transducers 
and activators of transcription 3 (p-STAT3) and activates HIF-1α.(291) 
Overexpression of miR-206 therefore inhibited HIF-1α activation and reduced tumour 
growth and angiogenesis in mouse models.(291) Downregulation of miR-206 could 
have the opposite effect and upregulate angiogenesis in NSCLC. This is consistent 
with data from NSCLC patients where low miR-206 expression was associated with 
poor survival.(291) 
In summary, there is increasing evidence that miRNAs are involved in the regulation 
of angiogenesis particularly through the HIF-1α/VEGF pathway (figure 1.10). 
Although there are a few examples of miRNAs contributing to angiogenesis in lung 
cancer evidence of miRNAs influencing endothelial function in COPD is limited. This 
combined with the lack of effective treatments for COPD; means that the 









Figure 1.10: MiRNAs in the setting of hypoxia, NSCLC and COPD and their effect on 
angiogenesis through the HIF-1α/VEGF pathway. The central pathway represents 
the main HIF-1α/VEGF pathway that upregulates angiogenesis. The purple boxes 
represent processes or diseases where altered miRNA expression has been shown 
to affect the HIF-1α/VEGF pathway. The left side of the figure demonstrates miRNAs 
(in pale blue) that upregulate angiogenesis. Genes are in pale orange. The right side 
of the figure demonstrates miRNAs that downregulate angiogenesis. Blue upward 
arrows indicate that a miRNA/gene is upregulated. Red downward arrows indicate 
that a miRNA/gene is downregulated. CUL2 = cullin-2, p-STAT3 = phosphorylated-
signal transducers and activators of transcription 3, HIF-1α= hypoxia inducible factor 










1.5.2 The study of messenger RNAs in lung disease 
Studies investigating gene expression in lung tissue from COPD patients have been 
in place since the early 2000s. One study comparing gene expression in whole lung 
tissue from patients with and without emphysema demonstrated that genes involved 
in oxidative stress and inflammation were increased in emphysema patients.(292) 
More surprisingly, genes involved in extracellular matrix (ECM) production were also 
increased.(292) This suggests that there is an attempt to remodel connective tissue 
in patients with emphysema, but this is ultimately unsuccessful. In the same study 
angiogenesis related genes (such as endothelial cell growth factor 1) were 
downregulated and SERPINF1 (serpin family F member 1, a known inducer of 
endothelial cell apoptosis) was upregulated providing support for endothelial 
apoptosis in the development of emphysema.(292) Similarly, other studies into whole 
lung gene expression have also demonstrated an increase in apoptosis-related 
genes in patients with emphysema.(293)  
A recent large study (n=581) into gene expression in COPD lung tissue provides 
further evidence that ECM genes are upregulated in COPD.(294) Expression of 
these genes negatively correlated with lung function suggesting that expression of 
these genes increases as tissue destruction in COPD worsens.(294) Campbell et al 
have also provided support for faulty tissue repair in COPD.(295) They performed a 
study comparing gene expression in different areas of the same COPD lung.(295) 
Genes involved in the transforming growth factor-β (TGF-β) pathway, actin 
organisation and integrin signalling were reduced in areas of worse emphysematous 
destruction.(295)  
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It is likely that changes in gene expression are important in the development of 
COPD. For example, in a study comparing the expression of genes involved in 
inflammation, tissue remodelling and vessel maintenance between COPD patients, 
smokers and non-smoking controls there were significant differences between the 
groups, as well as large overlap between COPD patients and smokers, suggesting 
that gene expression changes in smokers precede the development of COPD.(296) 
Early studies were generally based on expression of genes in whole lung tissue. 
More recently, gene expression studies have been performed on different cell types 
in COPD. For example, COPD gene signatures have been isolated from epithelial 
cells using brushing techniques at bronchoscopy.(297) These gene expression 
changes were also similar to changes seen in small airway epithelium in COPD 
patients suggesting that a ‘field of injury’ might be present in such patients throughout 
the bronchial epithelium.(297) Another study which looked at small airway epithelium 
has identified the Notch pathway as being of importance in COPD.(298) The Notch 
pathway is important in the control of epithelial differentiation in lung 
development.(298) Several Notch ligands and receptors are downregulated in 
COPD. (298) As the Notch pathway is important in lung development, perhaps the 
downregulation of this pathway in COPD is consistent with the faulty remodelling 
seen in COPD patients. Pierrou et al also looked at gene expression in the bronchial 
epithelium.(299) However, they identified genes relating to oxidative stress as being 
the most differentially expressed between patients with and without COPD.(299) 
Many of these changes were also seen in the epithelium from patients who were 
smokers (without COPD) suggesting that they may be important in the development 
of COPD.(299) 
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Another cell type which has been investigated in COPD is the fibroblast. Fibroblasts 
isolated from lung resections have been shown to express higher levels of the 
inflammatory marker serum amyloid A 2 (SAA2) in comparison to controls.(300) 
Fibroblasts isolated from COPD patients also respond to cigarette smoke extract 
(CSE) in vitro in a different manner to control fibroblasts in terms of gene expression 
in the TGF-β-Smad pathway.(301) As this pathway is important in ECM repair this 
change in response may be important in destruction to the ECM seen in emphysema. 
Perhaps this response in the TGF-β-Smad pathway represents a set of patients who 
are more susceptible to damage from cigarette smoke than controls.  
Whole lung gene expression studies comparing patients with lung cancer to controls 
have also shown alteration in gene expression.(302) In addition differential gene 
expression studies have been performed on individual cell types in cancer-affected 
lung. For example, gene expression in epithelial cells from lung cancer patients 
shows alterations in chemokine signalling, cytokine receptors and cell adhesion 
pathways.(303) Pulmonary endothelial cells also show a difference in gene 
expression between tumour and normal tissue, such as matrix 
metalloproteinases.(304) 
Studies have also looked at lung gene expression in lung cancer patients with and 
without COPD. For example, Boelens et al demonstrated that tumour tissue from 
patients with COPD was more likely to show a loss of 5q or a low expression of 5q 
genes than tumour tissue from patients without COPD.(169) However, expression of 
chemokine ligand 1 (CXCL14) (305) and cathepsin inhibitor Cystatin A (CSTA) (306) 
are upregulated in both COPD and lung cancer. Mutations in genes associated with 
lung cancer also seem to vary between patients with and without COPD. For 
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example, the KRAS (KRAS proto-oncogene, GTPase) (307), EGFR (Epidermal 
growth factor receptor) and ALK (ALK receptor tyrosine kinase) (308) mutations 
occur infrequently in COPD patients. Epigenetic control of gene expression may also 
be different between lung cancer patients with and without COPD. For example, 
Tessema et al demonstrated that methylation of microtubule-associated protein 1B 
(MAP1B), a cytoskeletal protein involved in cell motility, is more prevalent in lung 
tissue and lung tumours from patients with COPD.(309) As the gene suppression is 
seen in COPD lung tissue in addition to the tumour tissue it is possible that this 
alteration in gene expression occurred prior to the development of lung cancer. 
In conclusion, there is evidence that gene expression in COPD lung is altered. Some 
changes in gene expression are also seen in lung cancer providing further evidence 
for shared pathogenesis. In a similar way to miRNA data, there have been a few 
studies investigating the gene expression in individual cell types in the lung including 
the endothelium in lung cancer. However, the expression of genes in the COPD 
endothelium has not been investigated yet. 
1.5.3 Pathway analysis of genomic data in the setting of lung cancer and COPD 
In recent years pathway analysis has become an important method for analysing 
genomic data. Microarray data produces huge lists of differentially expressed RNAs 
and it can be difficult to gain insight about underlying biology from the lists alone. 
Pathway analysis attempts to group genomic data into smaller sets of related 
RNAs.(310) Therefore, rather than thousands of individual data points, the 
researcher can evaluate several hundred groups of data which simplifies the 
investigation. Also, by grouping data into pathways rather than individual RNAs it 
allows the researcher to gain an increased understanding about how differentially 
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expressed RNAs might be important in disease processes.(311) For example, Meng 
et al used pathway analysis to explore changes in long noncoding RNAs in sinonasal 
squamous cell carcinoma and identified multiple alterations in tumourigenic 
processes.(312) 
Ingenuity pathway analysis (IPA; Qiagen) is a tool available as a web-based software 
application for this purpose. IPA studies data according to information available in the 
Ingenuity Knowledge Base, a manually curated database with data on genetic 
pathways, disease processes and pharmacology.(313) By using inbuilt algorithms 
IPA can provide the user with evidence on important biological mechanisms, 
pathways, regulators and functions relevant to the changes observed in microarray 
data. One can also predict the downstream effects of these pathways on other 
biological processes and diseases such as cancer. 
IPA has been used multiple times in current literature in the analysis of respiratory 
disease including lung cancer and COPD. For example, He et al were interested in 
the development of lung cancer related to carbon nanotubes (CNTs).(314) They 
analysed gene expression in pulmonary epithelial cells exposed to CNTs and 
investigated the role of mesothelin (MSLN), a protein involved in carcinogenesis in 
lung cancer and mesothelioma.(314) By using IPA they were able to identify that 
MSLN was likely to act by inducing cyclin E (a protein involved in the cell cycle) 
expression, which increased cell proliferation.(314) They were able to support this 
hypothesis with further in vitro work.(314) Therefore, not only was a lung cancer 
target identified (MSLN), but the biological processes relevant to disease were also 
revealed allowing the group to gain more information on the precise function of the 
protein of interest. IPA has also been used to assess the effects of external stimuli on 
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cellular processes. For example, one group performed microarrays on lung epithelial 
cells exposed to cigarette smoke to determine the effects of smoke on cellular 
function.(315) Microarrays identified differentially expressed genes after exposure to 
smoke, but by utilising IPA the group were able to identify deregulation of important 
pathways such as the transforming growth factor beta-1 (TGF-β1) pathway.(315) 
Similarly, IPA has also been used to assess the cellular response to treatment for 
disease such as hesperidin (a glycoside flavonoid with anti-cancer effects).(316) 
When NSCLC cells were exposed to hesperidin there were significant changes in 
several important functions which could explain the anti-cancer effects such as 
changes in cell-cell interaction and signalling, cell-mediated immune response and 
the inflammatory response.(316) 
IPA has also been used in the analysis of miRNAs in lung cancer. For example, 
Wang et al identified differentially expressed miRNAs in the blood of lung cancer 
patients in comparison to controls.(317) In this study expression of miR-675 was 
particularly dysregulated and Wang et al explored miR-675’s function further in 
IPA.(317) IPA demonstrated that miR-675 was important in cell death and survival 
pathways which could help explain its’ importance in the development of lung 
cancer.(317) Similarly, Ma et al looked at differences in miRNA expression in blood of 
patients with NSCLC and different epidermal growth factor receptor (EGFR) 
mutations.(318) The exon 19 deletion mutation (del19) has a favourable prognosis in 
comparison to single-point substitution mutation L858R in exon 21 (L858R).(318) The 
difference in miRNA expression seen between patients with the two different 
mutations was associated with alteration in several key pathways such as cell 
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survival, movement and proliferation which are key in the pathogenesis of lung 
cancer.(318) 
In a similar fashion to lung cancer, COPD has been investigated using IPA. For 
example, an analysis of mRNA microarrays in peripheral blood mononuclear cells 
(PBMCs) has been conducted; IPA demonstrated that important immune system and 
inflammatory response pathways were altered in COPD patients.(319) There is also 
evidence that genetic pathways may change as COPD progresses. IPA of whole 
blood gene expression in patients admitted to intensive care in comparison to those 
admitted to a medical ward suggested that many upregulated genes were involved in 
neutrophil function.(320) Interestingly, the upregulated neutrophil pathways were 
associated with an increased risk of need for advanced respiratory support and 
bacterial infection.(320) This raises the possibility that monitoring of these pathways 
could help to identify patients with COPD with a worse prognosis. Other groups have 
also used IPA as a new way to interpret old data in COPD. For example, Kaneko et 
al performed a literature search to identify genes of importance in COPD and 
uploaded them into IPA.(321) This resulted in the identification of several pathways 
increased in COPD including those related to the immune response.(321) 
Finally, IPA has also been used previously in the identification of pathways common 
to lung cancer and COPD. One study looking at protein expression in 
bronchoalveolar lavage (BAL) in patients with COPD, lung cancer or both diseases 
demonstrated that the nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) pathway is altered in both conditions.(322) NF-κB is a transcription factor 
that is important in inflammation and aberrant expression has previously been 
associated with carcinogenesis.(323, 324) 
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1.6 Isolation of Human Pulmonary Endothelial Cells (HPECs) for culture 
The isolation of human endothelial cells for culture has been in place for the past 3-4 
decades.(325, 326) Initially cells were primarily isolated by perfusing arteries and 
veins with collagenase and collecting flushed cells after digestion.(325, 326) 
However, the isolation of microvascular endothelial cells is more challenging and 
requires methods to select for these cells in order to avoid the contamination of cell 
cultures with other cells such as fibroblasts.(327-330) It has also been shown that 
endothelial cells from different organs in the body are inherently different from one 
another.(331, 332) This makes it difficult to use more easily available endothelial cell 
types like Human Umbilical Vein Endothelial Cells (HUVECs) when investigating 
markers identified in other endothelial cell isolates.(331) This prompted the 
development of techniques to isolate HPECs in the 1990s.(329, 330) Two 
publications on endothelial extraction were made around the same time: Carley et al 
and Hewett and Murray.(329, 330) Carley et al obtained lung tissue in a similar way 
to this study: by collecting tumour-free lung tissue removed at surgery for lung 
cancer.(329) The pleura was removed by scalpel (to reduce mesothelial cell 
contamination) and the tissue was minced and incubated with 0.1% collagenase for 1 
hour.(329) The digested material was filtered, resuspended in media and plated on 
1.5% gelatin coated plates.(329) After cells had been allowed to grow, the cells were 
removed from the plates and endothelial cells were selected for using fluorescent-
activated cell sorting (FACS) by identifying endothelial cells with 1,1’-dioctadecyl-
1,3,3,3’,3’-tetramethyl-indocarbocyanine perchlorate-labeled acetylated low-density 
lipoprotein (DiI-Ac-LDL).(329) Cells isolated from the FACS sorting were then plated 
and allowed to grow to confluence.(329) These cells stained weakly for von 
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Willebrand Factor (vWF), immunostained for angiotensin converting enzyme (ACE; 
known to be expressed by lung endothelium) and bound Ulex europaeus agglutinin-1 
(UEA-1, which binds to L-fucose residues on endothelial cells).(329) The cells also 
appeared to grow into tube like structures in Matrigel (a protein mixture secreted by 
Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells).(329) 
Hewett and Murray obtained tissue from an alternate source: peripheral lung tissue 
from transplant surgery.(330) The initial part of their method was very similar to 
Carley et al. The pleura was removed and the lung was minced before 
digestion.(330) However, the lung was digested at room temperature for 16-20 hours 
in dispase prior to 15 minutes at 370C in trypsin/ethylenediamine tetra-acetic acid 
(EDTA).(330) Again, the digested material was filtered and the cell solution was 
plated but on fibronectin plates.(330) After the cells reached confluence the cells 
were removed using trypsin and mixed with UEA-1-coated magnetic beads for 10 
minutes at 40C.(330) The beads were then resuspended in growth medium and 
plated on to 0.2% gelatin coated plates.(330) These cells formed characteristic 
‘cobblestone’ morphology similar to HUVECs in culture and expressed typical 
endothelial antigens such as E-selectin.(330) The cells also formed tube like 
structures in matrigel.(330) 
Due to the complex method in preparing HPECs many researchers have resorted to 
buying the cells commercially.(333-335) However, in recent years a few laboratories 
have continued to extract HPECs on site.(336-338) The methods used by these 
researchers are primarily based on the methods used by Hewett and Murray.(330) All 
of these techniques consist of mincing and digesting lung tissue prior to filtering and 
purifying with magnetic beads attached to different markers for endothelial cells such 
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as UEA-1, and CD31 (platelet and endothelial cell adhesion molecule 1).(336-338) 
Interestingly, these cells also have a cobblestone morphology and appear to 
resemble the cells from the Hewett and Murray paper more strongly than the paper 
from Carley et al.(329, 330, 336-338) One team also confirmed that this bead method 
could be used to extract HPECs from COPD tissue.(336) This, in addition to previous 
work performed in the Bicknell laboratory in the University of Birmingham for the 
isolation of HPECs for RNA work, resulted in the decision to base an extraction 
method using UEA-1 coated magnetic beads.(304) 
 
1.7 Hypotheses of this thesis 
This study was performed to investigate the possibility of shared pathogenesis 
between COPD and lung cancer in the context of the pulmonary endothelium. 
Epidemiological studies demonstrating an increased risk of lung cancer in patients 
with COPD (section 1.3) suggest common disease processes. Neutrophil 
transendothelial migration (TEM) is upregulated in COPD (section 1.4.1) and results 
in increased inflammatory cells in the lung. As inflammation is associated with cellular 
processes related to cancer such as cell proliferation (section 1.2.3) the upregulation 
of TEM in COPD could provide a mechanistic link between the two conditions.  
Upregulation of TEM could be related to the endothelial dysfunction seen in COPD 
(section 1.4.1), but the pathogenesis of endothelial dysfunction remains unclear. 
Previous studies have demonstrated that miRNA and mRNA expression is abnormal 
in pulmonary COPD and lung cancer tissue, but endothelial specific studies are 
lacking. Therefore, this study was performed to identify alterations in microRNA and 
mRNA expression in COPD and lung cancer that could help to explain the 
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endothelial dysfunction seen in these conditions and that could potentially identify 
new shared treatment targets. 
In order to investigate this hypothesis microRNA and mRNA expression was 
analysed using microarray. This method was chosen as previous studies had used 
this successfully in the context of whole lung genomic studies and in studies involving 
other pulmonary cell types. In particular this approach had been used with success 
investigating mRNA expression in pulmonary endothelial cells in lung cancer in the 
same laboratory previously.(304) An alternative method for performing this would be 
to use next generation sequencing (NGS) which has also been used to assess 
miRNA and mRNA expression in lung cancer.(339, 340) The main advantage of NGS 
is that it covers all areas of the transcriptome whereas microarray analysis uses 
probes, which provide limited coverage.(341) However, at the time of commencing 
this study there was limited access to NGS, which was also prohibitively expensive, 
and therefore the decision was made to continue with microarray analysis. 
1.8 Aims 
 
This project was undertaken to investigate new gene and miRNA targets in COPD 
and NSCLC lung tissue. 
1) Characterise the miRNA and gene expression profile of COPD and 
NSCLC tissue. 
There is evidence that gene and miRNA expression varies in lung tissue 
between normal lung and COPD and lung cancer.(269, 302) However, there is 
little data published on miRNA and gene expression in individual cell types. 
This is important as whole lung tissue gene/miRNA expression studies can 
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miss signals coming from individual cell types and it can be difficult to attribute 
results to specific cells. To address this further fresh tissue was isolated from 
non-COPD, COPD and NSCLC lung, which was used to extract macrophages 
and endothelial cells. Macrophages are inflammatory cells that phagocytose 
and kill micro-organisms. There are increased numbers present in COPD and 
they behave in an abnormal manner.(342) Endothelial cells may be of 
importance in COPD and lung cancer as inflammatory cells (such as 
neutrophils) must pass through endothelial tissue to reach the lung itself.(188) 
Due to time constraints endothelial cells only were chosen for further work. 
Endothelial cells were chosen primarily due to the lack of previous work in this 
area. The macrophage data was stored for further work.  
2) Describe biological pathways of relevance to COPD pathogenesis within 
endothelial tissue, particularly those aspects shared with lung cancer 
Gene and miRNA expression data produces huge datasets which can make 
the biological interpretation of such data difficult.(310) Therefore, to further 
interpret expression data a pathway analysis was performed using Ingenuity 
Pathway Analysis (IPA). This uses information on known molecular pathways 
to interpret expression data and to provide disease associations which allows 
the user to gain a deeper insight into their results. 
3) Isolate and culture HPECS 
Endothelial cells can vary between tissue types.(331) Consequently, it is ideal 
to investigate new endothelial targets using endothelial cells from the organ of 
interest. Thus, one aim of this thesis was to isolate and culture human 
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pulmonary endothelial cells (HPECs) for use for functional experiments to 
investigate new targets identified by the first aim. 
4) Describe the function of miR-181b-3p in human endothelial tissue 
The endothelial target that was most significantly differentially expressed 
between groups was taken forward for functional validation work. Several 
assays (such as matrigel and spheroid assays) were used to compare 
endothelial function in cells with and without an increase in expression of this 








2.1 Patient data collection 
 
2.1.1 Patient selection 
45 patients undergoing thoracic surgery between December 2013 and November 
2014 were included in the study. These patients were recruited from an existing 
tissue retrieval system: Midlands Lung Tissue Consortium (MLTC); (07/MRE08/42). 
Patients about to undergo thoracic surgery at Birmingham Heartlands Hospital (BHH) 
were consented by research staff during their pre-operative clinic appointments to 
donate excess lung tissue to research. Informed, written consent was obtained for 
each patient. An example of the consent form used is in Appendix 1. The majority of 
these patients were undergoing lobectomy or pneumonectomy for suspected lung 
cancer. However, patients were also recruited who were undergoing lung volume 
reduction surgery. 
An additional 7 patients previously recruited in the same manner (by the 
Turner/Bicknell groups between July 2011 and April 2012) were also included in the 
analysis. 
2.1.2 Clinical data 
Clinical data was collected by the thoracic surgical teams at BHH as well as the 
thoracic research nursing team. Extraction of clinical data from BHH records was 
performed solely by me. 
Baseline data including age, sex, body mass index (BMI), pack year history of 
smoking (calculated by multiplying number of cigarettes per day by number of years 
smoked and dividing by 20) and presence of chronic bronchitis was obtained from 
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the MLTC research database and computer databases at BHH. Copies of clinic and 
referral letters were available in BHH medical records. Pathological reports were 
reviewed to obtain tumour stage and type.  
CT scans were performed either at BHH or referring hospitals. The images from CT 
scans not performed at BHH were transferred electronically to the BHH computer 
system. CT scan reports (where available) and images were examined for the 
presence of emphysema.  
Lung function was performed either at BHH or referring hospitals. FEV1 was 
recorded for all patients in the research notes. Where available FVC, FEV1/FVC, 
total lung capacity (TLC), residual volume (RV), transfer factor for carbon monoxide 
(TLCO) and corrected gas transfer (KCO) were recorded using research notes and 
by contacting referring hospitals. FEV1 and FEV1/FVC values were compared to 
predicted values using standard reference equations for Caucasian adults (Appendix 
2). This was used to calculate FEV1pp (percentage predicted) for all patients.  
Patients were defined as having a diagnosis of COPD if they had a FEV1/FVC less 
than the lower limit of normal and/or presence of emphysema on the CT scan with a 
history of smoking. 




Table 2.1: Summary of information collected for each patient. 
Data collected Type Information used 
Age Clinical information Research database 
Sex Clinical information Research database 
Body mass index (BMI) Clinical information Research database 
Pack year history of 
smoking 
Clinical information Research database/clinic 
letters 
Chronic bronchitis Clinical information Clinic letters 
Tumour stage Pathology Pathology reports 
Tumour type Pathology Pathology reports 
Presence of emphysema Radiological CT reports/images 
FEV1pp Lung function Computer databases and 
reference equations. 
FEV1/FVC Lung function Computer databases and 
reference equations. 
 
Clinical information for each patient was collected using multiple sources including 
the research database at BHH, computer records, clinic letters and pathology 
reports. Collected information for each patient was stored anonymously in a spread 
sheet format. FEV1pp = Forced expiratory volume in one second percentage 

















2.2 Statistical analysis of clinical data 
All statistical analysis was performed using IBM SPSS statistics version 22 (SPSS 
Inc, Chicago, USA). Patients with and without COPD were compared according to: 
age, sex, body mass index (BMI), smoking status, pack year history, FEV1pp and 
tumour stage. The Shapiro-Wilk test was used to determine the normality of each 
variable. Normally distributed variables are displayed as mean and standard error 
(SE). Non-parametric variables are displayed as median and interquartile range 
(IQR). Variables that were normally distributed were compared using t-tests. 
Variables not normally distributed were compared using the Mann-Whitney-U test. 
Categorical variables were compared using Chi-squared or Fisher’s exact tests 
depending on the number of patients in each group. Variables were determined as 
being statistically significantly different from one another using the cut off of p<0.05. 
Where experiments included different numbers of patients from the overall cohort, 
the above statistical analysis was repeated for each individual experiment. 
2.3 Collection of lung tissue 
Lung tissue was excised by surgical staff at BHH and kept in 0.9% saline. The rest of 
the lung tissue was transferred to pathology at BHH where it was examined by a 
pathologist. Where enough tissue was available tumour tissue was also taken and 
kept in 0.9% saline. Tissue samples were kept on ice and transferred to the 
University of Birmingham laboratories for further processing on the same day. 
2.3.1 Extraction of macrophages 
1 l of 0.9% saline was attached to a giving set and placed into a pressure bag. The 
giving set was connected to the needle from the inside of a 16 G cannula (after 
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removing the safety device with forceps). The lung sample was washed with saline 
by holding the sample with forceps and placing the needle into the lung tissue. The 
wash was collected into a bottle using a funnel. The lung was washed until the wash 
became clear. The wash was known as a bronchoalveolar lavage (BAL). The BAL 
was placed into 50 ml falcon tubes (as many as required to hold all of the BAL) and 
centrifuged at 40 g for 5 minutes to pellet the cells. The supernatants were removed 
and the cell pellets were collected to create a cell solution. 20 ml of cell solution was 
required. If necessary supernatant was used to make the cell solution up to 20 ml. If 
more than 20 ml of cell solution was collected this was placed into a second falcon 
tube. 12 ml of lymphoprep (Axis-Shield; 1114545) was added to a new falcon tube 
and 20 ml cell solution was overlaid onto the lymphoprep slowly using a pipette. This 
mixture was centrifuged at 100 g, acceleration 1, brake 0, temperature 200C for 30 
minutes. The interlayer was aspirated using a Pasteur pipette and placed into a new 
falcon tube. The volume of cell solution was made up to 50 ml with Dulbecco's 
Phosphate-buffered saline (DPBS); (Life Technologies (Gibco) 14190-094). This was 
centrifuged at 50 g for 10 minutes. The supernatant was discarded and the cells were 
resuspended in 30 ml DPBS. This was then centrifuged at 50 g for 5 minutes. The 
supernatant was discarded and the cells were resuspended in 10 ml DPBS. The cell 
solution was centrifuged at 50 g for 5 minutes and the supernatant was discarded. 
The cells were resuspended in 700 µl Trizol (Sigma TRI Reagent (Trizol); T9424) in 
an Eppendorf tube and stored at -800C. This method has previously been validated 




Figure 2.1: Extraction of endothelial cells for future RNA work. A fresh lung sample is 
minced before being added to collagenase V for digestion. The digested sample is 
passed through a filter before being combined with ulex coated magnetic beads. The 
beads bind to endothelial cells before a magnet is used to isolate the beads from the 









2.3.2 Extraction of endothelium 
This method is summarized in figure 2.1. The lung tissue was divided into samples of 
approximately 3 cm in length. Larger pieces of lung are not digested as easily and 
produce a lower yield of endothelium. 25 mg collagenase (Collagenase type V; 
(C9263 Sigma-Aldrich, UK): 25 mg/ml in DMEM (41966-029 Life Technologies 
(Gibco)), 1 ml aliquots at -20oC) and 75 µl actinomycin (Actinomycin D; (A4262 
Sigma-Aldrich, UK): 1 mg/ml in DMSO (Dimethyl sulfoxide; Sigma Aldrich; D2650); 
75 µl aliquots at -200C) were defrosted in a dry bath. 12.5 ml DMEM was added to a 
falcon tube. 25 mg of collagenase was added to the DMEM and vortexed to mix in 
fully. Finally, 75 µl actinomycin and 20 µl DNAse solution (RNase-Free DNAse Set; 
(79254 Qiagen)) were added to create ‘digestion solution’. One piece of lung was 
then added to 7.5 ml digestion solution, cut into fine pieces on a 10 mm plate and 
transferred to a falcon tube. 5 ml of digestion solution was used to wash the plate to 
obtain any remnants of tissue and this was transferred to the same falcon tube. The 
lung was then digested by placing the solution into a 370C shaker for 1 hour. This 
was repeated for each 3 cm of lung tissue. 
The following steps were repeated for each piece of lung. Streptavidin Dynabeads 
(Life Technologies (Invitrogen) M-280) were vortexed to resuspend them. For each 
sample 50 µl of beads was used for the first 1 g of tissue and 25 µl for each gram 
thereafter. Prior to use it is necessary to wash the beads with DPBS which is done 
using a magnet. The beads were placed into a falcon tube and the bead solution was 
made up to 500 µl with DPBS (Life Technologies (Gibco) 14190-094). The falcon 
tube containing the beads was placed into a magnet and inverted. The solution in the 
tube was removed before removing the falcon tube from the magnet. 500 µl of DPBS 
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was added to the beads and they were placed into the magnet again before the 
DPBS was removed as previously. The beads were resuspended in 250 µl of DPBS. 
Distilled water was added to Lectin from Ulex Europaeus (gorse, furze) (L8262 
Sigma) to form a solution of 1 mg/ml. 12.5 µl of ulex solution was added to the beads 
and the tube was shaken to mix the beads with ulex. The bead solution was then 
placed into a 370C shaker for 30 minutes in order to bind the ulex to the beads. 
Following digestion the lung solution was filtered through a 100 µm filter (VWR 
International; 734-0004) before being passed through a similar 70 µm filter (VWR 
International; 734-0003). The lung solution was then centrifuged at 200 g for 5 
minutes to pellet the cells. The supernatant was removed without disturbing the cell 
pellet and placed into a second falcon tube in order to prevent loss of cells. The cell 
pellet was resuspended in 5 ml DPBS and both the cell solution and supernatant 
were centrifuged again at 200 g for 5 minutes prior to removal of supernatants from 
both tubes, which were then discarded. The two cell pellets were combined in 250 µl 
of DPBS in an Eppendorf tube. The bead solution was then added and the resultant 
mixture blended on a wheel in a cold room for 30 minutes. 
After mixing, the cell solution was transferred into a falcon tube labelled as 
‘endothelial cells’, which was placed into a magnet and inverted. The solution was 
removed whilst the tube remained in the magnet and placed into another falcon tube 
labelled ‘lung bulk’. The ‘endothelial cells’ tube was then removed from the magnet 
and beads resuspended in 500 µl of DPBS. The ‘endothelial cells’ tube was placed 
into the magnet again and the process was repeated until the solution removed was 
clear. The ‘lung bulk’ tube was centrifuged at 200 g for 5 minutes to pellet the cells, 
prior to removal of supernatant and resuspension of the undisturbed cell pellets in  
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Figure 2.2: RNA extraction using the Qiagen miRNeasy kit. Chloroform is added to 
cell samples stored in Trizol and shaken. This is then centrifuged to separate the 
sample into 3 phases. The RNA-rich (aqueous phase) is extracted and combined 
with ethanol to bind the RNA. The sample is washed with a series of buffers before 









700 µl Trizol (Sigma TRI Reagent (Trizol); T9424). The beads were also 
resuspended in 700 µl Trizol and stored separately at -800C.  
The entire method was repeated with tumour tissue to obtain tumour endothelium 
where available. 
2.4 Preparation of samples for microarray analysis 
 
2.4.1 RNA Extraction 
This method is summarized in figure 2.2. RNA extraction was done using 
commercially available kits: Qiagen miRNeasy Mini Kit (217004) and the Qiagen 
RNase-Free DNase Set (79254). The kits include all the reagents and sample tubes 
required for RNA extraction. Prior to each extraction the bench was cleared and 
wiped with RNAseZap (ThermoFisher Scientific; AM9780) to limit RNAase exposure. 
All equipment was also wiped with RNAseZap. Only RNAse and DNAse free filter tips 
were used for the extraction.  
Cell samples stored in Trizol were defrosted and vortexed for 1 minute. Samples 
were then placed on to the bench top at room temperature for 5 minutes. During this 
time the centrifuge was pre-cooled to 40C. 140 µl chloroform (Sigma Chloroform 
minimum 99%; C2432) was added to each sample which was then shaken for 15 
seconds. Each sample was then placed on the bench top for 2 minutes prior to 
centrifugation for 15 minutes at 12000 g and 40C. This separates the sample into 3 
phases: an upper, colourless phase containing RNA, a white interphase and a lower, 
red phase containing other organic material. For each sample the upper aqueous 
phase was transferred into 100 µl aliquots into a collection tube. 1.5 volumes of 
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100% ethanol (Sigma; E7023) was added to the aqueous phase before being directly 
transferred on to the RNeasy Mini spin column in one 2 ml collection tube. This was 
centrifuged at 8000 g for 15 seconds at room temperature. Flow-through was 
discarded, and 350 µl Buffer RWT was added to the spin column followed by 
centrifugation at 8000 g for 5 minutes. The flow-through was again discarded. 10 µl 
DNase I stock solution was added to 70 µl Buffer RDD (from the Qiagen RNase-Free 
DNase Set) and was mixed by gently inverting. The DNase I incubation mix was 
pipetted directly on to the spin column and placed on to the bench top for 15 minutes. 
It is important to pipette the incubation mix directly on to the spin column membrane 
to avoid the mix sticking to the column wall resulting in incomplete DNase digestion. 
350 µl Buffer RWT was then pipetted to the spin column and centrifuged for 15 
seconds at 8000 g and the flow-through was discarded. 500 µl of Buffer RPE was 
added to the spin column and centrifuged for 15 seconds at 8000 g and the flow 
through was discarded. Another 500 µl of Buffer RPE was added to the spin column 
and centrifuged for 2 minutes at 8000 g to dry the column membrane and to remove 
residual ethanol. The spin column was then transferred to a new collection tube and 
centrifuged at full speed for 1 minute to eliminate any possible carryover of Buffer 
RPE. The spin column was transferred to a new 1.5 ml collection tube and 30 µl of 
RNAse-free water was pipetted directly on to the spin column membrane. The 
column was then centrifuged at 8000 g for 1 minute. The eludate was then pipetted 
back on to the spin column which was centrifuged again at 8000 g for 1 minute. This 
acts to increase the final concentration of the RNA solution. 
The concentration of each RNA sample was checked using a nanodrop 
(ThermoFisher Scientific Nanodrop 2000/2000c spectrophotometer). Prior to use the 
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nanodrop was cleaned and 1 µl RNAse-free water was used to blank set the 
nanodrop on the RNA setting. 1 µl of each sample was then added to the nanodrop 
to determine its’ concentration in ng/µl. RNA samples were frozen at -800C until they 
were required.  
2.4.2 Quality control of RNA prior to microarray analysis  
RNA samples with concentrations > 5 ng/µl were analysed by a core University 
service within Biosciences for their RNA Integrity Number (RIN).  The RIN is 
calculated using the traces from electrophoresis of RNA, which are analysed using 
the Agilent 2100 Expert software to generate the RIN. RIN is a number in the range 
1-10. 1 represents completely degraded RNA and 10 represents an intact RNA 
sample.(344) Samples with RIN>5 were included in the microarray analyses. An 
example of electrophoresis and an individual sample trace is presented in figure 2.3. 
2.4.3 Labelling RNA for mRNA microarray analysis  
This was performed according to instructions in the Agilent One-Color Microarray-
Based Gene Expression Analysis: Low Input Quick Amp Labeling protocol. 25 ng of 
RNA was used for each reaction. The amount of RNA solution containing 25 ng of 
RNA was transferred to a 1.5 ml microcentrifuge tube and the volume increased to 
2.5 µl with RNAse free water. 2 µl of Spike mix (Agilent One-Color RNA Spike-in Kit; 
5188-5282) was then added to each tube. Labelling was performed using Agilent 
Low-Input Quick Amp Labeling Kit, One-Color (5190-2305), which contains the 
required consumables. 0.8 µl of T7 Primer was added to 1 µl of nuclease-free water 
for each sample. The T7 Primer mix was added to the RNA sample prior to 






Figure 2.3: Quality control of extracted RNA. A: An example of electrophoresis of 10 
RNA samples (and control). Intact RNA is visualised by sharp bands at 4000 and 
2000 representing 28S and 18S rRNA bands respectively. B: An individual trace of a 
good quality RNA sample with RIN of 8.3 
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The 5x First Strand Buffer was warmed at 800C for 3 minutes and was vortexed to 
ensure resuspension. The cDNA master mix was prepared by adding 2 µl 5x First 
Strand Buffer, 1 µl 0.1 M DTT, 0.5 µl mM dNTP Mix and 1.2 µl Affinity Script RNase 
Block Mix per reaction. Each RNA sample was briefly spun in a microcentrifuge 
before 4.7 µl of cDNA master mix was added. This was then incubated at 400C for 2 
hours and 700C for 15 minutes. The samples were then incubated on ice for 5 
minutes. A Transcription master mix was created by mixing the following: 0.75 µl 
nuclease-free water, 3.2 µl 5x Transcription buffer, 0.6 µl 0.1 M DTT, 1 µl NTP Mix, 
0.21 µl T7 RNA Polymerase Blend and 0.24 µl Cyanine 3-CTP. 6 µl of Transcription 
Master Mix was added to each sample before incubating the samples at 400C for 2 
hours. 
The next step involved using the Qiagen RNeasy Mini Kit (74104) to purify the cRNA 
samples. 84 µl of nuclease-free water was added to the cRNA sample. 350 µl of 
Buffer RLT was then added to the sample and mixed using a pipette. 250 µl of 
ethanol was added to the mix, which was then transferred to an RNeasy Mini Spin 
Column in a 2 ml collection tube. The sample was spun in a centrifuge at 40C for 30 
seconds at 10 000 g, flow-through was discarded and 500 µl of Buffer RPE was 
added to the column. This was centrifuged at 40C for 1 minute at 10 000 g. The 
collection tube was discarded and the spin column was transferred to a new 
collection tube (1.5 ml) for centrifugation at 40C for 30 seconds at 10 000 g. The 
collection tube was discarded and replaced with a new collection tube (1.5 ml). 30 µl 
of RNase free water was added directly onto the spin column filter membrane. After 1 
minute the sample was centrifuged at 40C for 30 seconds at 10 000 g. The resultant 
cRNA sample was kept on ice. 
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After purification the sample was measured using a nanodrop with the Microarray 
Measurement setting (ThermoFisher Scientific Nanodrop 2000/2000c 
spectrophotometer). The nanodrop was cleaned prior to use and blank set with 
nuclease free water. RNA-40 was selected as the sample type. 1 µl of each sample 
was loaded on to the nanodrop. The following values were recorded: Cyanine 3 dye 
concentration (pmol/µl), RNA absorbance ratio (260nm/280nm) and cRNA 
concentration (ng/µl). These values were used to determine the yield and specific 
activity of each sample using the equations below: 
YIELD:  (Concentration of cRNA) x 30µl (elution volume) = µg of cRNA 
1000 
 
SPECIFIC ACTIVITY: Concentration of Cy3     x 1000 = pmol Cy3 per µg cRNA 
Concentration of cRNA 
 
Only results with a yield >0.825 and a specific activity > 6 were sent for microarray 
analysis. 
2.4.4 Hybridsiation of mRNA for microarray 
This was performed by me, under supervision, in the Biosciences department at the 
University of Birmingham according to instructions in the Agilent One-Color 
Microarray-Based Gene Expression Analysis: Low Input Quick Amp Labeling 
protocol. 
Initally hybridization was performed using the Agilent Gene Expression Hybridization 
Kit (5188-5242). The following was mixed in a 1.5 ml nuclease-free microfuge tube: 
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600 ng labelled cRNA, 5 µl 10x Gene Expression Blocking Agent, 1 µl 25x 
fragmentation buffer and nuclease-free water to bring the total volume to 25 µl. This 
mix was incubated at 600C for 30 minutes to fragment the RNA. Immediately after 
this the mixture was cooled on ice for one minute and 25 µl of 2x Hi-RPM 
Hybridization Buffer was added to stop the fragmentation reaction. The mixture was 
then centrifuged at 10 000 g for one minute to reduce bubble formation and was 
stored on ice. 
A clean gasket (Agilent Hybridization Gasket slide kit; G2534-60014) was loaded into 
an Agilent SureHyb chamber base. The gasket was then loaded horizontally with 8 
hybridized samples as in figure 2.4. 40 µl of sample was loaded into each well. An 
Agilent slide (SurePrint G3 Unrestricted GE 8X60K; G4858A) was placed active side 
down parallel to the gasket slide so that the ‘Agilent’ barcode faced down. The 
SureHyb chamber cover was clamped over the slides and hand-tightened. The 
chamber was rotated vertically to ensure that the bubbles in the slides were mobile 
(figure 2.5). 
The chamber was then loaded into a hybridization chamber at 650C for 17 hours. 
During this time the Gene Expression Wash Buffer 2 (Agilent Gene Expression Wash 






Figure 2.4: Diagram of a loaded Agilent gasket. Eight hybridized RNA samples were 
loaded into the gasket horizontally. The gasket is read and the results are printed in 
the order above. 
 
Figure 2.5: Magnified view of a RNA sample loaded into a gasket. The bubble seen 
should be freely mobile so that the sample can move freely within the gasket and 






After hybridization the array-gasket was removed and placed into Gene Expression 
Wash Buffer 1 (Agilent Gene Expression Wash Pack; 5188-5327). Whilst the array-
gasket was submerged the array was separated from the gasket using forceps. The 
slide was removed from the wash buffer and placed into a slide rack also submerged 
in Gene Expression Wash Buffer 1, which was stirred with a magnetic stirrer for one 
minute. The slide rack was then removed and submerged into another dish 
containing Gene Expression Wash Buffer 2. This was stirred using a magnetic stirrer 
for one minute. The slide rack was removed slowly (over 5-10 seconds) from the 
wash buffer. The dry slide was then uploaded into a microarray scanner. 
2.5 Microarray Analysis 
 
All microarray analysis (other than Ingenuity Pathway Analysis) was performed using 
packages within the computer software R. R is available as a free to download 
software online (https://cran.r-project.org/mirrors.html) and is both a language and an 
environment for statistical computing and graphics.(345) 
2.5.1 Quality analysis of microarray results 
The Bioconductor package arrayqualitymetrics was used in R to determine the 
quality of each sample in the microarray experiments. Bioconductor is an online 
provider of freely accessible software for bioinformatics. It provides tools, which use 
the R software for the analysis of genomic data such as microarrays. (346) 
Arrayqualitymetrics produces a file containing information about the quality of each 
sample included in a microarray experiment. Results appear in the user’s current 
working directory and a summary can be viewed in the HTML page “index.html”. 
Arrayqualitymetrics highlights samples that are outliers according to 4 criteria: 
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distances between arrays, array intensity distributions, variance of arrays and array 
quality.(347) All text files (results) for each sample in each microarray experiment 
were saved together with a summary file (“targets.txt”) in the same folder. This 
consisted of the name of each sample text file and whether or not that sample was 
from a patient with or without COPD. An example of a typical “targets.txt” file is 
shown in figure 2.6.  
To process array data in arrayqualitymetrics it is necessary to create an object 
consisting of the data called an ExpressionSet. This was done by processing the 
data initially using the programme limma (Linear Models for Microarray Data). Limma 
is a package designed for the analysis of gene expression microarray data and can 
be used to assess differential gene expression. It uses linear models to assess gene 
expression in multifactor experiments and borrows information across genes to 
provide a stable analysis for small sample sizes.(348) R was opened on the desktop 
and the Bioconductor package limma was installed using the following commands: 
source("https://bioconductor.org/biocLite.R") 
biocLite("limma") 
Limma was opened using the command: Library(limma). The working directory was 
set using setwd(“~/Desktop/wheremyfilesare”). The “targets.txt” file was read into 
limma (targets <- readTargets("targets.txt")) which was used to upload the data into 
an RGList object called x (x <- read.maimages(targets, path=".", 
source="agilent",green.only=TRUE)). To correct for background the background 
signal was then subtracted from the signal from each array (y <- 
backgroundCorrect(x, method="normexp", offset=16)). Array data was normalised 
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between arrays (y <- normalizeBetweenArrays(y, method="quantile")) and replicate 
spots were averaged (y.ave <- avereps(y, ID=y$genes$ProbeName)). This resulted 
in the production of an Elist object (y.ave). In order to upload this information into 
arrayqualitymetrics y.ave needed to be converted into an ExpressionSet. This was 
done using the R package Biobase. This is part of the Bioconductor project and is 
used in different packages to convert data into the ExpressionSet format.(349) 
Biobase was installed into R using the following commands: 
source("https://bioconductor.org/biocLite.R") 
biocLite("Biobase") 
Biobase was opened using the command: library(Biobase). The Elist object y.ave 
was converted into an ExpressionSet using “eset <- ExpressionSet(assayData = 
assayDataNew(exprs = y.ave$E))”.  Arrayqualitymetrics was installed into R using 
the following commands: 
source("https://bioconductor.org/biocLite.R") 
biocLite("arrayQualityMetrics") 
Once arrayqualitymetrics was opened using “library(arrayQualityMetrics)” the 
ExpressionSet (eset) was run through arrayqualitymetrics using the following 
command: arrayQualityMetrics(expressionset = eset, outdir = "Report_for_eset", 
force = TRUE). A report (Report_for_eset) was formed in the current working 
directory. The file “index.html” in this report was reviewed and samples that were 
outliers in terms of quality control were excluded from further analysis. An example of 
a poor quality sample is seen in figure 2.7. 
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SampleNumber              FileName          Condition 
1                               copd1 true.txt  copd 
2                               copd2 true.txt  copd 
3                               copd3 true.txt  copd 
4                               normal1 true.txt  normal 
5                               normal2 true.txt  normal 
6                            normal3 true.txt  normal 
 
Figure 2.6: A “targets.txt” file used in arrayqualitymetrics. This is a file created in the 
program ‘notepad’ which numbers all samples within the microarray experiment and 

























Figure 2.7: Output from arrayqualitymetrics. This demonstrates that microarray 
sample 5 is an outlier in comparison to other microarrays performed based upon two 
criteria. A: Individual array quality plot. Samples of good quality concentrate around 0 
on the axis. Sample 5’s intensity is spread out around the axis. B: Principle 
components analysis looking at distance between arrays. Sample 5 is far away from 







2.5.2 Assessment of differential gene expression using Limma  
The text files for samples that passed the quality control in each microarray 
experiment were saved in a folder on the computer desktop. A summary file called 
“targets.txt” was created in the same folder consisting of the name of each sample 
text file and whether or not that sample was from a patient with or without COPD (as 
in figure 2.6). 
R was opened on the desktop and the Bioconductor package limma was installed 
using the following commands: 
source("https://bioconductor.org/biocLite.R") 
biocLite("limma") 
Limma was opened using the command: Library(limma). The working directory was 
set using setwd(“~/Desktop/wheremyfilesare”). The “targets.txt” file was read into 
limma (targets <- readTargets("targets.txt")) which was used to upload the data into 
an RGList object called RG (RG <- read.maimages(targets, path=".", columns = list(G 
= "gMedianSignal", Gb = "gBGMedianSignal", R = "gProcessedSignal",Rb = 
"gIsPosAndSignif"), annotation = c("Row", "Col","FeatureNum", 
"ControlType","ProbeName")). To correct for background the background signal was 
then subtracted from the signal from each array (RG <- backgroundCorrect(RG, 
method="normexp", offset=16)). Array data was normalised between arrays (RG$G 
<- normalizeBetweenArrays(RG$G, method="quantile")) and green channel intensity 
values were log2 transformed (RG$G <- log2(RG$G)). The RGList object was 
converted into a MAList object for further manipulation: E <- new("MAList", 
list(targets=RG$targets, genes=RG$genes,source=RG$source, M=RG$Gb, 
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A=RG$G)). Replicate spots in the array data were averaged using: E.avg <- 
avereps(E, ID=E$genes$ProbeName). A design matrix was created for the linear 
modelling function in three steps: 
f <- factor(targets$Condition, levels = unique(targets$Condition)) 
design <- model.matrix(~0 + f) 
colnames(design) <- levels(f) 
The intensity values were applied to lmfit which fits the linear model for each gene (fit 
<- lmFit(E.avg$A, design)). A contrast matrix was set up to compare the two test 
groups (COPD and non-COPD): contrast.matrix <- makeContrasts("copd-normal", 
levels=design). The matrix was applied to the modelled data and the statistics for the 
data were computed: fit2 <- contrasts.fit(fit, contrast.matrix). This data was then 
outputted into the current working directory as follows:  
output <- topTable(fit2, adjust="BH", coef="copd-normal", genelist=E.avg$genes, 
number=1000000) 
write.table(output, file="Treatment1_vs_Treatment2.txt", sep="\t", quote=FALSE) 
This produced the text file “Treatment1_vs_Treatment2.txt” which was copied and 
pasted into an excel file for further analysis. The appearance of the 
“Treatment1_vs_Treatment2.txt” file can be seen in table 2.2. To obtain the gene 
name for each probe in the limma output file the function VLOOKUP was used 
comparing the list of probe names to a reference list of probes and gene names from 
agilent which was available to download online.(350) 
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Table 2.2: Output from limma. 
Probe Row Col FeatureNum ControlType ProbeName logFC AveExpr t P.Value adj.P.Val B 




5.68436 0.000299 0.94705 
-
4.42954 








Each probe from the microarray experiment is listed in the first column. The other columns show the rest of the data extracted 
from limma. The logFC column gives the value of the contrast between the two patient groups. The AveExpr column is the 
average expression of the probe across all the arrays and channels in the experiment. P value lists whether or not the 
expression was significantly different between groups. Adj p val gives the p value adjusted for significance testing. 
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2.5.3 Assessment of false discovery rate (FDR) 
The package LBE was used to determine the false discovery rate (FDR) values for 
the differential miRNA and gene expression analyses.(351) FDR adjusts the test for 
significance to control for the expected proportion of incorrect rejections of null 
hypotheses in multiple tests.(352) 
The p values from a limma output were copied and pasted into a text file 
(“pvalues.txt”) in a folder on the Desktop. R was opened on the Desktop and LBE 
was installed into R using the following commands: 
source("https://bioconductor.org/biocLite.R") 
biocLite("LBE") 
LBE was opened in R (Library(LBE)) and the working directory was set to the folder 
containing “pvalues.txt”: setwd(“~/Desktop/wheremyfileis”). The p value data was 
read into R (pvalues = read.table(“pvalues.txt”)) and the table was converted into a 
vector (unlist(pvalues, use.names = FALSE)). The LBE function was used to 
calculate the FDR based upon the p value data: LBE.res <- LBE(pvalues [[1]], a = 
NA, l = 0.05, ci.level = 0.95, qvalues = TRUE, plot.type = "none", FDR.level = 0.05, 
n.significant = NA). A text file of the results was created using the function: 
LBEwrite(LBE.res). This appeared in the current working directory and was copied 






2.5.4 Assessment of differential gene expression using Significance 
Analysis of Microarrays (SAM) 
SAM is a statistical technique that finds genes that are significantly differentially 
expressed between groups in microarray experiments.(353) SAM calculates a 
statistic for each gene (d statistic) that measures the relationship between the 
expression of that gene and the different groups. SAM is installed via R using the 
following commands: 
install.packages(c("samr", "matrixStats", "GSA", "shiny", "shinyFiles", "openxlsx")) 
source("http://bioconductor.org/biocLite.R") 
biocLite("impute") 





This brings up a browser window with a user interface in which it is possible to 
upload data. 
For each array experiment the text files from samples passing the quality control 
analysis were opened and saved as excel files. The function VLOOKUP was used to 
extract the probe ID, gene ID and ‘gProcessedsignal’ (microarray signal) from each 
individual excel file (using Feature number as the control). Samples from patients 
without COPD were labelled as group 1 and those with COPD as group 2. This was 




Table 2.3: Example of a SAM input file. 
    1 1 2 2 
GE_BrightCorner GE_BrightCorner 26160.82 24726.47 14630.95 24073.52 
DarkCorner DarkCorner 3.104816 3.44231 3.483712 2.878703 
DarkCorner DarkCorner 3.115946 3.405396 3.470299 38.07094 
 
The first and second columns contain probe and gene names. The other columns 
contain the gProcessedsignal for each sample. ‘gProcessedsignal’ is the intensity 
with which each probe was recorded in the microarray. Samples are labelled into the 
two test groups (non-COPD (1) and COPD (2)). 
 
 
Figure 2.8: An example SAM plot. This is a graphical representation of the statistics 
for each probe recorded in a microarray analysis. Probes that are upregulated in 





The SAM input file was uploaded into the browser interface and results were limited 
to fold change 2. Fold change 2 was chosen as this represents a large biologically 
significant difference in expression between groups and has been previously used in 
other microarray studies.(354) SAM was run and an excel results file was produced 
containing a list of significant results and a plot of the statistics for each gene (figure 
2.8). To obtain the gene name for each probe in the SAM output file the function 
VLOOKUP was used comparing the list of probe names to a reference list of probes 
and gene names from agilent which was available to download online.(350) 
2.5.5 Ingenuity Pathway Analysis (IPA) 
The data used for the IPA was drawn from the results of the SAM analysis performed 
in sections 3.3.2 (miRNA) and 3.4.2 (mRNA). Data was split into 4 different analyses 
according to the date that each microarray was performed. Data could not be directly 
combined owing to inherent significant differences between datasets most likely as a 
result of a variation in dye fluorescence between arrays. The results of the microarray 
analyses were limited to fold change 2 in order to restrict the IPA to only those genes 
with a significantly different expression between non-COPD and COPD. Therefore, 4 
datasets were run through IPA: 
x 2014 miRNA microarray data limited to probes significantly differentially 
expressed in 2015. 
x 2015 miRNA microarray data limited to probes significantly differentially 
expressed in 2014. 




x 2016 mRNA microarray data limited to probes significantly differentially expressed 
in 2014. 
Each array result was uploaded into IPA separately and a core analysis was 
performed. The core analysis compares the results of a microarray to existing 
knowledge in the Ingenuity Knowledge Base. This is a manually curated database 
consisting of millions of findings drawn from peer reviewed literature, public 
databases (such as miRBase) and experimental datasets.(355) Therefore, 
microarray results are compared to known relationships identified from multiple tissue 
types and disease processes. Significantly altered pathways are identified and 
Ingenuity places these into groups of related pathways (diseases and biological 
functions). For example, all pathways associated with cancer. The groups with the 
most significantly altered pathways are flagged up in the IPA. This process is outlined 
in figure 2.9. This can identify networks and pathways not previously identified in the 
tissue under study. Thus, a range of diseases and associations may be significant in 
the IPA including diseases not in the tissue of interest. This requires the researcher 
to examine whether or not these associations may have biological relevance.  
IPA uses two main statistical methods to determine statistical significance of 
pathways under study: 
1. P-value of overlap. This is used for all types of analysis in the IPA. The null 
hypothesis is that there is no overlap between the molecules in an array 
dataset and a particular known disease or pathway. Right tailed Fisher’s exact 
tests are used and the significance is set at p<0.05. 
2. Z-score. This is used when determining the downstream effects of microarray 
data on certain processes and performs a correlation between what is known 
 
 94 
and the researcher’s data. A z-score > 2 predicts activation of a pathway and 
< 2 predicts inhibition.(355) 
The results of the core analyses were reviewed and significantly altered pathways 
were identified for each subset. Firstly, a summary file was created which outlines the 
top canonical pathways, predicted upstream regulators, associated diseases, 
molecular pathways and biological networks associated with the microarray dataset. 
Each pathway analysis was opened in IPA and explored further. For example, 
significantly up- and down-regulated canonical pathways were opened in IPA. Where 
possible, IPA was used to predict the downstream effect of the microarray changes 
on effector molecules and disease processes. An example of how IPA was used to 
predict downstream biological effects is shown in figure 2.10. 
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Figure 2.9: The process by which Ingenuity identifies significant associations with diseases and biological functions. 
Microarray data is compared to known cellular processes in the Ingenuity knowledge base and significantly altered (p<0.05) 















Figure 2.10: Example of a canonical pathway significantly altered in a microarray analysis. Molecules highlighted in magenta 
were measured in the microarray analysis. Molecules in red or pink were upregulated in the analysis and molecules in green 




2.6 Reverse transcription 
2.6.1 Reverse transcription of RNA to cDNA for RNA samples of 
concentration >300 ng/µl 
This method uses the Applied Biosystems High Capacity RNA-to-cDNA kit 
(4387406). This kit can be used for the conversion of 20 ng-2 µg RNA to cDNA. The 
kit consists of a buffer and an enzyme mix, which were initially thawed on ice. A 50 µl 
stock solution of RNA was created for each sample by diluting RNA to a 
concentration of 111 ng/µl. A multi-mix of buffer and enzyme was created by adding 
10 µl 2X RT Buffer to 1 µl 20X RT Enzyme Mix per sample. 9 µl of RNA stock 
solution was added to 11 µl multi-mix to create 20 µl of reaction mix which was 
placed into a PCR tube. The tubes were then centrifuged at 1000 g for 1 minute to 
spin down the contents and to eliminate air bubbles. 
The thermal cycler (TC-PLUS; Techne) was run for 60 minutes at 370C, 5 minutes at 
950C then 100C continuously. Samples were removed from the thermal cycler and 
stored at -150C to -250C. 
2.6.2 Reverse transcription of RNA to cDNA for RNA samples of 
concentration <300 ng/µl 
This method uses the Invitrogen SuperScript IV VILO Master Mix (11756050). The kit 
is able to convert 10 pg-25 µg RNA to cDNA. 35 µl of RNA stock solution was 
created for each RNA sample by diluting RNA with nuclease free water to a 
concentration of 1 ng/µl. 5 µl of stock solution was combined with 4 µl of SuperScript 
IV VILO Master Mix and 11 µl of nuclease-free water to create a 20 µl reaction mix 
which was placed into a PCR tube. The tubes were then centrifuged at 1000 g for 1 
minute to spin down the contents and to eliminate air bubbles. The thermal cycler 
(TC-PLUS; Techne) was run for 10 minutes at 250C, 20 minutes at 500C, 5 minutes 
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at 850C then 100C continuously. Samples were removed from the thermal cycler and 
stored at -150C to -250C. 
2.6.3 Reverse transcription of miRNA 
This method uses the TaqMan MicroRNA Reverse Transcription Kit (Applied 
Biosystems; 4366595). The kit components were initially thawed on ice. A Reverse 
Transcription master mix was created by mixing 0.15 µl 100 mM dNTPs, 1 µl 
MultiScribe Reverse Transcriptase (50 U/µl), 1.5 µl 10X Reverse Transcription Buffer, 
0.19 µl RNase Inhibitor (20 U/µl) and 4.16 µl of nuclease-free water per sample. The 
master mix was mixed gently and centrifuged at 1000 g for 1 minute. The master mix 
was then kept on ice. 30 µl of RNA stock solution was created for each RNA sample 
by diluting RNA with nuclease free water to a concentration of 1 ng/µl. 5 µl of RNA 
stock solution was combined with 7 µl of master mix in a 0.2 ml reaction tube, was 
mixed gently, centrifuged at 1000 g for 1 minute and kept on ice. The 5X RT primer 
was thawed on ice prior to vortexing and centrifugation at 1000 g for 1 minute. 3 µl of 
5X RT primer was added to the RNA/master mix solution. This was mixed by gently 
inverting prior to centrifugation at 1000 g for 1 minute. The final solution was kept on 
ice for at least five minutes prior to loading the thermal cycler. The thermal cycler 
(TC-PLUS; Techne) was run for 30 minutes at 160C, 30 minutes at 420C, 5 minutes 
at 850C before being held at 100C. The cDNA was stored at -150C to -250C. 
2.7 Real-time Polymerase chain reaction (qPCR) 
2.7.1 qPCR of mRNA 
This was performed using the Universal Probe Library for qPCR (Roche; 
04683633001). This consists of 90 hydrolysis probes that can be used with 
appropriate primers for qPCR. The mRNA of interest was initially searched for on the 
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Roche Universal Probe Library website.(356) This gave the correct probe to use as 
well as sequences for the forward and reverse primer. The forward and reverse 
primer were ordered online via the Roche website. Primers used in this thesis are in 
table 2.4. 
The cDNA to be used for the qPCR reaction was diluted four fold in order to produce 
80 µl of diluted cDNA from each 20 µl reverse transcription reaction. A master mix of 
qPCR components was created from the following: 0.5 µl nuclease free water, 0.5 µl 
forward primer, 0.5 µl reverse primer, 10 µl EXPRESS qPCR Supermix Universal 
(Invitrogen; 11785200) and 0.5 µl probe for each reaction. The master mix was 
placed into a 1.5 ml Eppendorf tube, shaken to mix and centrifuged at 1000 g for 1 
minute to displace the contents to the bottom of the tube. 12 µl of master mix was 
pipetted into wells on a 96-well plate. 8 µl of diluted cDNA was added to each master 
mix aliquot. The plate was centrifuged at 650 g for five minutes to drive the contents 
into the wells. The 96 well plate was transferred to a PCR machine (Applied 
Biosystems 7500 Fast) and was programmed to run as follows: step 1:15 minutes at 
960C, step 2: 40 cycles of 15 seconds at 960C, 30 seconds at 580C and 30 seconds 
at 720C, step 3: 3 minutes at 720C. 
2.7.2 qPCR of miRNA 
This was performed using TaqMan microRNA assay kits (Applied Biosystems; 
4427975). The TaqMan assay (20x) and cDNA samples were thawed on ice and 
resuspended by vortexing. The assay and cDNA were then centrifuged at 1000 g for 
one minute. The master mix (TaqMan Universal PCR Master Mix II, no UNG; Applied 
Biosystems, 4440040) was mixed by gently swirling the bottle. The qPCR reaction 
mix was prepared in a 1.5 ml Eppendorf tube for each sample. The samples were all  
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Table 2.4: Probes (Roche Universal Probe library) and primers used for mRNA qPCR 
Gene Probe Primers 
CD31 31 AGA-AAA-CCA-CTG-CAG-AGT-ACC-AG 
TGG-CCT-CTT-TCT-TGT-CCA-GT 
DLC1 17 GAG-CAG-TGT-CAT-GCC-TTG-G 
AAG-AAG-CGA-ATG-AGT-TCT-GTC-A 
HHIP 52 TTC-ACA-AAC-TTG-TTC-AAA-GTG-GA 
ATG-CGA-GGC-TTA-GCA-GTC-C 
LTA4H 64 CTG-CTC-TCA-CGG-TCC-AGT-C 
TTT-TCT-ATT-GTA-AGG-TCC-TTT-GTA-TCC 
PPIL2 81 TCT-AAC-CCT-CCG-CGT-CCT 
TTC-ATC-ATT-GCA-CTG-CTT-CC 
TMEM154 48 CGT-GGT-ATT-CCT-TGC-AAC-ATA-CT 
TCA-AAA-ATA-GGG-ACT-TTC-ACG-TT 
TP53 12 AGG-CCT-TGG-AAC-TCA-AGG-AT 
CCC-TTT-TTG-GAC-TTC-AGG-TG 
Flotillin 2 28 TGT-TGT-GGT-TCC-GAC-TAT-AAA-CAG 
GGG-CTG-CAA-CGT-CAT-AAT-CT 
 
This table outlines the genes that were tested for in qPCR analyses performed in this 
study. The sequences of the primers used are given in addition to the probe that was 








run in triplicate. The following were pipetted into an Eppendorf for each sample: 1.8 
µl TaqMan Small RNA assay (20x), 2.4 µl cDNA, 18 µl master mix and 13.81 µl 
nuclease-free water to create a total volume of 36.01 µl. The Eppendorf was capped 
and inverted several times to mix before being centrifuged at 1000 g for one minute. 
10 µl of qPCR reaction mix was transferred into a well of a 384-well plate. The plate 
was sealed and centrifuged at 650 g for one minute. The plate was inserted into a 
PCR machine (Roche Lightcycler) and the reaction volume was set at 10 µl. The 
PCR machine was programmed to run as follows: step one: 950C for 10 minutes, 
step two: 40 cycles of 950C for 15 seconds and 600C for 60 seconds. 
2.7.3 Analysis of qPCR results 
All qPCR results were analysed using the delta Ct method. mRNA targets were 
normalised to the housekeeping gene Flotillin 2 to calculate the ∆Ct. (∆Ct =Ct of test 
mRNA – Ct of Flotillin 2.) Fold changes for mRNAs were calculated using the 
following formula: 
∆∆Ct= ∆Ct(test group(sample 1,2,3….)) – Mean ∆Ct(control group) 
Fold change = 2-(∆∆Ct) 
To see if the difference between groups was statistically significant a one-tailed t-test 
was used to compare the mean ∆Ct in both groups. The Shapiro-Wilk test was used 
prior to this to confirm that the two groups were normally distributed. 
MiRNA qPCR was performed in a similar manner but miRNA targets were normalised 




Figure 2.11: Culture of Mouse Lung Endothelial Cells (MLECs). A fresh lung sample 
is initially minced before being added to collagenase I for digestion. The digested 
sample is passed through a filter before being centrifuged. The cell pellet is 
resuspended in medium and placed in a 10 cm plate. This is cultured until near 
confluence. The cell culture is then incubated with CD16/32 coated magnetic beads. 
The beads bind to macrophages, which are then removed (negative selection). The 
cells are replated and cultured until near confluence again. The cell culture is then 
incubated with CD102 coated beads, which bind to endothelial cells before a magnet 
is used to isolate the beads from the rest of the solution (positive selection). The 
beads are resuspended in medium and placed in a 10 cm plate. This is cultured until 







2.8 Culture of Mouse Lung Endothelial Cells (MLECs) 
2.8.1 Collagenase digestion of lung tissue 
This method is outlined in figure 2.11. Mouse lung tissue was kindly donated by Dr 
Victoria Heath from the University of Birmingham. Strain C57BL6 (a non-
inflammatory strain) was used and mice were culled by a schedule 1 method of 
culling (CO2). Lungs were dissected out with scissors. Ethical approval for this mouse 
was covered by Home Office licence number PPL 70/8704. Prior to tissue digestion, 
MLEC/HPEC (human pulmonary endothelial cell) media and collagenase solution 
was prepared in a sterile environment in the tissue culture hood. MLEC/HPEC media 
was prepared by mixing the following: 400 ml DMEM-F12 with glutamine (11320033; 
Life Technologies (Gibco)), 45 mg heparin in 1 ml (Sigma; H3149), 5 ml 
Penicillin/streptomycin (Gibco; 15140-122), 1 ml gentamicin/amphotericin (R01510; 
Life Technologies (Gibco)), 250 µl Endothelial Cell Growth Supplement (E2759; 
Sigma Aldrich): 15 mg/ml in DMEM-F12 at 40C and 100 ml Fetal Bovine Serum 
(Gibco; 10270106). The MLEC/HPEC media was sterilised by filtering the solution 
through a filter bottle. Collagenase solution was prepared by adding 0.1 g of type I 
collagenase (Gibco; 17100017) in 25 ml PBS. The solution is then incubated at 370C 
for 1 hour. A further 25 ml PBS is added before filter sterilising with a 0.2 µm filter. 
PBS solution was created by mixing 5 PBS tablets (Sigma; P4417) with 1 l distilled 
water before autoclaving the solution. 0.1% gelatin solution was also created by 
adding 0.5 g gelatin (Fluka Biochemika; 04055) to 500 ml water followed by 
autoclaving the solution. Three 10 cm plates were prepared in the hood in order to 
clean the lung tissue (DMEM-F12, 70 % ethanol and MLEC/HPEC medium). Each 
plate consisted of 12 ml of solution. Tweezers were cleaned with 70% ethanol and 
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were used to hold and wash the lungs by placing the lungs in DMEM-F12 followed by 
70% ethanol for 30 seconds. The lung was finally transferred to the MLEC/HPEC 
medium plate. To aid tissue digestion the mouse lungs were minced using a sterile 
scalpel until the lungs resembled pâté. The lungs were mixed with 10 ml of 
collagenase solution and incubated for 1 hour at 370C in a falcon tube. The solution 
was mixed by shaking the sample by hand after 30 minutes. During this incubation 
period a 10 cm gelatin coated plate was prepared by placing 10 ml 0.1% gelatin on to 
a 10 cm plate and incubating this at 370C. After the one hour digestion phase 10 ml 
MLEC/HPEC media was added to the lung solution to stop further digestion of tissue 
from occurring. The lung tissue was then placed into a petri dish and was passed in 
and out of a 20 ml syringe using a 19 gauge needle four times in order to limit 
clumping of cells. The solution was then filtered through a 70 µm filter into a falcon 
tube to remove cell debris. 20 ml MLEC/HPEC media was added to the lung solution 
prior to centrifugation at 200 g for 10 minutes. The supernatant was removed leaving 
5 ml media at the bottom of the falcon tube. The cell pellet was resuspended and 10 
ml MLEC/HPEC medium was added. The gelatin was removed from the 10 cm plate 
and the lung solution was added. This was then incubated at 370C, 5% CO2 
overnight. 
2.8.2 Negative selection of macrophages using magnetic beads  
The lung culture was purified by the negative selection of macrophages on day two. 
Initially the MLEC/HPEC media was removed and the plate was washed twice using 
PBS. 5 ml of fresh MLEC/HPEC media was then added. The cells were then 
incubated at 40C for 20 minutes to reduce the metabolism of the cells and prevent 
endocytosis of antibody. During this incubation step 10 µl of antibody to CD16/32 
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(ThermoFisher Scientific; Rat anti-mouse; 14-0161-82) was added to 3 ml PBS and 
stored on ice. After the 20 minute incubation step the MLEC/HPEC media was 
removed and the 3 ml antibody solution was added to the lung cells. The cells were 
incubated at 40C for 30 minutes to allow the antibody time to bind to the macrophage 
cells. In order for the antibody to cover all the plate the solution was swirled around 
the plate after 15 minutes. During this phase the beads were prepared. 100 µl of 
magnetic dynabeads (ThermoFisher Scientific; 11035) were added to 1 ml PBS. The 
bead solution was added to a magnet and the solution was removed, effectively 
washing the beads. This was repeated two more times. After the third wash the 
beads were resuspended in 100 µl PBS. 50 µl of bead solution was then combined 
with 3 ml MLEC/HPEC medium. The antibody solution was removed from the plate 
and the plate was washed with PBS to remove traces of antibody solution. The 3 ml 
bead solution was added to the plate, which was incubated at 40C for 30 minutes 
again with the plate swirled after 15 minutes. During this incubation phase a 10 cm 
gelatin coated plate was created by adding 10 ml 0.1% gelatin to a 10 cm plate and 
incubating this at 370C, 5% CO2. The bead solution was removed from the plate and 
this was washed three times with PBS to remove all traces of beads. The beads/cells 
were then removed from the plate by adding 2.5 ml 2x trypsin (Gibco; 15400054) and 
incubating the cells for two minutes at 370C, 5% CO2. Detachment of cells was 
observed under the microscope and 9 ml MLEC/HPEC media was added to 
inactivate the trypsin.  The cells were transferred to a 15 ml falcon tube and placed 
into a magnetic holder for five minutes to give the beads time to attach to the magnet. 
The solution was removed and placed on to the prepared gelatin plate. The plate was 
placed into the incubator at 370C, 5% CO2. The cell culture was reviewed each day 
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and media was replaced every other day until large colonies of endothelial cells were 
visible. 
2.8.3 Positive selection of endothelial cells by magnetic beads 
Initially the medium was removed and replaced with 5 ml of fresh MLEC/HPEC 
medium. The plate was incubated at 40C again for 15 minutes in order to reduce cell 
metabolism. During this time a 10 cm gelatin plate was prepared by adding 10 ml 
0.1% gelatin to a 10 cm plate and incubating this at 370C, 5% CO2. The plate was 
labelled as ‘MLEC positive P1’. Anti-ICAM2 (CD102) antibody solution was prepared 
by adding 10 µl of anti-ICAM2 antibody (BD Pharmigen, Rat anti-mouse; 553326) to 
3 ml PBS on ice. The medium was removed from the plate and replaced with the 
antibody solution. The plate was incubated at 40C for 30 minutes, but the plate was 
swirled after 15 minutes in order to distribute the antibody around the plate. During 
this time the beads were washed as above and resuspended in 100 µl of PBS. 50 µl 
of beads was combined with 3 ml of PBS. After the incubation period the antibody 
solution was removed and the plate was washed with PBS to remove excess 
antibody. The bead solution was added to the plate, which was incubated at 40C for 
30 minutes, but swirled at 15 minutes to distribute the beads across the plate. After 
this time the bead solution was removed and the plate washed three times with PBS 
to ensure no traces of bead solution remained on the plate. The cells were removed 
using trypsin as in section 2.8.2 and 9 ml of media was added to neutralise the 
trypsin. The cell solution was transferred to a 15 ml falcon tube and placed into a 
magnetic holder for 5 minutes to give time for the beads to bind to the magnet. The 
solution was removed and discarded. The beads were resuspended in 10 ml 




Figure 2.12: Culture of Human Pulmonary Endothelial Cells (HPECs). A fresh lung 
sample is minced before being added to collagenase V. The digested sample is 
passed through a filter before being overlaid on lymphoprep. The cells are 
centrifuged which leads to the erythrocytes concentrating at the bottom of the tube. 
All cell layers above the erythrocytes are removed and centrifuged. The cell pellet is 
resuspended in medium and placed in a 6 well plate. The cell culture is then 
incubated with ulex coated magnetic beads. The beads bind to endothelial cells 
before a magnet is used to isolate the beads. The beads are resuspended in medium 








2.9 Culture of Human Pulmonary Endothelial Cells (HPECS) 
In order to have the ability to carry out functional validation work the culture of lung 
endothelial cells was attempted. This would ideally provide the opportunity to study 
the effects of altering a target of interest in the cell of interest rather than an 
alternative cell (such as Human Umbilical Vein Endothelial Cells (HUVECs)). The 
advantage of this is that alternative cell lines may not express the target of interest 
thus rendering functional validation in them impossible. This method was adapted 
from the endothelial extraction method in 2.3.2 and similar work on extracting 
pulmonary endothelial cells in mice.(357)  
2.9.1 Collagenase digestion of lung tissue 
Lung tissue was collected in the same manner as section 2.3.  Three 100 mm plates 
were prepared. Plate 1: 12 ml DMEM-F12 (11320033; Life Technologies (Gibco)). 
Plate 2: 12 ml 70% ethanol. Plate 3: 12 ml MLEC/HPEC medium (section 2.8.1). 
Tweezers were placed in the ethanol plate before being used to transfer the lung 
sample to the DMEM-F12 plate for 30 seconds. The lung sample was then washed 
with ethanol for 30 seconds and transferred to the plate containing medium. The lung 
was divided into portions approximately 3x2 cm. One portion was minced on the lid of 
a 100 mm plate until it resembled pâté. The portion was added to a sterile 50 ml 
falcon tube with 12.5 ml collagenase solution and incubated for one hour in a 370C 
shaker. Collagenase solution was created by adding 25 mg collagenase 
(Collagenase type V; (C9263 Sigma-Aldrich, UK): 25 mg/ml in DMEM, 1 ml aliquots 
at -200C) to 12.5 ml DMEM-F12 (11320033; Life Technologies (Gibco)). The 
collagenase solution was filter sterilised using a 0.22 µm filter. 
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The other portions of lung were then minced and digested in the same fashion. 
Gelatin plates were then prepared by pipetting 3 ml 0.1% gelatin (section 2.8.1) into a 
well of a 6-well plate and incubating at 370C (for at least 15 minutes). 10 ml medium 
was added to the first lung portion to stop digestion, which was passed in and out of 
a 10 ml pipette to disaggregate the cells. The lung solution was then passed through 
a 100 µm cell strainer (734-0004; VWR International) into a 50 ml falcon tube. 20 ml 
medium was added to the falcon tube, which was then centrifuged for 10 minutes at 
200 g. The supernatant was removed by pouring into another falcon tube leaving 5 
ml liquid at the bottom. The cell pellet was resuspended by pipetting gently and 
adding 20 ml medium. In order to remove the erythrocytes from solution (which are 
metabolically active and can limit endothelial growth) the cell solution was then 
overlaid on to 12 ml lymphoprep (1114545; Axis-Shield) and centrifuged at 100 g for 
30 minutes (acceleration 1). All layers above the erythrocyte layer were removed with 
a sterile 10 ml pipette into another 50 ml falcon tube. The cell solution was 
centrifuged at 200 g for 10 minutes, and supernatant was removed with a sterile 
pipette. This process was repeated with the other lung portions. Two cell pellets 
(from two lung portions) were combined and resuspended in 5 ml medium in order to 
increase the number of endothelial cells on one plate. The gelatin was removed from 
the 6-well plate and the cell suspension was added to the plate and incubated at 
370C, 5% CO2 overnight.  
On day one the media was removed and the cells were washed four times with 
DMEM-F12. 3 ml medium was then added to the cells. The media was changed 
every other day until the cells grew to cover most of the plate, but were not confluent 
(to prevent cell clumping).  
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2.9.2 Positive selection of endothelial cells by magnetic beads 
Firstly, Streptavidin Dynabeads (M-280; Life Technologies (Invitrogen)) were 
vortexed to resuspend the beads in solution. 5 µl of beads were combined with 200 µl 
PBS (section 2.8.1) in a 15 ml falcon tube. The beads were washed by placing the 
bead solution into a magnetic holder and pipetting off the solution whilst the tube was 
still in place. The beads were then resuspended in 200 µl PBS and placed into the 
magnetic holder again before the PBS was removed. The beads were resuspended 
in 1 ml MLEC/HPEC medium (section 2.8.1) and 12.5 µl of Ulex solution (section 
2.3.2) was added to the beads. The bead solution was then placed in a 370C shaker 
for 30 minutes so the Ulex could bind to the beads. During this time the cells were 
removed from the plate by using 2 ml 2x trypsin (Gibco; 15400054) and placing this 
in the incubator at 370C, 5% CO2 for five minutes. Detachment of the cells was 
observed under the microscope. 5 ml MLEC/HPEC media was added to the cells to 
neutralise the trypsin and the cells were transferred to a 15 ml falcon tube for 
centrifugation at 200 g for 5 minutes. The cell pellet was resuspended in the bead 
solution and vortexed very briefly to obtain a single cell suspension. The cells/beads 
were then placed on a wheel in the cold room at 40C for 30 minutes to give the cells 
time to bind to the beads. The mixing of the cells on the wheel should encourage the 
proper mixing of cells and beads. During this time 2 wells of a 6 well plate were 
prepared by adding 0.1% gelatin (section 2.8.1) and placing in the incubator at 370C, 
5% CO2. After the mixing in the cold room the cells were transferred into a 15 ml 
falcon tube, which was placed into a magnetic holder. Whilst the tube was still in the 
magnet the media was removed and combined with 2 ml fresh MLEC/HPEC media. 
This was then plated on to a plate labelled ‘HPEC negative P1’. The beads were 
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resuspended in 3 ml media and added to the other plate labelled ‘HPEC positive P1’. 
Both plates were incubated overnight at 370C, 5% CO2. Cells were cultured and split 
until enough beads were removed for flow cytometry. 
2.10 Cell storage 
Surplus cells used throughout this study were stored at -800C. This was done by 
pelleting the cells in solution using centrifugation at 200 g for 5 minutes. The 
supernatant was removed and the cells were resuspended in 1 ml of freezing media 
and placed into a cryogenic storing tube (Thermofisher Scientific; 375418). Freezing 
media was created by adding 1 ml Dimethyl sulfoxide (DMSO) (Sigma Aldrich; 
D2650) to 9 ml of Fetal Bovine Serum (Gibco; 10270106). Cells were initially frozen 
in a ‘Mr Frosty’ freezing container (ThermoFisher Scientific; 5100-0001) in order to 
slowly cool the cells to prevent cellular damage prior to storing in boxes at -800C.  
Cells that were frozen were slowly defrosted using a water bath at 370C under direct 
supervision. 10 ml of cell media (depending on cell type) was added to the cells 
which were centrifuged at 200 g for 5 minutes. The supernatant was removed to 
remove traces of DMSO prior to plating. 
2.11 Flow cytometry 
2.11.1 Flow cytometry to look for CD31 expression in cells isolated from 
mouse lung 
This was performed at the University of Wolverhampton. Initially the MLECs were 
removed from the plate using 2.5 ml 2x trypsin (Gibco; 15400054) as in section 2.8.2. 
400 000 cells were added to each of three tubes: control, CD102 (BD Pharmigen, 
Rat anti-mouse; 553326) and CD31 (BD Pharmigen, Rat anti-mouse; 550274). The 
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cells were centrifuged at 160 g for 5 minutes and the supernatant was discarded. The 
cells were resuspended in 500 µl of 4 % Formaldehyde (Sigma; HT50-1-2) in order to 
fix the cells and were left for 15 minutes at room temperature. During this time each 
primary antibody solution was prepared on ice. 3 µl of antibody was added to 150 µl 
FACS buffer (1:50 dilution). FACS buffer was created by mixing bovine serum 
albumin (BSA) (Sigma; A2058) at a ratio of 0.2% with PBS (section 2.8.1). Sodium 
azide (Sigma; 71289) is then added at a ratio of 0.02% with the PBS/BSA. 
After the fixation phase 8 µl PBS was added to each of the three tubes which were 
centrifuged at 1200 g for 5 minutes to remove the formaldehyde. After this 150 µl 
FACS buffer was added to the control tube, 150 µl of CD102 solution was added to 
the CD102 tube and 150 µl of CD31 solution was added to the CD31 tube. The tubes 
were left at room temperature for 2 hours to allow the antibodies to bind. During this 
time the secondary antibody (BD Pharmigen; anti-rat/FITC (fluorescein 
isothiocyanate); 553881) was prepared by combining 7 µl of secondary antibody to 
700 µl FACS buffer. To prevent degradation of the FITC the secondary antibody was 
kept in the dark. After the 2 hour incubation period the cells were washed with 10 ml 
PBS and were centrifuged at 1200 g for 5 minutes. The cells were resuspended with 
200 µl secondary antibody solution per each tube. The cells were incubated for 1 
hour in the dark to allow the secondary antibody time to bind. After this incubation 
step the cells were washed again with 10 ml PBS and centrifuged at 1200 g for 5 
minutes. Finally the cells were resuspended in 300 µl PBS and were analysed using 
a flow cytometer (BD Biosciences; BD Accuri C6 plus) using the flow cytometer 
software. The unstained cytogram was used initially and a gate was created by 
drawing a plot around the main cell population. This gate was used to limit results for 
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the other cell conditions (i.e. only results falling within the gate were included in the 
histogram plot). The histogram for the unstained cells was compared to the 
histograms for the other cell conditions. Data was presented as percentage positive 
stained cells. 
2.11.2 Flow cytometry to look for CD31 expression in cells isolated from 
the lung 
To confirm whether or not the cells isolated using the method in 2.9 were endothelial 
cells flow cytometry to look at CD31 expression was performed. Prior to flow 
cytometry the cells to be used were washed with PBS (section 2.8.1) twice. Cells 
were then treated with 5 ml cell dissociation buffer (Sigma; C5789) and placed into 
an incubator at 370C for 30 minutes. The cells were removed and placed into a 15 ml 
falcon tube before being centrifuged at 200 g for 5 minutes. This has the effect of 
removing the dissociation buffer. The cells were then resuspended in 5 ml of 
MLEC/HPEC medium (section 2.8.1) in order to count the cells. 10 µl of cell solution 
was removed and placed into a cell haemocytometer. Around 300 000 cells were 
used per condition in the flow cytometry experiment. Surplus cells were removed and 
frozen for storage at -800C (section 2.10).  
The cells were centrifuged at 200 g for 5 minutes and the supernatant was removed. 
The cells were then washed by resuspending them in 5 ml PBS and centrifuging at 
200 g for 5 minutes. The supernatant was removed and cells were resuspended into 
PBS (100 µl per condition). 100 µl of cell solution was added to each eppendorf 
representing each condition in the experiment: unstained cells, secondary antibody 
only, secondary antibody and isotype antibody control and test (CD31 antibody and 
secondary antibody). A stock solution of CD31 antibody (Dako; JC70A) was made by 
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diluting the stock antibody solution in a ratio of 1:20 with FACS buffer (section 2.11.1) 
and vortexed to mix. 5 µl of CD31 antibody was added to the test eppendorfs and 
vortexed. In a similar fashion a stock solution of isotype control antibody (Sigma, 
Mouse IgG1 Negative Control Antibody; CBL610) was created by diluting the 
antibody solution at a ratio of 1:20 with FACS buffer and vortexed to mix. 5 µl of 
isotype antibody was added to the isotype antibody control eppendorfs and vortexed. 
All eppendorfs were transferred to ice and incubated for 1 hour. The eppendorfs were 
centrifuged at 2500 g for 5 minutes and the supernatant was removed in order to 
remove excess antibody. To further wash the cells the pellets were resuspended in 
250 µl of FACS buffer, centrifuged at 2500 g for 5 minutes with the removal of the 
supernatant afterwards twice. Each cell pellet was then resuspended in 100 µl FACS 
buffer. The secondary antibody, anti-mouse/FITC (fluorescein isothiocyanate) 
(Sigma; F2883) was diluted in a ratio of 1:100 using FACS buffer. 10 µl of this was 
added to the eppendorfs: secondary only, secondary antibody, isotype antibody 
control and test. All eppendorfs were incubated on ice for 30 minutes. To protect the 
FITC from degradation this was performed in the dark. After this the eppendorfs were 
centrifuged at 2500 g for 5 minutes. To further wash the cells the pellets were 
resuspended in 250 µl of FACS buffer, centrifuged at 2500 g for 5 minutes with the 
removal of the supernatant afterwards twice. The cells were resuspended in 300 µl of 
FACS buffer and transferred into FACS tubes. The cells were run through the FACS 
machine (Becton-Dickinson Fluorescence activated cell sorter (FACSCalibur)) and 
the results processed using the online available software FloJo. The unstained 
cytogram was used initially and a gate was created by drawing a plot around the 
main cell population (figure 2.13). This gate was used to limit results for the other cell 
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conditions (i.e. only results falling within the gate were included in the histogram plot). 
The histogram for the unstained cells was compared to the histograms for the other 
cell conditions (figure 2.14). Data was presented as percentage positive stained cells. 
2.11.3 Flow cytometry for cell cycle analysis 
 
Analysis of cell cycle was achieved by fixing cells in alcohol and staining with 
propidium iodide. Propidium iodide binds to DNA proportionally to the amount of DNA 
in the cell. Therefore, cells in S phase fluoresce more brightly than G1 cells. Cells in 
the G2 phase are approximately twice as bright as G1. (358) 
Firstly cells were washed using PBS (section 2.8.1) before being removed from the 
plate using 2x trypsin (section 2.9.3). Cells were added to 5 ml HUVEC media to 
inactivate the trypsin and were centrifuged at 200 g for 5 minutes to pellet the cells. 
HUVEC media was created by mixing the following in the sterile hood: 500 ml 
DMEM-F12 with glutamine (11320033; Life Technologies (Gibco)), 45 mg heparin in 
1 ml (Sigma; H3149), 5 ml Penicillin/streptomycin (Gibco; 15140-122), 5 ml L-
glutamine (Gibco; 25030-024), 1 ml bovine brain extract (created in Bicknell/Heath 
laboratory at University of Birmingham; in 1 ml aliquots at -200C) and 50 ml Fetal 
Bovine Serum (Gibco; 10270106). HUVEC media was then sterilised by filtering the 
solution through a filter bottle. 
The media was removed by suction and 1 ml 85 % ice-cold ethanol (VWR; 
20821.330) was added to the cells and vortexed to mix. This fixes the cells. Cells 
were stored at 40C until propidium iodide staining was performed but were used 




Figure 2.13: A cytogram plot from the program ‘FloJo’: The dots represent individual 
cells. A gate has been drawn around the main cell population. 
 
Figure 2.14: A histogram plot from flow cytometry:  The plot compares unstained cells 
(green) to cells stained for CD31 (blue), secondary antibody only (orange) and 




alcohol was removed. 1 ml propidium iodide staining solution was added to the cells 
which were vortexed to mix. Propidium iodide solution was created by mixing the 
following: 1 ml PBS, 10 µl Propidium Iodide (Invitrogen; P3566), 10 µl RNAse A 
(Qiagen; 1007885) and 10 µl 10 % Triton-X-100 (Sigma; X100). The propidium iodide 
solution was vortexed to mix and kept away from light. 
The cells were transferred to an eppendorf tube and covered in foil to prevent light 
from damaging the propidium iodide stain. The cells were incubated at 370C, 5 % 
CO2 for 20 minutes to ensure staining of cells. Cells were centrifuged again to 
remove excess staining solution at 3800 g for 5 minutes. The supernatant was 
discarded and cells were resuspended in 300 μl FACS buffer. Cells were run through 
the CyAn flow cytometer (Beckman-Coulter, United Kingdom) and the results were 
analysed using FloJo. Two cytogram plots (figure 2.15) were used to isolate the 
desired population of cells and to identify single cells only. A histogram of cell counts 














Figure 2.15: Cytogram plots from the program ‘FloJo’ used for cell cycle analysis. A: 
An initial gate was drawn to identify the main cell population. B: A second gate was 
drawn to identify single cells within the main cell population. The single cell 




Figure 2.16: A histogram plot of cell counts for cell cycle analysis. The plot 
demonstrates the group of cells in G1 (blue), S (mustard) and G2 (green). The 

















2.12 Cell culture for cellular functional work 
 
All functional work was carried out using Human Umbilical Vein Cells (HUVECs) 
which were purchased through Lonza (C2519A). These are pooled donor cells. On 
arrival HUVECs were washed by adding them to 10 ml HUVEC media (section 
2.11.3) and centrifuged at 200 g for 5 minutes to pellet the cells. The cell pellets were 
then resuspended in 10 ml HUVEC media and plated on to 0.1% gelatin coated 
(section 2.8.1) T75 flasks. Cells were cultured at 370C, 5% CO2. Once confluent the 
media was removed from the cells, which were then washed with 5 ml PBS (section 
2.8.1). 2 ml 2x trypsin (Gibco; 15400054) was added to the cells which were placed 
into the incubator at 370C, 5% CO2. Cell detachment was observed at intervals under 
the microscope. 10 ml HUVEC media was added to the cells to neutralise the trypsin 
before centrifuging the cells at 200 g for 5 minutes. The cell pellet was resuspended 
in 30 ml of HUVEC media and divided equally into 3 different 100 mm 0.1% gelatin 
coated plates. The new plates were returned to the incubator at 370C, 5% CO2 until 
cells were confluent. Cells were passaged in this way until passage 3 or 4 and used 
for functional work at this point. Surplus cells were stored and defrosted for use as 
per section 2.10. 
2.13 miRNA Inhibition and Overexpression 
 
Transfection of miRNA mimics and inhibitors can be used to determine the effects of 
overexpression and inhibiting a miRNA on a cell. MiRNA mimics are synthetic 
double-stranded miRNAs that mimic naturally occurring miRNAs after transfection. 
MiRNA inhibitors are modified single-stranded RNAs that bind to and inhibit miRNAs 
after transfection.(359) Both mimics and inhibitors can be transfected using 
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lipofectamine as a transfection reagent. Nucleic acids have a negative charge which 
prevents them from crossing cell membranes (which are also negatively charged) 
thereby requiring another agent to assist miRNA mimics and inhibitors to cross the 
cell membrane. Lipofectamine (a liposome formulation) acts by forming a complex 
with the RNAs, which allows them to overcome the negative charge on the cell 
membrane and enter the cell.(360) Once a miRNA or inhibitor is in a cell then 
functional work can be performed to see the effects of over-/under- expression of that 
particular miRNA. 
2.13.1 Transfection of a miRNA inhibitor or mimic into HUVEC in a 6 well 
plate 
On day one 5 ml 0.1% gelatin (section 2.8.1) was placed into a well of a 6 well plate. 
This was transferred into an incubator at 370C, 5% CO2 for at least 15 minutes so 
that the gelatin formed a coating on the plate. 2.5x105 HUVEC were plated into the 
well in 5 ml HUVEC media (section 2.11.3) which resulted in a near confluent 
HUVEC culture. Cultures should be near confluence as cells require contact in order 
to grow. However, 100% confluence can result in contact inhibition making cells less 
likely to take up RNAs reducing the success of transfection.(361) On day two 
transfection was performed. To maintain sterile conditions transfection was 
performed in a tissue culture hood after decontamination of the hood with 70% 
ethanol. To reduce the chance of contamination with RNases the hood was then 
cleaned with RNaseZap (ThermoFisher Scientific; AM9780). All pipettes and tube 
holders were also cleaned with RNaseZap. All plastic ware used during the 
transfection was single use and RNase/DNase free.  
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Mimics and inhibitors come as dried powder that needs to be dissolved into RNase 
free water prior to use. All mimics and inhibitors used were Qiagen miScript miRNA 
mimics or inhibitors (5 nmol). Prior to opening all mimics and inhibitors were 
centrifuged for one minute to drive the contents of the tubes down into the wells. 
Mimics and inhibitors were dissolved in 250 µl RNase free water and vortexed to mix 
to create stock solutions of 20 µM. Mimics and inhibitors were used at a final 
concentration of 10 nM. Therefore, the 20 µM stock solution was diluted in the first 
instance by combining 10 µl of 20 µM stock with 190 µl optimem (ThermoFisher 
Scientific; 31985070). This was vortexed to mix completely resulting in a 1000 nM 
stock solution. 10 µl of 1000 nM stock was combined with 160 µl optimem to create a 
mimic/inhibitor mix. 3 µl lipofectamine (Lipofectamine® RNAiMAX Transfection 
Reagent, ThermoFisher Scientific; 13778075) was also combined with 27 µl optimem 
and both mixtures were left to incubate at room temperature for 10 minutes. The 30 
µl lipofectamine mix was then combined with the mimic/inhibitor mix, flicked to mix 
and left at room temperature for a further 10 minutes. During this time the cells were 
removed from the incubator, media was removed and cells were washed twice with 2 
ml PBS (section 2.8.1) to ensure all traces of media were removed. The 
lipofectamine/mimic/inhibitor mix was then combined with 800 µl optimem before 
being transferred on to the cells. The cells were left in the incubator at 370C, 5% CO2 
for 4 hours to allow time for transfection to occur. After this time the mimic/inhibitor 
was removed and replaced with 5 ml HUVEC media. Cells were left alone on day 3 
and by day 4 they were ready for assays to be performed. All mimic/inhibitor 
experiments were also performed using the following controls: 
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x Negative siRNA (AllStars Negative Control siRNA, Qiagen; 1027280): 
Negative control for miRNA mimic. Final concentration 10 nM. This is a 
double-stranded scrambled non-coding short RNA sequence. 
x Negative miRNA inhibitor (miScript Inhibitor Negative Control, Qiagen; 
1027271): Negative control for miRNA inhibitor. Final concentration 10 nM. 
This is a single-stranded RNA sequence complementary to the negative 
siRNA above. 
x Lipofectamine only. The lipofectamine mix (30 µl) was combined with 170 µl of 
optimem rather than mimic/inhibitor mix. 
x Optimem only: 1000 µl optimem was added to the cells rather than 
lipofectamine/mimic/inhibitor mix. 
Some mimic or inhibitor experiments were also performed using plates other than 6 
well plates. The number of cells used and volumes of inhibitor, mimic and 










Table 2.5: The number of HUVEC plated and volumes of inhibitor, mimic and 
lipofectamine used for different plates in various mimic or inhibitor experiments. 






12-well 8x104 6.8 µl 1000 nM 
stock 
108.2 µl  optimem 
2 µl  lipofectamine 
18 µl  optimem 
10cm or T25 flask 1x106 2 µl 20 µM stock 
678 µl optimem 
12 µl lipofectamine 
108 µl optimem 
 
This table outlines the plates used for the miRNA inhibitor and mimic functional 
experiments (chapter 6.) For each type of plate used the number of HUVEC plated is 
listed. The volumes of inhibitor/mimic, lipofectamine and optimem used are given for 














2.14 Cell growth assay 
This assay was performed to determine the effect of miRNA overexpression on cell 
growth. MiRNA mimic and the appropriate controls were transfected into HUVECs as 
per section 2.13 in T25 flasks. 4 hours after transfection the plates were washed with 
PBS (section 2.8.1) and 2x trypsin (Gibco; 15400054) was used to remove cells as 
per section 2.12. 5 ml HUVEC media (section 2.11.3) was added to each flask to 
neutralise the trypsin and cells were transferred into 15 ml falcon tubes. Cells were 
centrifuged at 200 g for 5 minutes to remove the trypsin. The supernatant was 
removed and the cells were resuspended in 5 ml HUVEC media. The cells were 
counted by a haemocytometer and diluted to a concentration of 12 500 cells per ml 
using HUVEC media. 1 ml of cell solution (from each condition) was added to 3 wells 
of 3 0.1% gelatin (section 2.8.1) coated 12 well plates and placed into an incubator at 
370C, 5% CO2. The following day cells from 1 plate were washed with PBS and 
removed using 2x trypsin (as above). The cells were resuspended in 100 µl HUVEC 
media and counted with a haemocytometer. This was repeated the next day for 
another plate and on the third day for the following plate. The number of cells from 
days 1-3 were compared for each condition to gain an estimate of cell growth during 
this time. 
2.15 Matrigel tube formation assay 
Matrigel is a basement membrane protein mixture that was originally isolated from 
mouse sarcoma cells. (362) When endothelial cells are plated on to matrigel they 
assemble to form tubes in a mesh-like manner. (363) This allows analysis of the 
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differentiation phase of angiogenesis where endothelial cells initially migrate from 
existing blood vessels. (364)  
Initially 1 ml PBS (section 2.8.1) was added to a well of a 12 well plate and removed 
by suction to wet the well. 70 µl of matrigel (Corning; 356234) was then placed 
immediately into the well and allowed to spread throughout the well by rocking the 
plate back and forth gently. The matrigel was then allowed to solidify by placing the 
plate into the incubator at 370C, 5% CO2 for 30 minutes. During this time endothelial 
cells from a 6 well plate were washed with PBS and removed using 2x trypsin (Gibco; 
15400054) (section 2.12). Cells were placed into 5 ml of HUVEC media (section 
2.11.3) to inactivate the trypsin and pelleted by centrifuging at 200 g for 5 minutes. 
The supernatant was removed and cells were resuspended in 1 ml HUVEC media 
and counted using a haemocytometer. Cells were diluted to a concentration of 140 
000 cells per ml using HUVEC media and 1 ml of cell solution was added to the 
matrigel well. The plate was uploaded into an IncuCyte incubator (Essen BioScience, 
United States) at 370C, 5% CO2. This incubator contains a microscope which was 
programmed to take pictures at 6, 12, 18 and 24 hours using IncuCyteZoom2015A 
software (Essen BioScience, United States). The images were downloaded and 
analysed using the online available software ImageJ. 
2.16 Scratch wound assay 
This assay measures endothelial cell migration by timing how long endothelial cells 
take to close an induced wound in an endothelial monolayer.(365) 
48 hours prior to commencing the assays a 96 well ImageLock plate (Essen 
Biosciences; 4379) was gelatin coated by placing 100 µl 0.1% gelatin (section 2.8.1) 
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into each well of the plate prior to incubating for at least 15 minutes at 370C, 5% CO2. 
8000 endothelial cells (in 100 µl HUVEC media (section 2.11.3)) were placed into 
each well of the plate. The cells were placed into the incubator at 370C, 5% CO2 for 
48 hours.  
A ‘Woundmaker 96’ (Essen Biosciences; 4493) was used to create the wounds in this 
experiment. This is effectively a tool consisting of a metal plate and 96 metal pins 
which fits to the ImageLock plate. Initially the Woundmaker was placed into 70% 
ethanol to sterilise the pins. The pins were dried in the sterile field of a tissue culture 
hood prior to being placed on the ImageLock plate. The Woundmaker was moved 
across the ImageLock plate creating a linear wound in each well. The media was 
removed from each well using a multi-channel pipette prior to washing each well with 
100 µl PBS (section 2.8.1) in order to removed dislodged cells. Finally 100 µl of 
HUVEC media was added to each well and the ImageLock plate was inserted into an 
Incucyte incubator at 370C, 5% CO2. The incubator was programmed to take images 
at 0, 6, 12, 18 and 24 hours using IncuCyteZoom2015A software. The images were 




Figure 2.17: Overview of the spheroid assay: Endothelial cells are mixed with 
methocellulose, placed into droplets, inverted and are incubated overnight (1). 
Endothelial cells form spheroids in the droplet (2). The spheroids are resuspended in 















2.17 Spheroid assay 
2.17.1 Preparation of the spheroid assay 
An overview of this assay is presented in figure 2.17. This assay effectively analyses 
endothelial sprouting from a collection of endothelial cells known as a spheroid.(365) 
Initially endothelial cells are labelled with a fluorescent dye, CFSE 
(Carboxyfluorescein succinimidyl ester), in order to identify them easily on 
microscopy. Cells were washed with PBS (section 2.8.1) and removed from plates by 
treating with 2x trypsin (Gibco; 15400054) (section 2.12). 5 ml HUVEC media 
(section 2.11.3) was added to the cells to neutralise the trypsin before pelleting the 
cells by centrifuging at 200 g for 5 minutes. The supernatant was removed and cells 
were resuspended in 200 µl of PBS. 200 µl CFSE-PBS solution was added to the 
cells, which were then incubated in a water bath at 370C for 10 minutes. CFSE-PBS 
solution was created by mixing 1 ml PBS and 1 µl CFSE (Invitrogen; C34570) in a 
sterile hood. 5 ml HUVEC media was added to the cells, which were pelleted by 
centrifuging at 200 g for 5 minutes. The supernatant was removed and cells were 
washed again with 5 ml HUVEC media by centrifuging at 200 g for 5 minutes. 
The cells were counted using a haemocytometer. 1.12 ml of cells in HUVEC media 
(at a concentration of 1.25 x 104 cells/ml) was added to 280 µl methocellulose 
solution. Methocellulose solution is created by placing 6g methylcellulose (Sigma; 
M0512) into a 500 ml bottle. A magnetic stir bar is added to the bottle which is 
autoclaved. 250 ml M199 (see below) is added and pre-heated to 650C. This mixture 
is stirred for 30 minutes before adding a further 250 ml M199. The mixture is stirred in 
a cold room overnight. The following day the mixture is transferred into 50 ml falcon 
tubes and centrifuged at 3500 g at 40C for 3 hours. 45 ml of the supernatant is 
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transferred into fresh tubes – this is 1.2% methocellulose. The M199 used in the 
methocellulose solution is created by mixing one vial of M199 powder (Sigma; 
M5017) with 1 l of water. 2 g of sodium bicarbonate (Sigma; S5761) is added before 
sterilising the solution by filtering through a filter bottle in the hood. 
20 µl of cells/methocellulose was added to each well of a 60 well microplate (Nunc; 
439225). The lid of the plate was attached and the plate was inverted. This creates 
hanging droplets. Spheroids should form within each droplet. The plate was 
incubated overnight at 370C, 5 % CO2. Spheroids were harvested from the plate by 
aspirating each drop using a p1000 tip and were placed into a 15 ml falcon tube. The 
spheroids were centrifuged at 160 g for 5 minutes and the supernatant was 
aspirated.  
Collagen mix 1 was created by mixing the following on ice in a sterile hood: 1.37 ml 
collagen (Type I Rat tail, Temecula; 92590), 250 µl 10x DMEM (see below) and 880 
µl sterile water. The 10x DMEM solution used in collagen mix 1 was made by adding 
one vial of DMEM 10X powder (Sigma; D5030) to 1 l of water and filter sterilizing in 
the hood using a filter bottle. 
Collagen mix 2 was created by mixing the following on ice in the hood: 1.5 ml EBM2 
media (Lonza; CC-4542 + CC-5036) and 1 ml methocellulose solution. 
10 µl sodium hydroxide (Sigma-Aldrich; S2770) was added to collagen mix 1 prior to 
mixing collagen mixes 1 and 2 in a ratio of 1:1. 200 µl of the combined collagen mix 
was used to resuspend the spheroids which were then placed on to a well of a 24 
well plate. The plate was incubated at 370C, 5 % CO2 for 10 minutes to allow the 
collagen to solidify. 100 µl of EBM2 media (endothelial cell growth media, Lonza; CC-
4542 + CC-5036) was added to the well and the plate was placed back into the 
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incubator at 370C, 5 % CO2 for 8 hours. It is important to use media with VEGF 
(vascular endothelial growth factor) during this step to ensure sprouting. After this 
time the media was aspirated and 100 µl of 4 % paraformaldehyde was added to the 
well. The plate was covered in foil and placed into the incubator at 370C, 5 % CO2 for 
30 minutes to fix the cells. Cells were washed with 100 µl PBS which was aspirated 
before storing the cells in 1000 µl PBS. Foil was placed back around the plate which 
was stored at 40C until the plate was ready to be viewed. Spheroids were imaged 
using a Zeiss 780 Zen confocal microscope.  
2.17.2 Analysis of spheroids using ImageJ 
Fluorescent spheroid images were uploaded into ImageJ and were analysed using 
the ‘Spheroid Analysis’ plugin developed at the University of Birmingham by Victoria 
Salisbury.(366) The plugin works by modifying the original fluorescent images in 
several steps (figure 2.18). Initially a binary image is produced where the endothelial 
objects appear as white on a black background (A). The binary image is used to 
create a mask of the endothelial sprouts (excluding the spheroid itself as this is not 
required for analysis) (B). This mask generates two images, one demonstrating 
sprouts connected to the spheroid (C) and the second demonstrating sprouts not 
connected representing cells which had begun to migrate away from the spheroid 
mass (D). The mask is further altered using a second plugin (Skeletonize), which 
converts sprouts into one pixel in diameter (E). Finally a third plugin (Analyze 
Skeleton) assesses the length and number of sprouts and produces these results in 
a table. A final image demonstrating the analysed network over the original image is 






    
 
Figure 2.18: Analysis of an endothelial spheroid using the ‘Spheroid Analysis’ plugin 
in ImageJ. A: Original image showing a fluorescent spheroid with sprouting which is 
uploaded into ImageJ. Images B-G are created by analysing this image by running 
the ‘Spheroid Analysis’ plugin. B: Binary image. C: Mask of sprouts. D: Connected 
sprouts. E: Disconnected sprouts. F: Skeleton image of sprouts. G: Final image 
demonstrating the analysed network overlying the original fluorescent spheroid. 
















MICRORNA AND MESSENGER RNA 





There will be significant differences in pulmonary endothelial microRNA (miRNA) and 
messenger RNA (mRNA) expression by microarray between COPD and non-COPD 
tissue. Some of these differences will be also be present in pulmonary endothelial 
lung cancer tissue. 
3.2 Aims of this chapter 
This chapter will detail the analyses performed in investigating endothelial miRNA 
and mRNA expression by microarray in COPD, non-COPD and lung cancer. 
Initial array results and possible targets will be described prior to validation work by 
qPCR. An overall conclusion for the chapter will then be presented. 
3.3 miRNA expression in the lung endothelium 
 
3.3.1 Subjects 
Baseline demographics of the entire cohort of patients are shown in table 3.1. There 
were more patients in the 2015 array group (13 vs 8 patients). Patient groups did not 
differ in terms of any of the demographics listed. There was no significant difference 
in tumour stage in the 2 groups (table 3.2). 
3.3.2 Combined analysis of 2014 and 2015 microarrays  
As there were no significant differences between microarray groups the groups were 
combined into one analysis comparing COPD and non-COPD patients (tables 3.3 
and 3.4). There was no difference between groups in terms of sex, age, BMI, current 
smoking status or tumour stage. FEV1pp was significantly lower in the COPD group 
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(p=0.026), as expected. Pack year history was greater in the COPD group and 
approached significance (p=0.061). 
Limma analysis 
Samples were analysed using Limma to perform differential miRNA expression 
analysis as per section 2.5.2. Background signal was corrected for and signal 
intensity was normalised between arrays prior to analysis. The package LBE was 
used to determine the false discovery rate (FDR) values for the differential miRNA 
analysis (section 2.5.3). 4 miRNAs were significantly differentially expressed between 
the 2 groups (p<0.05) and had a log fold change (logFC) >1: miR-4495, miR-4462, 
miR-3923, miR-892c-5p. miR-3923 is known to be expressed in the endothelium, but 
the other miRNAs are not known to be endothelial expressed. The FDR was not 
significantly different for any miRNA between groups. A summary of the array result 
can be found in table 3.5. 
Significance Analysis of Microarrays (SAM) 
SAM is an alternative tool to Limma for the analysis of microarray data. In addition to 
presenting data in a tabular format it also presents data in a graphical form and 
results can be limited by fold change. As only 4 miRNAs were significantly 
differentially expressed between COPD and non-COPD groups (using limma) when 
2014 and 2015 groups were combined a SAM analysis was performed (section 2.5.4) 
comparing all 2014 miRNA microarray and all 2015 miRNA microarray results. The 





Table 3.1: Patient demographics comparing 2014 to 2015 miRNA microarrays. 
Variable All 2014 2015 p value 
Total patients 21 8 (38.1%) 13 (61.9%)  
Male patients 10 (47.6%) 5 (62.5%) 5 (38.5%) 0.387 
COPD 11 (52.4%) 5 (62.5%) 6 (46.2%) 0.659 
Age 67.00 (14.50) 66.00 (18.75) 67.00 (14.00) 0.860 
BMI 26.19 (8.72) 27.44 (6.93) 21.78 (7.06) 0.374 
Pack year 
history 
29.76 (25.37) 35.00 (17.73) 26.54 (29.33) 0.472 
Current 
smoker 
2 (9.5%) 0 2 (15.4%) 0.505 
FEV1pp 85.09 (25.73) 83.08 (26.42) 85.09 (36.00) 0.340 
 
A comparison of patient demographics for all patients included in the 2014 and 2015 
microarray analyses. Continuous variables that are normally distributed are 
presented in standard font as mean (standard deviation). T-tests were used to 
identify significant differences between normally distributed groups. Continuous 
variables that are not normally distributed are presented in italics as median 
(interquartile range). The Mann-Whitney U test was used to identify differences 
between non-normally distributed groups. Categorical variables are presented with 
percentages and fisher’s exact test was used to identify significant differences 
between groups.  
Table 3.2: Number of patients with each tumour stage in the 2014 and 2015 miRNA 
microarrays.  
Disease stage All 2014 2015 p value 
No cancer 2 (9.5%) 0  2 (15.4%) 0.523 
0 (in situ) 0 0 0 
IA 4 (19.0%) 1 (12.5%) 3 (23.1%) 
IB 4 (19.0%) 1 (12.5%) 3 (23.1%) 
IIA 2 (9.5%) 2 (25%) 0 
IIB 3 (14.3%) 1 (12.5%) 2 (15.4%) 
IIIA 5 (23.8%) 3 (37.5%) 2 (15.4%) 
Lung 
metastases 
1 (4.8%) 0 1 (7.7%) 
 
This table lists the total number of patients with each stage of cancer in the miRNA 
microarray analyses. Percentages of patients with each tumour stage are listed in 
brackets. The number (and percentage) of patients with each stage is also listed by 
year. Fisher’s exact test was used to determine if there was a significant difference 
between the proportion of patients with each stage of cancer in 2014 and 2015. 
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Table 3.3: Patient demographics comparing COPD to non-COPD patients in the 
combined miRNA microarray analysis. 
Variable All Non-COPD COPD p value 
Total patients 21 10 11  
Male patients 10 (47.6%) 5 (50.0%) 5 (45.5%) 1.000 
Age 64.10 (11.33) 63.50 (12.07) 64.64 (11.17) 0.825 
BMI 25.77 (5.44) 27.48 (6.57) 24.20 (3.85) 0.174 
Pack year 
history 
30.00 (43.50) 6.50 (42.50) 30.00 (30.00) 0.061 
Current 
smoker 
2 (9.5%) 1 (10.0%) 1 (9.1%) 1.000 
FEV1pp 85.09 (25.73) 94.27 (10.77) 74.79 (23.41) 0.026 
 
A comparison of patient demographics for all patients included in the combined 
microarray analyses. Continuous variables that are normally distributed are 
presented in standard font as mean (standard deviation). T-tests were used to 
identify significant differences between normally distributed groups. Continuous 
variables that are not normally distributed are presented in italics as median 
(interquartile range). The Mann-Whitney U test was used to identify differences 
between non-normally distributed groups. Categorical variables are presented with 
percentages and fisher’s exact test was used to identify significant differences 
between groups. Significant p values (<0.05) are presented in bold. 
Table 3.4: Number of patients with each tumour stage in the combined miRNA 
microarray analysis. 
Disease stage All Non-COPD COPD p value 
No cancer 2 (9.5%) 0 2 (18.2%) 0.407 
0 (in situ) 0 0 0 
IA 4 (19.0%) 2 (20.0%) 2 (18.2%) 
IB 4 (19.0%) 2 (20.0%) 2 (18.2%) 
IIA 2 (9.5%) 0 2 (18.2%) 
IIB 3 (14.3%) 1 (10%) 2 (18.2%) 
IIIA 5 (23.8%) 4 (40.0%) 1 (9.1%) 
Lung 
metastases 
1 (4.8%) 1 (10.0%) 0 
 
This table lists the total number of patients with each stage of cancer in the miRNA 
microarray analyses. Percentages of patients with each tumour stage are listed in 
brackets. The number (and percentage) of patients with each stage is also listed by 
group (COPD vs non-COPD). Fisher’s exact test was used to determine if there was 
a significant difference between the proportion of patients with each stage of cancer 
in patients with and without COPD. 
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11 10 120 90 0 4 
 
This table outlines the number of patient samples with and without COPD included in 
the combined limma miRNA microarray analysis and the number of miRNAs 
significantly downregulated/upregulated in the COPD group. A moderated t-statistic 
is used to determine significance between groups. 
 
 
Figure 3.1: SAM plot for the analysis comparing 2014 and 2015 miRNA microarrays. 
This is a graphical representation of the statistics for each probe. Probes that are 
upregulated in group 2 (2015) are in red. Probes in green are downregulated in group 





181 probes were significantly differentially expressed with a fold change > 2 between 
the 2014 and 2015 miRNA microarrays. 61 probes were upregulated in the 2015 
microarrays and 120 probes were downregulated. Most of the probes that were 
differentially expressed were control probes. This result suggests that the 2014 and 
2015 miRNA microarrays were inherently significantly different from one another. 
This can occur due to differences in the fluorescence between arrays due to different 
consumables being used. As the dyes used in microarray analysis are photosensitive 
they can degrade over time resulting in different levels of fluorescence.(367) 
Therefore, the decision was made not to combine the 2014 and 2015 miRNA 
microarrays in one analysis and they were analysed using SAM separately. 
Combining SAM analyses from 2014 and 2015 results 
In an attempt to combine results from both miRNA microarray analyses the following 
analysis was performed. The list of miRNAs significantly differentially expressed 
(between COPD and non-COPD) with a fold change 2 from the 2014 arrays was 
compared to the 2015 array data. miRNAs that were not significant in the 2014 
arrays were deleted from the 2015 array data. This was used to create a SAM input 
file (table 2.3) for the 2015 arrays where only the probes relating to significantly 
differentially expressed miRNAs in 2014 microarrays were included. This shortened 
2015 array data was run through SAM limiting the results to fold change 2. 165 
probes were significantly (fold change 2) upregulated in COPD in this analysis. No 
probes were significantly downregulated. The SAM plot for this analysis and the 
corresponding heatmap is in figure 3.2. 
The opposite analysis was also performed: the list of miRNAs significantly 
differentially expressed (between COPD and non-COPD) with a fold change 2 from 
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the 2015 arrays was compared to the 2014 array data. miRNAs that were not 
significant in the 2015 arrays were deleted from the 2014 array data. This was used 
to create a SAM input file (table 2.3) for the 2014 arrays where only the probes 
relating to significantly differentially expressed miRNAs in 2015 microarrays were 
included. This shortened 2014 array data was run through SAM limiting the results to 
fold change 2. 1696 probes were significantly (fold change 2) upregulated in COPD 
in this analysis. No probes were significantly downregulated. The SAM plot for this 
and the corresponding heatmap is in figure 3.2. 
The two final SAM analyses (2015 data limited to significantly differentially expressed 
2014 miRNAs and 2014 data limited to significantly differentially expressed 2015 
miRNAs) were directly compared to one another using excel. Probes that were 
significantly differentially expressed in both analyses were identified. These probes 
related to 43 upregulated miRNAs that are in table 3.6. 
3.3.3 Computer prediction of targets of identified miRNAs 
The 43 miRNAs identified in the SAM analysis were uploaded into two computer 
prediction programs for miRNA targeting: TargetScan (368) and DIANA-Micro-T-CDS 
(369). Two programs were used in order to minimise missing targets. The results of 
the predictions for each miRNA were compared to the list of endothelial mRNA 
targets identified from the mRNA microarrays performed in section 3.4.2. 37 miRNAs 
were possible modifiers of the endothelial mRNAs of interest. A literature search was 
performed and 8 miRNAs were chosen for further validation work as these have been 
previously expressed in endothelium.(370-377) The miRNAs chosen for validation 







Figure 3.2: SAM plots and corresponding heatmaps for the miRNA microarray 
analysis using SAM. A: 2015 microarray data limited to probes significantly 
differentially expressed in 2014.  B: 2014 microarray data limited to probes 
significantly differentially expressed in 2015. These are graphical representations of 
the statistics for each probe. Probes that are upregulated are in red and those that 






Table 3.6: Significantly upregulated miRNAs in COPD 
























This table demonstrates the 43 miRNAs that were significantly upregulated in COPD 
vs non-COPD in both the SAM 2015 and 2014 miRNA microarray analyses.  
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Table 3.7: miRNAs selected for validation work 
miRNA  Previous evidence of endothelial expression Reference 
hsa-miR-181b-3p Expressed in HUVEC in vitro. Downregulates NK-
κB signalling. 
(370) 
hsa-miR-342-5p Associated with endothelial dysfunction in obese 
children (n=70) 
(371) 
hsa-miR-18b-3p Expressed in endothelial progenitor cells in vitro. (372) 
hsa-miR-193b-5p Altered expression in chronic hypoxia model in 
mouse aortic endothelial cells. 
(373) 
hsa-miR-374a-3p Controls pre-B-cell colony-enhancing 
factor/NAMPT expression in HPEC in response to 
mechanical stress in vitro. 
(374) 
hsa-miR-378a-5p Detected in human corneal endothelial cells. (375) 
hsa-miR-429 Increased levels in human aortic endothelial cells 
results in suppression of Bcl-2 and apoptosis. 
(376) 
hsa-miR-23c Enriched in endothelial cells and promotes 




This table outlines the 8 miRNAs that were chosen for validation work. These 
miRNAs were significantly upregulated in both the 2014 and 2015 SAM miRNA 
microarray analyses. All 8 miRNAs were predicted to target endothelial mRNAs of 
interest identified in the mRNA microarray analysis (section 3.4.2). The 8 miRNAs 
were chosen for further validation as they have been previously expressed in 
endothelium. Evidence for endothelial expression for each target is listed in the table 












3.3.4 qPCR validation of miRNA targets 
qPCR validation of all potential miRNA targets was performed prior to moving on to 
functional validation. This was performed as due to the large number of genes tested 
in microarray false positive results can occur.(378) Prior to performing qPCR for 
miRNA targets it was necessary to confirm that pulmonary endothelium was enriched 
in the samples extracted using ulex-coated magnetic beads. (To ensure that 
endothelial extraction had been successful). To do this qPCR was performed to 
compare CD31 expression in the endothelial isolates (n=14) to the bulk remainder 
tissue (n=6). Figure 3.3 illustrates the results of this qPCR experiment. The 
expression of CD31 was significantly increased in the endothelial isolate by over 2.5 
fold (p=0.012). It is worth noting that endothelial isolation using the same method has 
previously shown a greater enrichment for CD31 than seen in this experiment (eg 15-
fold in lung tumour). The reduced fold increase seen here is likely due to the fact that 
the lung is highly vascular and the proportion of endothelial cells in the lung is high 
(30%). (304) 
After endothelial enrichment was confirmed qPCR was performed to validate the 
expression of the potential miRNA targets in table 3.7. 4 COPD and 4 non-COPD 
samples were tested for expression of each of the miRNAs listed in table 3.7. Figure 
3.4 illustrates the results of the qPCR experiments for each miRNA. The expression 
of all miRNAs was increased in COPD. However, only miR-181b-3p, miR-429 and 
miR-23c were significantly increased in COPD.  
Significance testing between groups was performed using t-tests to compare mean 
delta Ct in COPD and non-COPD. Delta Ct was chosen as it is the outcome value 




Figure 3.3: qPCR validation of endothelial enrichment. qPCR was used to determine 
the expression of CD31 in endothelial isolates in comparison to bulk tissue isolates. 
Flotillin 2 was used as the house-keeping gene to which the data was normalised. 
Expression of CD31 in the endothelial isolate was normalised to that of the bulk 
tissue sample. The double delta Ct method was used to compare the expression 
levels. Fold change was calculated from the delta Ct levels for CD31 expression in 
endothelial isolates (n=14) in comparison to mean delta Ct for bulk tissue isolates 
(n=6). Figure represents mean fold change; error bars being SEM (standard error of 
the mean) fold change. A t-test was used to determine significance between mean 


































   
   
   
   
Figure 3.4: qPCR validation of potential miRNA targets. qPCR was used to determine 
the expression of each miRNA target in COPD in comparison to non-COPD. RNU48 
was used as the house-keeping small RNA to which the data was normalised. 
Expression of miRNA targets in COPD was normalised to that of non-COPD. The 
double delta Ct method was used to compare the expression levels. Fold change 
was calculated from the delta Ct levels for miRNA expression in COPD (n=4) in 
comparison to mean delta Ct for non-COPD (n=4). Figures represent mean fold 
changes; error bars being SEM fold change. A t-test was used to determine 



































































































































































3.3.5 Validation of potential miRNA targets using qPCR in lung cancer  
In order to identify potential miRNA targets in both COPD and lung cancer further 
miRNA qPCR experiments were performed using RNA isolated from lung tumour 
pulmonary endothelial cells (collected from patients in section 2.1.1). The expression 
of each miRNA in lung cancer (n=6) was compared to expression in non-COPD 
(n=4). MiR-181b-3p and -23c were not expressed in the lung tumour samples. 
However, miR-429 was significantly increased in the lung tumour samples by 9-fold. 
Figure 3.5 illustrates the results of the qPCR experiment for miR-429.  
3.4 mRNA expression in the lung endothelium 
3.4.1 Subjects 
Baseline demographics of the entire cohort of patients are shown in table 3.8. Patient 
groups did not differ in terms of any of the demographics listed. There was no 
significant difference in tumour stage in the 2 groups (table 3.9). 
3.4.2 Combined analysis of 2014 and 2016 microarrays 
As there were no significant differences between the 2014 and 2016 microarray 
groups the two groups were combined into one analysis comparing COPD and non-
COPD patients (tables 3.10 and 3.11). There was no difference between groups in 
terms of sex, age, BMI, current smoking status or tumour stage. FEV1pp was 
significantly lower in the COPD group (p=0.035). Pack year history was greater in the 








Figure 3.5: qPCR validation of miR-429 in lung cancer. qPCR was used to determine 
the expression of each miR-429 in lung cancer in comparison to non-COPD. RNU48 
was used as the house-keeping small RNA to which the data was normalised. 
Expression of miR-429 in lung cancer was normalised to that of non-COPD. The 
double delta Ct method was used to compare the expression levels. Expression was 
calculated from the delta Ct levels for miRNA expression in lung cancer (n=6) in 
comparison to mean delta Ct for non-COPD (n=4). Figures represent mean fold 
changes; error bars being SEM fold change. A t-test was used to determine 







































Table 3.8: Patient demographics comparing 2014 to 2016 mRNA microarrays. 
Variable All 2014 2016 p value 
Total patients 14 7 7  
Male patients 6 (42.9%) 2 (28.6%) 4 (57.1%) 0.592 
Age 64.14 (13.18) 65.00 (23.00) 68.00 (35.00) 1.000 
BMI 22.37 (4.82) 26.53 (4.65) 24.20 (5.06) 0.389 
Pack year 
history 
29.29 (23.28) 40.00 (20.00) 19.00 (18.00) 0.259 
Current 
smoker 
3 (21.4%) 2 (28.6) 1 (14.3%) 1.000 
FEV1pp 85.38 (23.97) 90.38 (11.14) 80.39 (48.78) 0.458 
 
A comparison of patient demographics for all patients included in the 2014 and 2016 
microarray analyses. Continuous variables that are normally distributed are 
presented in standard font as mean (standard deviation). T-tests were used to 
identify significant differences between normally distributed groups. Continuous 
variables that are not normally distributed are presented in italics as median 
(interquartile range). The Mann-Whitney U test was used to identify differences 
between non-normally distributed groups. Categorical variables are presented with 
percentages and fisher’s exact test was used to identify significant differences 
between groups.  
Table 3.9: Number of patients in each group with each tumour stage.  
Disease stage All 2014 2016 p value 
No cancer 3 0 3 0.057 
0 (in situ) 1 1 0 
IA 2 2 0 
IB 2 2 0 
IIA 0 0 0 
IIB 2 0 2 
IIIA 3 2 1 
Lung 
metastases 
1 0 1 
 
This table lists the total number of patients with each stage of cancer in the mRNA 
microarray analyses. Percentages of patients with each tumour stage are listed in 
brackets. The number (and percentage) of patients with each stage is also listed by 
year. Fisher’s exact test was used to determine if there was a significant difference 




Table 3.10: Patient demographics comparing COPD to non-COPD patients in the 
combined mRNA microarray analysis. 
Variable All Non-COPD COPD p value 
Total patients 14 6 8  
Male patients 6 (42.9%) 3 (50%) 3 (37.5%) 1.000 
Age 64.14 (13.18) 67.00 (15.99) 62.00 (11.31) 0.505 
BMI 22.37 (4.82) 27.26 (5.39) 23.94 (4.13) 0.215 
Pack year 
history 
29.29 (23.28) 17.33 (16.29) 38.25 (24.55) 0.097 
Current 
smoker 
3 (21.4%) 1 (16.67%) 2 (25%) 1.000 
FEV1pp 85.38 (23.97) 100.49 (16.74) 74.05 (22.90) 0.035 
 
A comparison of patient demographics for all patients included in the combined 
microarray analyses. Continuous variables that are normally distributed are 
presented in standard font as mean (standard deviation). T-tests were used to 
identify significant differences between normally distributed groups. Continuous 
variables that are not normally distributed are presented in italics as median 
(interquartile range). The Mann-Whitney U test was used to identify differences 
between non-normally distributed groups. Categorical variables are presented with 
percentages and fisher’s exact test was used to identify significant differences 
between groups. Significant p values (<0.05) are presented in bold. 
Table 3.11: Number of patients in each group with each tumour stage.  
Disease stage All Non-COPD COPD p value 
No cancer 3 1 2 0.904 
0 (in situ) 1 0 1 
IA 2 0 2 
IB 2 1 1 
IIA 0 0 0 
IIB 2 1 1 
IIIA 3 2 1 
Lung 
metastases 
1 1 0 
 
This table lists the total number of patients with each stage of cancer in the mRNA 
microarray analyses. Percentages of patients with each tumour stage are listed in 
brackets. The number (and percentage) of patients with each stage is also listed by 
group (COPD vs non-COPD). Fisher’s exact test was used to determine if there was 
a significant difference between the proportion of patients with each stage of cancer 





Samples were analysed using Limma to perform differential mRNA expression 
analysis as per section 2.5.2. 32 mRNAs were significantly differentially expressed 
between the 2 groups (p<0.05) and had a log fold change (logFC) >1: 20 
downregulated and 12 upregulated. None of the mRNAs are known to be endothelial 
expressed. The FDR was not significantly different for any mRNA between groups. A 
summary of the array result can be found in table 3.12. 
Significance Analysis of Microarrays (SAM) 
In a similar way to the miRNA data a SAM analysis was performed (section 2.5.4) 
comparing all 2014 mRNA microarray and all 2016 mRNA microarray results. The 
plot from this analysis is in figure 3.6. 
39154 probes were significantly differentially expressed with a fold change > 2 
between the 2014 and 2016 mRNA microarrays. 12695 probes were upregulated in 
the 2016 microarrays and 26459 probes were downregulated. This represents the 
vast majority of probes and included many control probes. This result suggests that 
the 2014 and 2016 mRNA microarrays were inherently significantly different from one 
another. Therefore, again, the decision was made not to combine the 2014 and 2016 






























8 6 138 89 20 12 
 
This table outlines the number of patient samples with and without COPD included in 
the combined limma mRNA microarray analysis and the number of mRNAs 
significantly downregulated/upregulated in the COPD group. A moderated t-statistic 
is used to determine significance between groups. 
 
Figure 3.6: SAM plot for the analysis comparing 2014 and 2016 mRNA microarrays. 
This is a graphical representation of the statistics for each probe. Probes that are 
upregulated in group 2 (2016) are in red. Probes in green are downregulated in group 





Combining SAM analyses from 2014 and 2016 results 
In an attempt to combine results from both mRNA microarray analyses the following 
analysis was performed. The list of mRNAs significantly differentially expressed 
(between COPD and non-COPD) with a fold change 2 from the 2014 arrays was 
compared to the 2016 array data. mRNAs that were not significant in the 2014 arrays 
were deleted from the 2016 array data. This was used to create a SAM input file 
(table 2.3) for the 2016 arrays where only the probes relating to significantly 
differentially expressed mRNAs in 2014 microarrays were included. This shortened 
2016 array data was run through SAM limiting the results to fold change 2. 1355 
probes were significantly (fold change 2) upregulated in COPD in this analysis. 
37799 probes were significantly downregulated. The SAM plot for this analysis and 
the corresponding heatmap are in figure 3.7. 
The opposite analysis was also performed: the list of mRNAs significantly 
differentially expressed (between COPD and non-COPD) with a fold change 2 from 
the 2016 arrays was compared to the 2014 array data. mRNAs that were not 
significant in the 2016 arrays were deleted from the 2014 array data. This was used 
to create a SAM input file (table 2.3) for the 2014 arrays where only the probes 
relating to significantly differentially expressed mRNAs in 2016 microarrays were 
included. This shortened 2014 array data was run through SAM limiting the results to 
fold change 2. 2113  probes were significantly (fold change 2) upregulated in COPD 
in this analysis. No probes were significantly downregulated. The SAM plot for this 
analysis and the corresponding heatmap are in figure 3.7. 
The two final SAM analyses (2016 data limited to significantly differentially expressed 
2014 mRNAs and 2014 data limited to significantly differentially expressed 2016 
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mRNAs) were directly compared to one another using excel. Probes that were 
significantly differentially expressed in both analyses were identified. 2071 genes 
(including duplicates) were significantly positively upregulated in COPD in both 
analyses. This list was compared to a known list of endothelial expressed genes. 
[Personal communication with R. Bicknell.] 6 known endothelial genes were 
upregulated in COPD:  
x DLC1 (Rho GTPase activating protein). 
x HHIP (Hedgehog interacting protein). 
x LTA4H (Leukotriene A4 Hydrolase). 
x PPIL2 (Peptidlyprolyl isomerase 2). 
x TMEM154 (Transmembrane protein 154). 
x TP53 (Tumour suppressor 53). 







Figure 3.7: SAM plots and corresponding heatmaps for the mRNA microarray 
analysis using SAM. A: 2016 microarray data limited to probes significantly 
differentially expressed in 2014.  B: 2014 microarray data limited to probes 
significantly differentially expressed in 2016. These are graphical representations of 
the statistics for each probe. Probes that are upregulated are in red and those that 







3.4.3 Tumour mRNA analysis 
In order to investigate whether there were any shared targets between COPD and 
lung cancer a further mRNA microarray was performed using three tumour 
endothelial samples. As the 2014 and 2016 non-COPD lung tissue endothelial arrays 
were inherently different from one another the decision was made to compare the 
three tumour endothelial samples to the non-COPD 2014 microarray data and the 
2016 microarray data in separate analyses. A similar univariate analysis was 
performed (as in section 3.4.2) comparing the demographics of patients from the 
tumour microarray data to the non-COPD patients from the 2014 and 2016 
microarray data (tables 3.13-3.16). 
There were no significant differences in baseline demographics between non-COPD 
patients in either microarray analysis and patients in the tumour microarray analysis. 
There was also no significant difference in tumour stage between non-COPD patients 
and tumour patients. 
SAM analysis: 2014 non-COPD versus tumour 
A SAM input file (table 2.3) was created for the 2014 non-COPD and tumour data. 
This was run through SAM limiting results to fold change 2. 7261 probes were 
significantly downregulated in the tumour group. No probes were upregulated. The 






Table 3.13: Patient demographics comparing 2014 non-COPD patients to tumour 
tissue patients. 
Variable All Non-COPD 
2014 
Tumour p value 
Total patients 6 3  3  
Male patients 1 (16.7%) 1 (33.3%) 0 1.000 
Age 66.67 (12.34) 72.67 (14.57) 60.67 (7.77) 0.277 
BMI 25.58 (4.69) 28.22 (4.13) 22.94 (4.12) 0.192 
Pack year 
history 
10.00 (48.75) 20.00  0 1.000 
Current 
smoker 
1 (16.7%) 0 1 (33.3%) 1.000 
FEV1pp 103.09 (33.59) 95.62 (13.12) 87.56 (33.81) 0.865 
 
A comparison of patient demographics for all patients included in the mRNA 
microarray analysis: non-COPD 2014 vs lung tumour. Continuous variables that are 
normally distributed are presented in standard font as mean (standard deviation). T-
tests were used to identify significant differences between normally distributed 
groups. Continuous variables that are not normally distributed are presented in italics 
as median (interquartile range). The Mann-Whitney U test was used to identify 
differences between non-normally distributed groups. Categorical variables are 
presented with percentages and fisher’s exact test was used to identify significant 
differences between groups.  
Table 3.14: Number of patients in each group (non-COPD 2014 and tumour) with 
each tumour stage.  
Disease stage All Non-COPD 
2014 
Tumour p value 
No cancer 0 0 0 0.400 
0 (in situ) 0 0 0 
IA 1 0 1 
IB 3 1 2 
IIA 0 0 0 
IIB 0 0 0 
IIIA 2 2 0 
Lung 
metastases 
0 0 0 
This table lists the total number of patients with each stage of cancer in the mRNA 
microarray analysis: non-COPD 2014 vs lung tumour. Percentages of patients with 
each tumour stage are listed in brackets. The number (and percentage) of patients 
with each stage is also listed by group (non-COPD vs tumour). Fisher’s exact test 
was used to determine if there was a significant difference between the proportion of 
patients with each stage of cancer in each group. 
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Table 3.15: Patient demographics comparing 2016 non-COPD patients to tumour 
tissue patients.  
Variable All Non-COPD 
2016 
Tumour p value 
Total patients 6 3 3  
Male patients 2 2 (66.7%) 0 0.400 
Age 61.00 (12.51) 61.33 (18.18) 60.67 (7.77) 0.956 
BMI 24.62 (5.59) 26.30 (7.26) 22.94 (4.12) 0.524 
Pack year 
history 
6.50 (42.00) 13.00  0 1.000 
Current 
smoker 
2 (33.3%) 1 (33.3%) 1 (33.3%) 1.000 
FEV1pp 96.45 (27.11) 105.36 (21.39) 87.56 (33.81) 0.484 
 
A comparison of patient demographics for all patients included in the mRNA 
microarray analysis: non-COPD 2016 vs lung tumour. Continuous variables that are 
normally distributed are presented in standard font as mean (standard deviation). T-
tests were used to identify significant differences between normally distributed 
groups. Continuous variables that are not normally distributed are presented in italics 
as median (interquartile range). The Mann-Whitney U test was used to identify 
differences between non-normally distributed groups. Categorical variables are 
presented with percentages and fisher’s exact test was used to identify significant 
differences between groups. Significant p values (<0.05) are presented in bold. 
Table 3.16: Number of patients in each group (non-COPD 2016 and tumour) with 
each tumour stage.  
Disease stage All Non-COPD 
2016 
Tumour p value 
No cancer 1 1 0 0.400 
0 (in situ) 0 0 0 
IA 1 0 1 
IB 2 0 2 
IIA 0 0 0 
IIB 1 1 0 
IIIA 0 0 0 
Lung 
metastases 
1 1 0 
This table lists the total number of patients with each stage of cancer in the mRNA 
microarray analysis: non-COPD 2016 vs lung tumour. Percentages of patients with 
each tumour stage are listed in brackets. The number (and percentage) of patients 
with each stage is also listed by group (non-COPD vs tumour). Fisher’s exact test 
was used to determine if there was a significant difference between the proportion of 
patients with each stage of cancer in each group.  
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SAM analysis: 2016 non-COPD versus tumour 
A SAM input file (table 2.3) was created for the 2016 non-COPD and tumour data. 
This was run through SAM limiting results to fold change 2. 25939 probes were 
significantly differentially expressed between the two groups (12646 were 
upregulated and 13293 were downregulated in the tumour data). The SAM plot for 
this analysis and the corresponding heatmap are in figure 3.8. 
Comparison of tumour microarray analyses to COPD microarray analysis 
To identify joint COPD and tumour targets the results of the tumour and COPD 
analyses were compared. Table 3.17 demonstrates whether the COPD targets from 
section 3.4.2 were also differentially expressed in lung tumour. None of the results for 
the COPD targets from the analysis: non-COPD 2014 vs lung tumour were consistent 
with results from the COPD vs non-COPD mRNA microarrays. However, in the non-
COPD 2016 vs lung tumour analysis, DLC1, PPIL2 and TP53 were upregulated in 
lung tumour thus potentially being shared targets. 
3.4.4 Validation of potential mRNA targets using qPCR 
In order to validate the expression of the potential mRNA targets in table 3.17 qPCR 
(section 2.6.2) was performed using RNA isolated from endothelial samples collected 
from patients in section 2.1.1. qPCR was completed for the six potential mRNA 
targets comparing target expression in COPD (n=7) and non-COPD (n=7). The 
results of this analysis are shown in figure 3.9. The expression of LTA4H was 
increased by over two-fold in COPD approaching statistical significance (p=0.067). 
The expression of the other genes did not vary between groups. PPIL2 was not 





Figure 3.8: SAM plots and corresponding heatmaps for the mRNA lung tumour 
microarray analysis using SAM. A: non-COPD 2014 microarray data vs lung tumour.  
B: non-COPD 2016 microarray data vs lung tumour. These are graphical 
representations of the statistics for each probe. Probes that are upregulated are in 
red and those that are downregulated are in green. SAM uses the d statistic to 






Table 3.17: A comparison of the results of the COPD mRNA microarray analysis and 
the two tumour mRNA microarray analyses for the 6 possible targets identified in the 
COPD analysis (section 3.4.2). 










DLC1 Up Down Up 
HHIP Up Down Down 
LTA4H Up Not significant Not significant 
PPIL2 Up Not significant Up 
TMEM154 Up Not significant Down 
TP53 Up Not significant Up 
 
This table lists the 6 targets that were identified in section 3.4.2 as being significantly 
upregulated in COPD. The third column lists whether or not these targets were 
significantly altered in the non-COPD 2014 vs lung tumour mRNA microarray 
analysis. The fourth column lists whether or not these targets were significantly 
altered in the non-COPD 2014 vs lung tumour mRNA microarray analysis. The d 








Figure 3.9: qPCR validation of potential mRNA targets. qPCR was used to determine 
the expression of each mRNA target in COPD in comparison to non-COPD. Flotillin 2 
was used as the house-keeping gene to which the data was normalised. Expression 
of mRNA targets in COPD was normalised to that of non-COPD. The double delta Ct 
method was used to compare the expression levels. Fold change was calculated 
from the delta CT levels for mRNA expression in COPD (n=7) in comparison to mean 
delta Ct for non-COPD (n=7). Figures represent mean fold changes; error bars being 















































































































3.5.1 miRNA expression in pulmonary endothelium 
This study has identified eight miRNAs which are upregulated in COPD endothelial 
cells: miR-181b-3p, -342-5p, -18b-3p, 193b-5p, 374a-5p, 378a-5p, -429 and -23c. 
However, only miR-181b-3p, -429 and -23c reached statistical significance. These 
miRNAs were not identified in the previous COPD microarray studies, but this is not 
unexpected as results from this study are endothelial cell specific whereas other 
studies looked at whole lung or other cell types.  
There is very little evidence about the function of miR-181b-3p. However, recently 
this miRNA has been shown to regulate epithelial-mesenchymal transition (EMT) in 
breast cancer cells in vitro.(380) miR-181b-3p appears to upregulate the expression 
of Snail, a protein of importance in inducing EMT.(380) miR-181b-3p inhibitors 
reduce migration and mesenchymal markers in highly invasive breast cancer cells in 
vitro.(380) Also, transfection of miR-181b-3p into breast cancer cells increases 
metastatic nodule formation in the lungs of mice.(380) Therefore, it is possible that 
the upregulation of miR-181b-3p in the COPD lung may be a reason for the 
increased malignancy seen in this patient group. Further support for this hypothesis 
comes from the evidence that miR-181b-5p (a related miRNA from the same 
precursor as miR-181b-3p), is upregulated in lung squamous cell carcinoma and 
adenocarcinoma. (381, 382) miR-181b-5p targets and suppresses Ras association 
domain family member 1 (RASSF1), a known tumour suppressor.(382) Another miR-
181b-5p target of importance is programmed cell death 4 (PCD4), a RNA-binding 
protein tumour suppressor of importance in several cancer types including lung 
cancer.(383, 384) miR-181b promotes cell proliferation and migration and 
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suppresses apoptosis in vitro in colorectal cancer (CRC) cells, potentially through the 
downregulation of PCD4.(383) There is evidence that miR-181b-5p may be important 
in EMT in the same way as miR-181b-3p: overexpression of miR-181b-5p in gastric 
cancer cells in vitro appears to induce EMT.(385) miR-181b also increases nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity by suppressing 
CYLD lysine deubiquitinase (CYLD).(386, 387) NF-κB is a ubiquitous transcription 
factor that plays an important role in the regulation of immune responses and 
inflammation;(323) aberrant activation of NF-κB can also result in oncogenesis.(324) 
By regulating CYLD, miR-181b seems to be important in cell proliferation and 
resistance to apoptosis.(386) Even transient expression of miR-181b-1 (stem loop 
precursor of miR-181b-3p and -5p) appears to be enough to upregulate NF-κB 
activity and transform cells to a malignant phenotype.(387) The miR-181b- NF-κB 
pathway may also be of importance in pulmonary inflammation. For example, 
lipopolysaccharide (LPS) stimulation of human bronchial epithelial cells results in the 
upregulation of miR-181b.(388) By overexpressing miR-181b in bronchial epithelial 
cells, p65 (a primary component of NF-κB) was increased in addition to interleukin 
(IL)-6 levels.(388) This suggests that miR-181b acts as a pro-inflammatory factor by 
the upregulation of the NF-κB pathway in vitro. There is other evidence that miR-
181b-5p is important in inflammation. For example, miR-181b is upregulated in 
sepsis and its’ suppression improved both bacterial clearance and mortality in mice 
models of sepsis.(389) miR-181b is also increased in gingival tissue in periodontitis, 
an inflammatory dental condition associated with COPD.(390, 391)  
There is recent evidence that miR-181b may be involved in angiogenesis. Xu et al 
discovered that miR-181b is upregulated in hypoxic conditions in retinoblastoma 
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cells.(392) This team then overexpressed miR-181b in retinoblastoma cells before 
transferring the retinoblastoma culture medium to Human Umbilical Vein Endothelial 
Cells (HUVECs).(392) Addition of the retinoblastoma medium increased capillary 
tube formation in the HUVECs.(392) In contrast, when the same experiment was 
performed with suppressing miR-181b in retinoblastoma cells, capillary tube 
formation of HUVECs was reduced.(392) This suggests that miR-181b enhanced the 
angiogenesis capability of HUVECs.(392) Therefore, it is possible that upregulation 
of miR-181b seen in COPD endothelial cells in this study might lead to an increased 
capability of these cells to undergo angiogenesis which again, might contribute to the 
increased risk of lung cancer seen in such patients. In summary, there is evidence 
that miR-181b-3p may have a role in EMT and could potentially increase lung cancer 
risk in COPD patients. There is also evidence that miR-181b-3p’s precursor (miR-
181b) and its’ related miRNA miR-181b-5p might increase cancer risk by the 
suppression of various tumour suppressors and by upregulating the NF-κB pathway. 
miR-181b also appears to be important in the upregulation of inflammation and 
therefore could potentially contribute to increased inflammation seen in COPD 
patients. Finally, miR-181b overexpression in endothelial cells appears to increase 
angiogenesis, an important mechanism involved in tumour progression (section 
1.4.2). 
However, the evidence for miR-181b’s involvement in malignancy, inflammation and 
angiogenesis is inconsistent. For example, Yang et al found reduced miR-181b 
expression in NSCLC tissue, which was associated with increased tumour size, 
higher cancer stage and reduced disease-free survival.(393) miR-181b has also 
been shown to be downregulated in glioma and gastric cancer cell lines.(394, 395) 
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Sun et al have shown conflicting results to the above studies related to the NF-κB 
pathway.(370) In their study miR-181b appeared to suppress the NF-κB pathway and 
was suppressed (in aortic tissue) in response to delivery of proinflammatory stimuli in 
mice.(370) Furthermore, patients with sepsis had reduced circulating levels of miR-
181b.(370) Similarly, miR-181b appears to be reduced in inflammatory plaques 
associated with atherosclerosis in mice and treatment with miR-181b microparticles 
reduces endothelial inflammation and atherosclerosis in mouse models. (396) Finally, 
miR-181b is also reduced in chick embryos in response to arsenic and its’ reduction 
seems to facilitate arsenic-associated angiogenesis.(397) Therefore, there is 
conflicting evidence about the role of miR-181b in tumorigenesis, inflammation and 
angiogenesis. Also, despite evidence linking miR-181b-3p to cancer this miRNA was 
not upregulated in lung cancer endothelial cells in this study. Most studies performed 
so far have only looked at miR-181b-3p’s precursor or related miRNAs rather than 
miR-181b-3p itself. Also, no studies of this miRNA have looked at its’ expression in 
COPD or pulmonary endothelial cells. Therefore, further functional validation work of 
miR-181b-3p is warranted. 
MiR-429 has been associated with various types of cancers. However, in a similar 
way to miR-181b, miR-429 has been both up- and down-regulated in cancer. For 
example, it is increased in colorectal and ovarian cancers, but reduced in renal 
cancer.(398-400) However, miR-429 does appear to be more consistently increased 
in lung cancer. For example, Lang et al demonstrated that miR-429 was increased in 
lung cancer tissue and lung cancer cell lines.(401) Overexpression of miR-429 also 
resulted in increased cell proliferation, migration and invasion in A549 lung cancer 
cells.(401) It is possible that miR-429 may cause this change in cell behaviour by 
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targeting and suppressing known tumour-suppressors: phosphatase and tensin 
homolog (PTEN), a phosphatase involved in apoptosis, Ras association domain 
family member 8 (RASSF8), a protein that maintains adherent junction function and 
TIMP metalloproteinase inhibitor (TIMP2) which suppresses metastasis.(401) 
Interestingly, miR-429 has also been shown to target DLC1 (a gene identified in the 
mRNA microarray part of this study). MiR-429 suppresses DLC1 which increases cell 
proliferation in vitro.(402) Another possible target of importance in the increase cell 
proliferation seen with upregulation of miR-429 is p27kip1.(403) P27kip1 is a cyclin-
dependent kinase inhibitor and is involved in the progression of the cell cycle.(403) In 
addition to miR-429 being upregulated in lung tumour versus normal lung miR-429 
has also been shown to be upregulated in serum from patients with lung cancer 
compared to serum from patients with COPD. (404) Perhaps, therefore, it is possible 
that miR-429 is upregulated in COPD initially and further increases in expression of 
this miRNA contribute to the development of lung cancer in these patients. This is 
supported by results from the qPCR experiments in this study. MiR-429 was 
increased by 2-fold in COPD pulmonary endothelial cells, but 9-fold in lung cancer 
pulmonary endothelial cells (in comparison to non-COPD controls). Genetic variants 
in miR-200 family, of which miR-429 is a part, have also been shown to be related to 
lung cancer. The SNP in rs9660710 in the miR-200b/200a/429 cluster is significantly 
associated with lung cancer risk and is located in the regulatory elements in lung 
cancer cells.(405) 
One mechanism of miR-429 upregulation that may be of particular importance in 
COPD is hypoxia. MiR-429 has been shown to be upregulated in hypoxic conditions 
in cardiomyocytes in vitro.(406) Downregulation of miR-429 in the same cell culture 
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also protected cells against apoptosis through the activation of notch1 (an 
intercellular signalling protein).(406) If miR-429 exerts similar effects on lung 
endothelial cells, it is possible that upregulation of miR-429 might result in endothelial 
apoptosis and consequent emphysema in COPD patients. Mir-429 is also 
upregulated in response to hypoxia in endothelial cells.(407) Bartoszewska et al 
demonstrated that miR-429 is upregulated by the hypoxia-inducible factor (HIF-) α in 
human umbilical vein endothelial cells.(407) Interestingly, miR-429 also 
downregulated HIF-α and therefore may act as a negative regulator of HIF-α during 
the cell response to hypoxia.(407) Another mechanism that may induce apoptosis in 
endothelial cells through upregulation of miR-429 is targeting Bcl-2, an anti-apoptotic 
protein.(376) In vivo studies using mouse models have demonstrated that miR-429 is 
upregulated in aortic endothelial cells of mice with atherosclerosis and that this is 
associated with endothelial apoptosis.(376) Again, if miR-429 has a similar function 
in pulmonary endothelial cells it is possible that this could result in pulmonary 
endothelial apoptosis and emphysema. Patients without emphysema are unlikely to 
be hypoxic and consequently this mechanism is most likely to be involved in the 
worsening of emphysema rather than emphysema initiation. 
MiR-429 may also play an important role in pulmonary inflammation. Studies in rat 
pulmonary macrophages have shown that miR-429 is upregulated in response to 
lipopolysaccharide (LPS) stimulation.(408) The miR-429 upregulation results in the 
production of pro-inflammatory cytokines through the targeting of DUSP1 (dual-
specificity phosphatase 1).(408) DUSP1 inactivated p38 MAPK (mitogen-activated 
protein kinase), an important intracellular signalling molecule which leads to the 
production of pro-inflammatory cytokines such as TNF-α (tumour necrosis factor α) 
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and IL-1β (interleukin-1β).(408) Thus, miR-429 effectively results in an increase in 
p38 MAPK activity and pro-inflammatory cytokine production. This may therefore 
have an important impact in COPD in which the level of pro-inflammatory cytokines 
are high. 
In conclusion, miR-429 appears to have a role in pulmonary inflammation and 
endothelial apoptosis which are two important mechanisms in COPD pathogenesis. 
Also, miR-429 seems to be upregulated in lung cancer and targets known tumour 
suppressors. As miR-429 is increased in both COPD and lung cancer in this study it 
provides a potential common target for both diseases. Therefore, further functional 
validation of miR-429 in the pulmonary endothelium is required to establish its’ 
importance in these diseases further. 
The available information on miR-23c is also limited. So far the only study in humans 
that looked at the expression of miR-23c was performed in prostate cancer cells. This 
showed an upregulation of miR-23c in prostate cancer chemoresistant cells in 
comparison to cells that were chemosensitive.(409) MiR-23c also appears to target 
the tumour suppressor PTEN in a similar way to miR-429 and may therefore play a 
role in tumourigenesis.(409) In support of this miR-23 may also increase cell 
proliferation; downregulation of miR-23 in vitro reduced the growth of lung cancer 
cells.(410) Other potential mechanisms of miR-23c action may come from studies 
looking at related miRNAs. For example, studies have demonstrated that miR-23 is 
upregulated in endothelial progenitor cells (EPCs) in patients with coronary artery 
disease compared to controls.(411) MiR-23 also targets VEGF – inhibition of miR-23 
led to increased VEGF levels and angiogenic activities of EPCs in vitro.(411) Further 
support for the role of miR-23 in angiogenesis comes from studies of glioblastoma. 
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Microvascular proliferation is important in the pathogenesis of glioblastoma; miR-23 
is downregulated in glioblastoma endothelial cells which results in the upregulation of 
two of its targets: ATP5A1 and ATP5B, both ATP synthase proteins involved in cell 
metabolism.(412) Both studies suggest that miR-23 inhibits angiogenesis through 
more than one mechanism. Upregulation of miR-23c could be a mechanism for the 
lack of angiogenesis seen in some COPD patients with emphysema, though 
evidence for this is conflicting. For example, one study which demonstrated that miR-
23 was enriched in HUVECs also showed that the anti-angiogenic proteins Sprouty2 
and Sema6A were targeted by miR-23 suggesting that miR-23 may be involved in 
the upregulation of angiogenesis instead.(377) 
MiR-23c may be increased in COPD as miR-23 is upregulated in response to 
hypoxia. MiR-23 also appears to target the apoptotic proteins caspase 7, BID (BH3 
interacting-domain death agonist) and NIX-BNIP3L (BCL2 interacting protein 3 like) 
which reduces apoptosis in response to hypoxia.(413) This mechanism could 
potentially be important in tumourigenesis. Other studies support this and have 
shown that miR-23 also targets the apoptotic protein Fas thereby reducing 
apoptosis.(414, 415)  
In summary, there is little information regarding miR-23 although it may be involved in 
malignancy. Related miRNAs also appear to be involved in angiogenesis and 
apoptosis, but this evidence is conflicting. There is also evidence that miR-23a, a 
related miRNA, is in fact a tumour suppressor rather than 23c which promotes 
tumourigenesis.(416, 417) Therefore, one has to approach extending results from 
related miRNAs to 23c function with caution. Its’ associations with cancer and the 
lack of previous investigations into its function make miR-23c a promising target to 
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investigate further. However, miR-23 did not seem to be expressed in lung cancer 
endothelial cells and therefore it is less likely to provide an endothelial mechanism for 
the common pathogenesis of COPD and lung cancer. 
3.5.2 mRNA expression in pulmonary endothelium 
This study identified 6 endothelial genes differentially expressed between COPD and 
non-COPD in microarray studies: DLC1, HHIP, LTA4H, PPIL2, TMEM154 and TP53. 
This was compared to the mRNA microarray of endothelium from tumours versus 
non-COPD lung tissue. All of these genes were differentially expressed between 
tumour and non-COPD with the exception of LTA4H, which suggested they might be 
possible shared markers of pathogenesis between COPD and lung cancer. 
Unfortunately, this was not supported by the qPCR validation studies. This is 
because each microarray contains thousands of genes and the probability of a false 
positive result increases with the number of hypotheses in a certain test.(418) Thus, 
the likelihood of false positive results occurring in a microarray is huge. It is possible 
to limit the number of false positives using statistical tests for multiple testing (such as 
the false discovery rate; FDR) but as these methods are more stringent it can result 
in important genes being missed.(418) Therefore, in this study, fold change was used 
to identify significantly differentially expressed genes with >2 used as a cut off (this 
suggests changes of biological relevance).(419) This approach should identify the 
majority of genes of interest, but will also identify multiple false positives requiring the 
need for validation by qPCR. There was very little change in expression of TMEM154 
and TP53 between COPD and non-COPD. PPIL2 was not obviously expressed in 
COPD or non-COPD pulmonary endothelium. DLC1, HHIP and LTA4H were 
increased in COPD with only LTA4H approaching significance (p=0.067). A one-
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tailed t-test was chosen in this instance as the microarray data provided a clear 
hypothesis for qPCR testing. 
Leukotriene A4 hydrolase (LTA4H) is an enzyme that has been previously 
investigated in COPD. It has both pro- and anti-inflammatory actions. Its’ hydrolase 
function catalyses the conversion of leukotriene A4 (LTA4) to leukotriene B4 (LTB4), 
a neutrophil chemoattractant.(420) However, its’ aminopeptidase function degrades 
proline-glycine-proline (PGP), a protein with sequence homology to CXC chemokines 
and also acts as a neutrophil chemoattractant.(421) Therefore, activation of LTA4H 
may result in both the development and resolution of inflammation.(422) Previous 
studies have shown that LTA4H is increased in the lung tissue of murine COPD 
models and sputum from COPD patients.(422, 423) Interestingly, smoke appears to 
inhibit the aminopeptidase function of LTA4H, but not its’ hydrolase function.(422) 
Therefore, increased LTA4H in COPD patients would lead to an increase in both 
LTB4 and PGP.(422) This effect persists in COPD patients even after smoking 
cessation and therefore makes an intriguing target for the treatment of inflammation 
in COPD.(422) The difficulty with inhibiting LTA4H completely is the risk of a further 
reduction in aminopeptidase activity and accumulation of PGP. Murine models have 
shown that blockage of the aminopeptidase function of LTA4H results in an increase 
in neutrophilic inflammation and protease imbalance resulting in degradation of the 
extracellular matrix.(424) There are different ways of approaching this. Firstly, it is 
possible to augment the aminopeptidase function of LTA4H. For example, in a 
mouse COPD model the drug 4MDM (which selectively increases aminopeptidase 
activity) resulted in decreased PGP in BAL and reduced numbers of neutrophils in 
mouse lungs.(423) This acted to prevent emphysematous remodelling in the mouse 
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model. Alternatively, a new selective LTA4H hydrolase inhibitor, ARM1 has been 
developed. (425) This would give the opportunity to selectively inhibit only the pro-
inflammatory functions of LTA4H. 
In addition to inflammation, there is also evidence that LTA4H may be important in 
endothelial apoptosis. Pulmonary hypertension (a condition that results in increased 
blood pressure in pulmonary vessels) is associated with macrophage accumulation 
near arterioles of the lung.(426) These macrophages express high levels of 
LTA4H.(426) Macrophage-derived LTB4 was shown to induce apoptosis in 
pulmonary artery endothelial cells (in vitro) by binding to its receptor BLT1 and 
inhibiting the sphingosine kinase 1- endothelial nitric oxide synthase pathway.(426) If 
LTA4H has similar effects on microvascular pulmonary endothelial cells it is possible 
that it could induce emphysema through endothelial apoptosis. 
There is less evidence available about LTA4H in lung cancer in comparison to 
COPD. This would concur with the microarray findings that did not identify LTA4H as 
an expressed target in lung cancer. However, LTA4H has been described in lepidic 
lung carcinoma in situ.(427) This in addition to its known inflammatory role may mean 
it could still potentially provide a link between the two conditions. None of the patients 
in this study had lepidic carcinoma and therefore perhaps this is why LTA4H was not 
differentially expressed between non-COPD and cancer groups. 
In summary, LTA4H looks to be a potential important marker in COPD through both 
inflammatory and apoptotic pathways. As it leads to the production of a 
chemoattractant, LTB4, it is possible that upregulation of LTA4H might result in the 




There are some limitations to this study. Firstly, it would be ideal to compare lung 
tissue from patients with COPD to tissue from patients with normal lungs. In this 
study only one patient without COPD did not have lung cancer. Therefore the miRNA 
and mRNA expression in non-COPD patients in this study could be different 
compared to patients without COPD or lung cancer. However, lung tissue is removed 
in this group of patients only rarely. For example patients with a suspicious nodule on 
CT scan that is confirmed as benign after removal. There were too few of these 
patients to provide an adequate control group for this study. Secondly, the COPD 
patients had only mild-moderate disease on average (mean FEV1pp 73%). In order 
to be fit for surgery all patients must have adequate lung function and thus most 
patients with severe COPD and lung cancer are not deemed suitable for surgery. I 
attempted to counter this selection bias by recruiting LVRS patients, however fewer 
procedures and smaller tissue volumes obtained in such patients limited the number I 
was able to recruit.  Therefore it is possible that genetic changes in more severe 
cases of COPD might have been missed.  
Samples collected by previous members of the Turner/Bicknell groups were also 
included in this study. All samples were collected in the same way and processed on 
the same type of microarray chip. However, it is possible that there may have been 
variability between how the samples were collected by different members of the team 
which could have possibly influenced results. 
There were also only small numbers of patients in each microarray experiment. 
Power calculations performed in R using the sizepower package were performed to 
estimate the number of patients required in each group to achieve 90% power at 
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detecting difference between COPD and non-COPD, using data from prior published 
work on COPD.(269) 10 samples were required per group for miRNA microarrays 
and this was achieved. However, 35 samples were required per group for mRNA 
microarrays. This was not possible to achieve due to lack of sample availability and 
cost implications. This may be the main reason that there were more significantly 
differently expressed targets seen in the miRNA validation work compared to the 
mRNA validation work. Similar power calculations suggested that 6 samples were 
needed in each group to compare normal tissue and cancer. Only 3 samples were in 
each group. However, this analysis did manage to identify differentially expressed 
mRNAs with a significant FDR and so appeared to have adequate power. 
3.6 Conclusions 
 
To our knowledge this is the first study comparing miRNA and mRNA expression in 
COPD and non-COPD pulmonary endothelial cells. There are significant differences 
in the miRNA and mRNA expression between these two groups. Three known 
endothelial miRNAs were validated using qPCR as being upregulated in COPD: miR-
181b-3p, -429 and -23c. miR-429 was also upregulated in lung cancer and provides 
the most promising target for shared pathogenesis between COPD and lung cancer. 
One mRNA of interest was also upregulated in COPD: LTA4H. This gene appears to 
be important in inflammation, transendothelial migration and apoptosis and therefore 
targeting this gene may provide a new pathway to target in COPD. As LTA4H was 
not differentially expressed in non-COPD versus lung cancer in the microarray 






PATHWAY ANALYSIS OF MICRORNA AND 





Intracellular pathways in pulmonary endothelial cells will differ significantly between 
COPD and non-COPD patients. Pathways relating to cancer development will be 
upregulated in COPD and will help to explain the increased risk of lung cancer 
development in patients with COPD. 
4.2 Aims of this chapter 
This chapter will outline the pathway analyses performed using microRNA (miRNA) 
and messenger RNA (mRNA) microarray data analysed in chapter 3. 
4.3 Introduction 
Pathway analysis of genomic data can provide a useful way of interpreting the 
biological significance of large datasets. Pathway analysis has been used 
successfully in the investigation of both COPD and lung cancer and identified shared 
biological pathways.  Thus it was appropriate to use IPA upon the miRNA and mRNA 
microarray data described in chapter 3 to identify potential pathways involved in 
COPD and whether or not they could help to explain the increased risk of lung cancer 
in COPD patients. 
4.4 Results 
4.4.1 Diseases and biological functions associated with COPD.  
Figures 4.1-4 demonstrate the top 10 diseases and biological functions associated 
with miRNA/mRNA expression in COPD endothelium for each of the 4 array 
analyses. Diseases and biological functions that are in the top 10 for all 4 analyses 
include: Cancer (the process most highly related to COPD in both mRNA arrays), 




Figure 4.1: The top 10 diseases and biological functions altered in the 2014 miRNA 
microarray data. A threshold for significance is illustrated in the figure. Diseases and 
biological functions are listed in order of significance. The p-value of overlap is used 
to determine significance between groups with a cut-off of <0.05. 
 
Figure 4.2: The top 10 diseases and biological functions altered in the 2015 miRNA 
microarray data. A threshold for significance is illustrated in the figure. Diseases and 
biological functions are listed in order of significance. The p-value of overlap is used 






Figure 4.3: The top 10 diseases and biological functions altered in the 2014 mRNA 
microarray data. A threshold for significance is illustrated in the figure. Diseases and 
biological functions are listed in order of significance. The p-value of overlap is used 
to determine significance between groups with a cut-off of <0.05. 
 
Figure 4.4: The top 10 diseases and biological functions altered in the 2016 mRNA 
microarray data. A threshold for significance is illustrated in the figure. Diseases and 
biological functions are listed in order of significance. The p-value of overlap is used 





In order to explore the molecular and cellular processes altered in COPD in further 
detail all molecular and cellular processes significantly different in COPD were 
downloaded.  
Important pathways that were independently identified in several of the subset 
analyses are listed in table 4.1. The results for significantly altered molecular and 
cellular processes are illustrated in figures 4.5-4.8.  
In a similar fashion to molecular and cellular functions, disease associations were 
also investigated in further depth by downloading all disease associations that were 
deemed significant by IPA. The total number of diseases significantly associated in 
COPD for each analysis can be seen in table 4.2. The results for the diseases 
associated with COPD are illustrated in figures 4.9-4.12. 
To identify whether or not the above disease associations were genuine, a literature 
search was performed to identify publicly available data on incidence and prevalence 
of co-morbid disease in COPD and to the co-morbidities present in the patients 
studied (table 4.3). The literature search was performed following a standard 
hierarchy. Initially systematic reviews were searched for each co-morbidity. Where 
this was not possible large cohort studies followed by case reports were used. 
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Amino Acid Metabolism     X X 
Carbohydrate Metabolism     X X 
Cell Cycle X X X X 
Cell Death and Survival X X X X 
Cell Morphology X X X   
Cell-mediated Immune Response X X     
Cell Signaling     X X 
Cell-mediated Immune Response     X   
Cell-To-Cell Signaling and Interaction X X X X 
Cellular Assembly and Organization X X X X 
Cellular Compromise X X X X 
Cellular Development X X   X 
Cellular Function and Maintenance X X X X 
Cellular Growth and Proliferation X X X X 
Cellular Movement X X X X 
Cellular Response to Therapeutics X       
DNA Replication, Recombination, and 
Repair X     X 
Drug Metabolism   X X X 
Free Radical Scavenging   X     
Gene Expression       X 
Hematopoiesis   X     
Humoral Immune Response   X X X 
Immune Cell Trafficking X X X X 
Lipid Metabolism   X X X 
Molecular Transport   X X X 
Post-Translational Modification     X X 
Protein Synthesis     X X 
Protein Trafficking     X X 
Small Molecule Biochemistry X X X X 
Vitamin and Mineral Metabolism       X 
 
This table lists the molecular and cellular processes identified by IPA as being 
significantly altered in COPD. Each column represents an individual array analysis 
and ‘X’ indicates that the process was significantly altered in COPD. The p-value of 





Figure 4.5: Molecular and cellular functions associated with differentially expressed miRNAs in COPD in the 2014 miRNA 
microarray data. The pie chart demonstrates the percentage of miRNAs (from the total number) involved in molecular and 
cellular functions significant according to IPA. The p-value of overlap is used to determine significance between groups with a 




Figure 4.6: Molecular and cellular functions associated with differentially expressed miRNAs in COPD in the 2015 miRNA 
microarray data. The pie chart demonstrates the percentage of miRNAs (from the total number) involved in molecular and 
cellular functions significant according to IPA. The p-value of overlap is used to determine significance between groups with a 






Figure 4.7: Molecular and cellular functions associated with differentially expressed mRNAs in COPD in the 2014 mRNA 
microarray data. The pie chart demonstrates the percentage of mRNAs (from the total number) involved in molecular and 
cellular functions significant according to IPA. The p-value of overlap is used to determine significance between groups with a 




Figure 4.8: Molecular and cellular functions associated with differentially expressed mRNAs in COPD in the analysis: 2016 
mRNA microarray data. The pie chart demonstrates the percentage of mRNAs (from the total number) involved in molecular 
and cellular functions significant according to IPA. The p-value of overlap is used to determine significance between groups 
with a cut-off of <0.05. 
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Auditory Disease X   X X 
Behaviour     X X 
Cancer X X X X 
Cardiovascular Disease X X X X 
Connective Tissue Disorders X X X X 
Dermatological Diseases and 
Conditions X   X X 
Endocrine System Disorders X X X X 
Gastrointestinal Disease X X X X 
Hematological Disease X X X X 
Hepatic System Disease X X X X 
Hereditary Disorder       X 
Immunological Disease X X X X 
Infectious Diseases X X X X 
Inflammatory Disease X X X X 
Inflammatory Response X X X X 
Metabolic Disease X X X X 
Neurological Disease X X X X 
Nutritional Disease     X X 
Ophthalmic Disease     X X 
Organismal Injury and Abnormalities X X X X 
Psychological Disorders X   X X 
Renal and Urological Disease X X X X 
Reproductive System Disease X X X X 
Respiratory Disease X X X X 
Skeletal and Muscular Disorders X X X X 
 
This table lists the diseases identified by IPA as being significantly associated with 
COPD. Each column represents an individual array analysis and ‘X’ indicates that the 
disease was significantly associated with COPD. The p-value of overlap is used to 




Figure 4.9: Diseases associated with differentially expressed miRNAs in COPD in the 2014 miRNA microarray data. The pie 
chart demonstrates the percentage of miRNAs (from the total number) involved in disease functions significant according to 





Figure 4.10: Diseases associated with differentially expressed miRNAs in COPD in the 2015 miRNA microarray data. The pie 
chart demonstrates the percentage of miRNAs (from the total number) involved in disease functions significant according to 





Figure 4.11: Diseases associated with differentially expressed mRNAs in COPD in the 2014 mRNA microarray data. The pie 
chart demonstrates the percentage of mRNAs (from the total number) involved in disease functions significant according to 





Figure 4.12: Diseases associated with differentially expressed mRNAs in COPD in the 2016 mRNA microarray data. The pie 
chart demonstrates the percentage of mRNAs (from the total number) involved in disease functions significant according to 
IPA. The p-value of overlap is used to determine significance between groups with a cut-off of <0.05.  
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Table 4.3: Diseases identified as significant in IPA and their relation to known comorbidities of patients included in the study 
and the current literature 
Comorbidities 
identified in IPA 
Comorbidities identified in 
patients included in the 
study 
Comorbidities identified in 
the literature 
Level of evidence References 
Auditory Disease  Not supported by current 
literature 
Cohort  (428) 
Behaviour Heroin misuse (1) Insomnia (OR 2.4) Cross-sectional (429) 
Cancer Lung (10) Lymphoma (1) 
Malignant myoepithelial 
carcinoma of left scapula (1) 





Cardiovascular disease (OR 
2.46); Hypertension (OR 1.33) 
Systematic review (431) 
Connective Tissue 
Disorders 
Polyarthritis (1) Osteoarthritis 
(1) 
COPD associated with 
Sjogren's syndrome, systemic 
sclerosis, rheumatoid arthritis 




 OR of COPD in psoriasis 
(1.90) 
Systematic review (434) 
Endocrine System 
Disorders 
Diabetes (2) Hyperthyroidism 
(1) Hypothyroidism (1) 






disease (Prevalence 30%); 
Colorectal polyps (OR 2.1) 
Cohort (435, 436) 
Haematological 
Disease 
 Anaemia (Prevalence 6.2% to 
46.3%) 





 OR of COPD in liver disease 
(2.1) 
Cohort (438) 
Hereditary Disorder  Alpha-1-Antitrypsin Deficiency 




 Human Immunodeficiency 
Virus (reduced CD4 counts) 
associated with reduced 
FEV1. 
Cross-sectional (440) 
Infectious Diseases  OR for COPD with a history of 
TB (3.05) 
Systematic review (441) 
Inflammatory Disease  CRP and IL-6 are related to 
FEV1/FVC. 30% of COPD  
patients show evidence of 
systemic inflammation 
Cross-sectional (66) 
Metabolic Disease  Metabolic syndrome 
(Prevalence 30%). Reduced 
plasma leptin/adiponectin 




Neurological Disease Childhood seizures (1) Peripheral neuropathy 
(Prevalence15%); Mild 
cognitive impairment (OR 
1.87); Stroke (HR 1.24); 





Nutritional Disease Vitamin B12 deficiency (1) Weight loss (OR 1.81) Case-control (448) 
Ophthalmic Disease  Increased corneal endothelial 





 Depression (OR 2.81); 
Anxiety (Prevalence 13-46%) 
Systematic review (450, 451) 
Renal and Urological 
Disease 
Renal stones (1) Chronic Kidney Disease (OR 
2.20) 





All diseases significantly associated with COPD according to the IPA are listed in the first column. The second column lists 
whether or not these comorbidities were present in patients from the study with the number of patients in brackets. The third 
column lists associations (and if possible the prevalence and risk) of these comorbidities to COPD from the literature. OR = 
odds ratio, HR = hazards ratio.  
Reproductive System 
Disease 
Ovarian cyst (1) Not supported by current 
literature 
  
Respiratory Disease COPD (12)    
 
Skeletal and Muscular 
Disorders 
  







4.4.2 Downstream disease analysis of miRNA and mRNA microarrays  
Downstream prediction was performed for each of the microarray analyses focusing 
on the targets of interest identified in chapter 3: miR-181b-3p, miR-429, miR-23c and 
LTA4H. A key for the diagrams produced by Ingenuity can be seen in Appendix 3.  
Downstream analysis for 2015 miRNA microarrays 
There were no significant downstream effects predicted for the 2015 miRNA 
microarrays. 
Downstream analysis for 2014 miRNA microarrays 
MiR-181 and miR-429 were both associated with cell functions related to cancer. 
However, results were conflicting. For example, miR-181 was associated with other 
miRNAs predicting upregulation of neoplasia of tumour cell lines and miR-429 was 
predicted (with other miRNAs) to increase cell proliferation of carcinoma cell lines. 
Both associations would support a relationship between COPD and lung cancer. 
However, both miR-181 and miR-429 were associated with the downregulation of 
‘cell proliferation of tumour cell lines’ and miR-429 with downregulation of ‘invasion of 
cell lines’. MiR-23 was associated with the upregulation of ‘cytokinesis of ventricular 
myocytes’ and the downregulation of ‘maturation of chrondrocyte cell lines’. The 





Figure 4.13: Downstream prediction of miRNA changes on cell proliferation of tumour cell lines in the 2014 miRNA microarray 
analysis. MiR-181 and -429 are involved in this pathway. Involved miRNAs are around the outside of the figure. All miRNAs are 






Figure 4.14: Downstream prediction of miRNA changes on neoplasia of tumour cell lines in the 2014 miRNA microarray analysis. 
MiR-181 was involved in this pathway. All miRNAs are upregulated and are in red. The centre shape is orange suggesting that this 






Figure 4.15: Downstream prediction of miRNA changes on cell proliferation of carcinoma cell lines in the 2014 miRNA microarray 
analysis. miR-429 is involved in this pathway. All miRNAs are upregulated and are in red. The centre shape is orange suggesting 







Figure 4.16: Downstream prediction of miRNA changes on invasion of cell lines in the 2014 miRNA microarray analysis. MiR-429 is 
involved with this pathway. All miRNAs are upregulated and are in red. The centre shape is blue suggesting that this function is 






Figure 4.17: Downstream prediction of miRNA changes on cytokinesis of ventricular myocytes in the 2014 miRNA microarray 
analysis. MiR-23 is involved in this pathway. All miRNAs are upregulated and are in red. The centre shape is orange suggesting 






Figure 4.18: Downstream prediction of miRNA changes on maturation of chrondrocyte cell lines in the 2014 miRNA microarray 
analysis. MiR-23 is involved in this pathway. All miRNAs are upregulated and are in red. The centre shape is blue suggesting that 
this function is downregulated in COPD. 
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Downstream analysis for 2016 mRNA microarrays 
LTA4H was involved in several pathways related to cancer including abdominal 
cancer, digestive organ tumour, intestinal cancer, intestinal tumour, neoplasia of 
epithelial tissue, renal lesion and tumourigenesis. All of these pathways involved very 
large numbers of genes and therefore the diagrams of the pathways in IPA could not 
accurately be reproduced here. Table 4.4 lists the overall downstream prediction for 
each pathway. The genes involved in each pathway in table 4.4 can be seen in 
Appendix 3. LTA4H also appeared to be involved in the downregulation of 
hypersensitivity reactions (figure 4.19). The full names of genes listed in figure 4.19 
can be viewed in Appendix 3. 
Downstream analysis for 2014 mRNA microarrays 
Some pathways related to cancer were downregulated including digestive organ 
tumour and malignant neoplasm of the large intestine. These pathways involved very 
large numbers of genes and could not be reproduced easily in this thesis. Table 4.5 
lists the overall downstream prediction for each pathway. The individual genes in 
each pathway can be seen in Appendix 3. LTA4H was also involved in the allergy 
pathway (figure 4.20), which was predicted to be downregulated in the same fashion 
as hypersensitivity reactions in the 2016 microarrays above.  However, LTA4H was 
also shown to be involved in the upregulation of metabolism of eicosanoid, synthesis 
of fatty acid and synthesis of lipid. These pathways are illustrated in figures 4.21-







Table 4.4: Downstream analysis predictions for diseases/cellular functions significant 






























The first column of this table lists significant diseases and functions associated with 
COPD pulmonary endothelial tissue. The second column lists whether or not each 
disease or function was predicted to be up- or down-regulated. The p-value of 





Figure 4.19: Downstream prediction of mRNA changes on hypersensitivity reactions in the 2016 mRNA microarray analysis. LTA4H 
is involved in this pathway. mRNAs that are upregulated are in red and those that are downregulated are in green. The centre 
shape is blue suggesting that this function is downregulated in COPD. 
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Table 4.5: Downstream analysis predictions for diseases/cellular functions significant 





































Renal lesion Down 
 
The first column of this table lists significant diseases and functions associated with 
COPD pulmonary endothelial tissue. The second column lists whether or not each 
disease or function was predicted to be up- or down-regulated. The p-value of 




Figure 4.20: Downstream prediction of mRNA changes on allergy in the 2014 mRNA microarray analysis. LTA4H is involved in this 






Figure 4.21: Downstream prediction of mRNA changes on metabolism of eicosanoid in the 2014 mRNA microarray analysis. 
LTA4H is involved in this pathway. All mRNAs are upregulated and are in red. The centre shape is orange suggesting that this 




Figure 4.22: Downstream prediction of mRNA changes on synthesis of fatty acid in the 2014 mRNA microarray analysis. 
LTA4H is involved in this pathway. All mRNAs are upregulated and are in red. The centre shape is orange suggesting that this 






Figure 4.23: Downstream prediction of mRNA changes on synthesis of lipid in the 2014 mRNA microarray analysis. LTA4H is 
involved in this pathway. All mRNAs are upregulated and are in red. The centre shape is orange suggesting that this function 
is upregulated in COPD. 
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4.4.3 miRNA and mRNA networks in COPD 
Networks relating to miR-181, miR-429, miR-23 and LTA4H were identified. The full 
names of all genes included in the networks can be viewed in Appendix 3. 
Network analysis for the 2015 miRNA microarrays 
2 networks that were significant in this analysis also involved 2 of the possible 
targets: miR-181 and miR-23. MiR-181 was involved in network 1 (figure 4.24) and 
was associated with ‘Cancer’, ‘Dermatological Diseases and Conditions’ and 
‘Organismal Injury and Abnormalities’. MiR-23 was involved in network 2 (figure 4.25) 
and was associated with ‘Cellular Development’, ‘Cellular Growth and Proliferation’ 
and ‘Connective Tissue Development and Function’. 
Network analysis for the 2014 miRNA microarrays 
2 networks that were significant in this analysis also involved 2 of the possible 
targets: miR-181 and miR-429. MiR-181 was involved in network 1 (figure 4.26) and 
was associated with ‘Organismal Injury and Abnormalities’, ‘Reproductive System 
Disease’ and ‘Cancer’. MiR-429 was involved in network 7 (figure 4.27) and was 
associated with ‘Connective Tissue Disorders’, ‘Developmental Disorder’ and 





Figure 4.24: A network identified in the 2015 miRNA microarrays. This is network 1 and it is associated with miR-181 (highlighted). 
MiR-181 is in red and is therefore upregulated. This appears to directly inhibit EPHB1 (EPH receptor B1), a tyrosine kinase which 






Figure 4.25: A network identified in the 2015 miRNA microarrays. This is network 2 and it is associated with miR-23 (highlighted). 
MiR-23 is in red and is upregulated. This appears to be partially through indirect stimulation through reduced levels of hydrogen 
peroxide. MiR-23 directly inhibits 6 mRNAs in the pathway, which are all predicted to be downregulated: SERINC5 (Serine 
incorporator 5), DYDC2 (DPY30 domain-containing protein 2), YOD1 (Ubiquitin thioesterase OTU1), FGF2 (fibroblast growth factor 






Figure 4.26: A network identified in the 2014 miRNA microarrays. This is network 1 and it is associated with miR-181 
(highlighted). MiR-181 is red and therefore is upregulated. This seems to be partly through indirect activation by Smad 2/3 (a 
transcription regulator) which is predicted to be upregulated. Another mechanism of upregulation appears to be through insulin 





Figure 4.27: A network identified in the 2014 miRNA microarrays. This is network 7 and it is associated with miR-429 
(highlighted). MiR-429 is upregulated in red. This appears to directly inhibit EIF2S1 (eukaryotic translation initiation factor 2 
subunit alpha) which is predicted to be downregulated. EIF2S1 is connected directly to 4 other mRNAs in the pathway. These 
include IMPACT and RAVER2 (ribonucleoprotein polypyrimidine tract protein-blinding 2) which are also both involved in 
regulation of mRNA translation. The final two mRNAs are NDRC (nexin-dynein regulatory complex) which is involved in cilia 




Network analysis for the 2016 mRNA microarrays 
There were no networks involving LTA4H that were significant in the 2016 mRNA 
microarrays. However, network 22 was significant and involved miR-429. This can be 
viewed in figure 4.28. This network was associated with ‘Developmental Disorder’, 
‘Hereditary Disorder’ and ‘Neurological Disease’ functions. 
Network analysis for the 2014 mRNA microarrays 
One network in the 2014 mRNA microarrays that was significant according to IPA 
involved LTA4H. This was network 4 (figure 4.29) and it was associated with 
‘Respiratory System Development and Function’, ‘Cardiovascular Disease’ and 
‘Cancer’. Therefore it is possible that through this pathway LTA4H might provide an 




Figure 4.28: A network identified in the 2016 mRNA microarrays. This is network 22 and it is associated with miR-429 (highlighted). 
MiR-429 is predicted to be upregulated and is in orange. This would be consistent with the miRNA array results. MiR-429 appears 
to inhibit 9 mRNAs that are predicted to be downregulated including KLF9 (Krueppel-like factor 9), which acts as a tumour 
suppressor and inhibits cellular proliferation. MiR-429 also targets CBX5 (Chromobox protein homolog 5) that appears to control 
angiogenic functions of endothelial progenitor cells. MiR-429 is also predicted to inhibit three mRNAs that are upregulated (in red). 
The yellow lines linking miR-429 to these mRNAs suggests that upregulation of miR-429 is inconsistent with upregulation of its 






Figure 4.29: A network identified in the 2014 mRNA microarrays. This is network 4 and it is associated with LTA4H which is 
upregulated. E2F1 (E2F transcription factor 1) which is also upregulated appears to be responsible for LTA4H activation as it is 





4.4.4 Canonical pathways in COPD 
Significantly affected canonical pathways in the 2014 and 2016 mRNA microarray 
analyses were identified. LTA4H was identified in the ‘Eicosanoid Signalling’ pathway 
in both mRNA microarray analyses and the results of this are presented in figure 
4.30. 
The Eicosanoid signalling pathway from the 2016 arrays shows an upregulation of 
LTA4H and therefore an upregulation of the conversion of LTA4 to LTB4. LTB4 binds 
to its receptors promoting an increase in chemotaxis, cell proliferation and 
angiogenesis.  
Other aspects of this pathway show upregulation of prostaglandins E2 (PGE2), F2 
alpha (PGF2A), D2 (PGD2) and I2 (PGI2), which are associated with other disease 
processes of interest such as inflammation and cancer. Lipoxin A4 was also 
upregulated in the pathway, which results in vasodilation and was associated with 
inflammatory disease. Thromboxane A2 was reduced in this pathway, which was 
associated with reduced asthma risk. This result is not consistent with the other 
pathway results, which predict an increased asthma risk. 
The Eicosanoid pathway from the 2014 arrays shows almost identical results to those 
from the 2016 array. However, unlike the results from 2016 the thromboxane A2 
pathway was predicted to be upregulated, which is therefore more consistent with the 
rest of the pathway results. 
The full names of genes included in the Eicosanoid signalling pathway can be viewed 




Figure 4.30: Eicosanoid Signalling pathway according to results from the 2014 mRNA microarray analysis. This demonstrates 
that the highlighted proteins LTA4H, PLA2, PTGS, PDGS and PTGER3 have been measured as upregulated in this pathway. 
PLA2, PTGS and PDGS are involved in prostaglandin synthesis. PTGER3 is a prostaglandin receptor. The other proteins in 
this pathway are predicted to be upregulated (in orange). All disease and cellular functions controlled by this pathway (such as 
chemotaxis, cell proliferation and angiogenesis) are also predicted to be upregulated (in orange) other than ‘thrombosis’ which 




4.5.1 Diseases associated with COPD 
Cancer 
There were several interesting findings in the IPA. Firstly, the data from the four 
independent microarray analyses support the concept that COPD and lung cancer 
are related. Cancer is the process most highly related to COPD in both mRNA arrays 
and is in the top 10 associations for the miRNA arrays further supporting the 
hypothesis that cancer and COPD are related. Some of the biological functions 
associated with the arrays might explain why cancer is an important association such 
as inflammation. COPD is a disease driven by inflammation with increased levels of 
both systemic inflammatory cells and cytokines.(64) Supporting this concept, 
‘inflammatory disease’ and the ‘inflammatory response’ were significant in all 
microarray datasets. This is also consistent with several other IPAs performed by 
different groups in COPD that all identify inflammatory pathways as being 
significantly altered.(319, 321, 322) These altered inflammatory pathways are of 
particular relevance in the setting of shared pathogenesis of COPD and lung cancer 
as malignancy risk appears to be increased in the setting of chronic 
inflammation.(149)  
Several of the molecular and cellular processes were significantly altered in all four 
analyses, giving extra confidence to the conclusion that these pathways are 
important, since there was independent replication in more than one dataset. 
Pathways that were independently identified in several of the subset analyses 
included cellular growth and proliferation, cellular development, the cell cycle, cellular 
movement, cell death and survival, cell signalling and cell-cell interaction. Again, 
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several of these processes such as cell death and survival and cell-cell interaction 
have also been identified in another COPD IPA further supporting this study’s results. 
(321) All of these pathways would have the potential to be important in 
carcinogenesis and provide support for the hypothesis that carcinogenesis is more 
likely to occur in COPD lung.(454-456) There is existing evidence from other 
microarray studies in COPD that would support these findings. For example, Yang et 
al demonstrated that the NF (nuclear factor) – κβ1 pathway is upregulated in COPD 
and this is associated with a reduction in apoptosis. (457) Similarly, Chen et al 
identified interleukin-6 (IL-6) as being upregulated in the JAK/STAT (Janus 
kinase/Signal transducer and Activator of Transcription) pathway that is associated 
with the promotion of inflammation and cell proliferation.(458) Finally, Wang et al 
identified down-regulation of the Wnt (wingless-type MMTV (mouse mammary tumor 
virus) integration site) pathway in COPD that would result in the dysregulation of 
cellular differentiation.(459) 
Cell-cell signalling and interaction would also be of importance in inflammation and 
transendothelial migration (TEM), which in turn is a determinant of the level of 
inflammatory cells in the lung. There is evidence to support that the migration of 
neutrophils is upregulated in COPD and that this is related to disease severity.(231-
233) Perhaps this could partly be due to the dysregulation of cell-cell interactions in 
the pulmonary endothelium. Furthermore, increased TEM could explain the 
increased inflammation seen in COPD (54) which is supported by these pathway 
results.  
A downstream analysis was also performed in order to attempt to predict the 
direction of the effect the cellular and molecular processes would have on disease 
 
 221 
processes. This downstream analysis was performed focusing on the miRNA and 
mRNA targets identified in chapter 3. In some cases these downstream predictions 
would support the hypothesis of underlying cellular changes in COPD resulting in an 
increased malignancy risk. For example, in the 2014 miRNA microarrays miR-181 
was predicted (in a network with 6 other miRNAs) to upregulate neoplasia of tumour 
cell lines. MiR-429 was also predicted to increase cell proliferation of carcinoma cell 
lines. This would be consistent with previous data suggesting that overexpression of 
miR-181 and -429 is associated with lung cancer.(381, 401) However, the picture 
from the array results is not as simple as this. Both miR-429 and -181 appear to be 
involved in a network leading to the reduction of cell proliferation of tumour cell lines 
in the same arrays. In addition to this, miR-429 is also involved in a network resulting 
in reduction of invasion of cell lines. These findings would appear to contradict the 
initial two networks, which suggested an increased malignancy risk. As these 
networks occurred in the same array this cannot be explained by patient subsets. 
One possible explanation could be that the knowledge database that the IPA is 
based on is drawn from published literature and both miR-181 and miR-429 have 
also been associated with reduction in malignancy. For example, miR-181 has been 
shown to be reduced in NSCLC and miR-429 is reduced in renal cell carcinoma.(393) 
(400) Perhaps these networks reflect malignancy associations from tissues other 
than pulmonary endothelium that, by coincidence, contain RNAs significantly 
differentially expressed in these arrays. For example, the study showing reduced 
miR-181 in NSCLC used whole lung miRNA expression and could therefore reflect 
miRNA expression in other cell types meaning its findings would not be applicable to 
endothelial cells.(393) This could potentially explain conflicting results but also 
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complicates the interpretation of the data. It is difficult to understand which networks 
might be relevant in the current setting and therefore, these particular networks fail to 
elucidate the shared pathogenic mechanisms between COPD and lung cancer. In 
theory conflicting results such as this could occur in many IPAs as the knowledge 
base reflects data from multiple cell types and diseases. However, a literature search 
could not readily identify examples of this and most publications on downstream 
analysis in IPA do not consist of conflicting results.(319, 321, 322, 460, 461) 
LTA4H was also involved in multiple significant downstream analyses that involved 
cancer, but in every case the cancer association was negative. This complicates the 
association of these array results with malignancy further. It also appears to 
contradict current literature that associates an increase in LTA4H with various 
malignancies.(427, 462, 463) However, LTA4H was primarily associated with 
gastrointestinal cancers rather than lung cancers in the downstream analysis. 
Interestingly, in a previous COPD IPA, gastrointestinal cancer pathways were also 
significantly altered.(321) Despite this, it is probably difficult to extrapolate these 
particular results to the risk of lung cancer in COPD. Also, the IPA analysis does not 
distinguish between cell types during the analysis. Therefore, some of the 
associations reported in the results may be associations found in different cell types 
from different tissues which could partly explain why there are some contradictory 
results seen. Regardless, it is difficult to make firm conclusions on cancer risk based 
on these downstream results. It would be necessary to repeat the microarrays, 
perhaps with greater numbers, to further clarify the roles of miR-429, -181 and 
LTA4H on these networks in a COPD setting. It would also be useful to perform all 
array analyses at one time which would allow one to compare all array results with 
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one another rather than performing separate smaller analyses with less statistical 
power. Further work to explore cell function more with respect to targets would be 
useful, and is described in the future work section (section 7.5.1). 
IPA was also used to see if the miRNA targets and LTA4H were involved in any IPA 
networks. Genes of particular interest in these networks are listed in Appendix 3. 
Each network identified as significant included genes previously recognised as 
important in various malignancies, frequently lung cancer, further reinforcing the 
potential link between this condition and COPD. Several genes had also been 
previously altered in COPD. One particularly interesting find is the downregulation of 
EPHB1 (EPH receptor B1) which is directly inhibited by miR-181b in the 2015 miRNA 
microarrays (network 1). This tyrosine kinase receptor is involved in transducing 
signals for cell migration and under-expression has been associated with multiple 
cancer types.(464-470) This could theoretically provide a mechanism of how 
upregulation of miR-181b in COPD could predispose to cancer. 
EPHB1 is indirectly linked to RHOA (ras homolog family member A) which again is 
predicted to be downregulated. RHOA is associated with pulmonary endothelial 
dysfunction in COPD and therefore may be of importance in this study.(226) 
However, previous studies have shown upregulation of RHOA in pulmonary 
endothelial dysfunction and consequently this result is not consistent with previous 
evidence. OGT (O-linked N-acetylglucosamine transferase), a gene connected to 
RHOA in network 1, may also have a role in COPD. Interestingly, OGT is also 
involved in the DNA damage response and could be of particular importance in 
COPD where oxidative stress is common.(79, 471) It is therefore possible that 
reduction in OGT expression as seen in this study could represent a defective 
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cellular response to oxidative stress. However, a review of the GEO database of 
microarray data from lung tissue does not show a difference in OGT expression 
between COPD and non-COPD. For example, an analysis of data uploaded by Spira 
et al does not show a statistically significant difference between OGT expression in 
normal lung and lung from patients with severe COPD.(292) All the available data 
originates from whole lung, consequently, to establish the role of OGT in pulmonary 
endothelial cells would require further investigation using this specific cell type. 
Other diseases 
Ingenuity compares microarray results to existing knowledge on millions of findings 
including those from different tissue types to that under investigation. This can result 
in the IPA identifying associations with multiple diseases from different organs. This 
occurred in all four IPAs. The literature search showed that the IPA data was 
consistent with the vast majority of expected panel of comorbidities. Areas of 
particular commonality were cardiovascular disease, endocrine diseases and 
malignancy.(430, 431) It was notable that auditory disease and reproductive system 
disease which were both identified in IPA were not supported by current evidence in 
the literature about comorbidities in COPD. This might reflect associations between 
COPD-related endothelial dysfunction and these conditions not previously identified 
in the literature. Interestingly, endothelial dysfunction has been linked to reproductive 
system disease previously. For example, patients with erectile dysfunction have 
reduced FMD in comparison to controls.(472) In females, endothelial dysfunction is 
associated with both polycystic ovary syndrome and pre-eclampsia in 
pregnancy.(473, 474) Perhaps an association with COPD and reproductive disease 
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has not been previously reported as patients with COPD are typically past 
reproductive age at presentation. 
There is less evidence for endothelial dysfunction playing a role in auditory disease. 
However, in mouse models of otitis media HIF and VEGF appear to be upregulated 
suggesting that vascular proliferation may be important in the pathogenesis of this 
condition.(475) Therefore, the fact that these diseases were identified in array data 
from endothelial cells might reflect the systemic importance of endothelial dysfunction 
in COPD and its importance in the development of associated comorbidities. 
Significant downstream analyses that were associated with disease processes other 
than cancer include downregulation of the ‘maturation of chrondrocytes’ pathway that 
was associated with miR-23. There is some evidence for the degeneration of 
chondrocytes in bronchial cartilage in COPD and perhaps this pathway reflects 
this.(476) MiR-23 was also involved in the ‘cytokinesis of ventricular myocytes’, which 
was upregulated. This could reflect hypertrophic changes in ventricular myocytes 
occurring as part of pulmonary hypertension in response to hypoxia in COPD. There 
is recent evidence to suggest these changes are associated with alteration in miRNA 
expression.(477)  
4.5.2 Pathways associated with COPD 
Transforming growth factor (TGF) 
‘Organismal injuries and abnormalities’ was a process that was significantly altered in 
COPD in all datasets. This is a general category and includes cellular functions 
occurring in several multicellular organisms including, primarily, humans, mice and 
rats.  It involves injury mechanisms such as bleeding, oedema and haemorrhage, as 
well as functions involved in abnormal tissue repair (lesions, ulcers, scars and 
 
 226 
wounds). [Personal communication with Dr Ruth Burton, Qiagen Discovery 
Informatics.] ‘Organismal injuries and abnormalities’ has also been associated with 
whole lung gene expression studies in COPD previously.(321) This broad category 
may well have some relevance in the setting of COPD in terms of abnormal tissue 
repair. Epithelial-mesenchymal transition, a process driven by transforming growth 
factor beta (TGF-β) has been identified as upregulated in COPD, particularly in the 
presence of airway fibrosis and provides a mechanistic link to lung cancer.(478)  
The transforming growth factor beta 2 (TGF-β2) pathway was involved in both the 
2015 (network 2) and 2014 (network 1) miRNA microarrays (figure 4.31). TGF 
signalling has been previously shown to be important in the development of several 
cancers including non-small cell lung cancer.(479, 480) In the 2014 miRNA 
microarrays miR-181 is directly linked to Smad 2/3, which is predicted to be 
upregulated. The Smad proteins are important in the TGF-β pathway; TGF-β binds to 
its cell surface receptors, which results in the phosphorylation and activation of Smad 
2/3 (figure 4.31). The Smad proteins act as regulators of transcription resulting in the 
increased expression of different genes.(481) Smad 3 in particular is important in the 
TGF-β mediated epithelial-mesenchymal transition pathway which is critical in 
carcinogenesis.(482) There is also evidence that the TGF-β pathway and EMT 
contributes to COPD pathogenesis: TGF-β and Smad proteins are increased in 
COPD and Smad levels appear to be related to the severity of airway 
obstruction.(483) The data presented here suggests that upregulation of this pathway 






Figure 4.31: The TGF-β pathway illustrated in a cell. TGF-β binds to the TGF-β receptor II. This recruits the TGF-β receptor I 
which is phosphorylated and activated. This in turn leads to the phosphorylation of Smad 2/3 which then bind to Smad 4. The 
Smad complex moves to the nucleus and stimulates the transcription of several genes. TGF-β = Transforming growth factor 




Leukotriene A4 Hydrolase (LTA4H) 
LTA4H was also associated with pathways other than those involved in malignancy. 
For example, it was associated with downregulation of hypersensitivity reactions and 
allergy in the mRNA microarrays. As previously discussed LTA4H results in the 
production of LTB4 (a neutrophil chemoattractant) and the destruction of PGP 
(another chemoattractant) and therefore has both pro- and anti- inflammatory effects 
(figure 4.32).(420-422) These networks would suggest that the anti-inflammatory 
effects have a stronger role in COPD contradicting previous evidence that LTA4H is 
increased in COPD and has a mainly pro-inflammatory role. (422, 423) In support of 
this, the lines connecting LTA4H to the hypersensitivity and allergy pathways are 
yellow. This means that the level of LTA4H seen in the arrays is not consistent with 
the overall effect on the network. I.e. increased LTA4H should, in theory, be 
associated with an increase in hypersensitivity reactions or allergy not a decrease as 
seen in figures 4.19-20. Therefore, it is likely that the overall reduction seen in figures 
4.19-20 is a result of the influence of genes other than LTA4H.  
In the 2014 mRNA microarrays LTA4H is also associated with an upregulation in 
metabolism of eicosanoid and lipid synthesis pathways, which is consistent with its 
leukotriene metabolism function.(420) This finding was further supported by the 
canonical pathway, ‘Eicosanoid signalling’, being upregulated (figure 4.30) in both the 
2014 and 2016 mRNA microarrays. Five genes in this pathway were upregulated in 
the 2014 microarrays: LTA4H, PLA2 (phospholipase A2), PTGS (prostaglandin-
endoperoxide synthase/cyclooxygenase), PTGDS (prostaglandin D2 synthase) and 
prostaglandin E receptor 3 (PTGER3). The same five mRNAs are upregulated in the 
2016 mRNA microarrays and the enzyme TXS (thromboxane A synthase 1) was 
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significantly downregulated. Interestingly, most of these proteins have been 
previously associated with COPD. For example, LTA4H, PLA2 and PTGDS have 
been upregulated in sputum or broncho-alveolar lavage from patients with 
COPD.(422, 484, 485) PTGS is increased in pulmonary fibroblasts isolated from 
patients with COPD and PTGER3 has been associated with cough.(486, 487) This 
evidence increases the likelihood that ‘Eicosanoid signalling’ is a genuinely important 
in COPD. PTGDS levels are also associated with FEV1 levels suggesting that this 
pathway may have relevance in the development of COPD.(485) Downstream 
prediction of these changes on ‘Eicosanoid signalling’ results in almost all pathways 
being upregulated with the exception of thromboxane synthesis in the 2016 
microarrays.  
The pathway controlled by LTA4H (conversion of LTA4 to LTB4) is predicted to 
upregulate several cellular processes that would be relevant to this study. Firstly, as 
discussed in chapter 3, an increase in LTB4 is associated with chemotaxis.(420) This 
would clearly be important in the transendothelial migration of inflammatory cells in 
COPD. Secondly, this pathway also appears to increase cell proliferation. An 
increase in cell proliferation would be relevant in the development of cancer and an 
increase in LTA4H has been shown to be increased in cancers including lepdic lung 
cancer as above.(427, 462, 463) There is evidence supporting increased cell 
proliferation in response to increased LTA4H. LTA4H is upregulated in chronic 
lymphocytic leukaemia cells with an aggressive phenotype rather than those with a 
lower, less aggressive proliferation rate.(488) However, it is not clear that this cellular 
proliferation mechanism is relevant in endothelial cells as previous studies have 
demonstrated that LTB4 induces endothelial apoptosis, which would be consistent 
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with the development of emphysema.(426) Similarly, IPA predicts that angiogenesis 
would be upregulated in response to increased LTA4H which appears to be 
inconsistent with its’ association with apoptosis. However, other in vitro studies have 
shown that VEGF upregulates LTB4’s receptor (BLT2) in HUVECs and knockdown of 
BLT2 is associated with reduced angiogenesis.(489) LTB4 has also been shown to 
be involved in angiogenesis in the setting of chronic inflammation that would be 
particularly relevant to COPD in which chronic inflammation occurs.(490) The 
evidence for and against LTB4 being associated with increased angiogenesis is 
therefore contradictory and it is unclear what functional role LTB4 might play in 
angiogenesis in the setting of COPD. 
Other genes predicted to be altered in this canonical pathway are explored in more 





Figure 4.32: LTA4H biology in the setting of COPD. LTA4H is an enzyme with a hydrolase function that results in the 
production of LTB4 from LTA4. LTB4 is a neutrophil chemoattractant with pro-inflammatory effects. LTA4H also has an 
aminopeptidase function which degrades PGP. PGP is another neutrophil chemoattractant and therefore LTA4H has anti-
inflammatory effects through its aminopeptidase function. Smoking inhibits the aminopeptidase function of LTA4H which 
consequently results in increased inflammation. 




Angiogenesis factors were also present in several significantly altered networks. 
In the 2015 miRNA microarrays miR-23 is linked to fibroblast growth factor 2 
(FGF2) which is associated with a worse prognosis in NSCLC.(491) The finding 
of miR-23 linking to FGF2 is of particular interest in endothelial cells as FGF2 is 
known to be important in angiogenesis, both in the normal and pathological 
setting.(492) This suggests that miR-23 may also have suppressive effects on 
angiogenesis through its interaction with FGF2 that could precipitate the 
development of emphysema. However, this is less likely to provide a 
mechanistic link between COPD and lung cancer as FGF tends to be increased 
in NSCLC.(491) In fact, anti-FGF agents are already in development for NSCLC 
such Cediranib. Unfortunately however, an initial phase III study has been 
disappointing with increased toxicity in the Cediranib arm with no increase in 
survival compared to traditional chemotherapy.(255) In the 2014 miRNA 
microarray VEGF is upregulated. As previously discussed this is the major 
growth factor involved in the angiogenesis pathway and therefore it is 
particularly relevant that this is increased in endothelial cells. It is known that 
VEGF is altered in COPD (210, 211) and is an important negative prognostic 
marker in lung cancer (243). Therefore, this supports the network in figure 4.25 
being relevant in the relationship between the two conditions. 
 
4.5.3 Limitations 
Limitations described in section 3.5.3 also apply to the IPA as the same data was 
used. Briefly, most patients included in the study had lung cancer and so RNA 
expression in the non-COPD group could be different compared to patients without 
COPD or lung cancer. This could influence the pathways that emerged in the IPA. 
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Secondly, the COPD group had mild-moderate disease on average resulting in 
pathways associated with more severe cases of COPD being missed. However, due 
to surgery constraints these limitations are difficult to overcome as discussed in 3.5.3. 
Due to difficulties in combining microarray data (sections 3.3.2 and 3.4.2) each 
microarray experiment had to be analysed separately. This resulted in 4 separate 
smaller datasets rather than 2 larger ones for each type of RNA studied. Clearly this 
resulted in reduced statistical power. This would be possible to overcome in the 
future by processing all samples on the same day using the same consumables. 
Analysis using Ingenuity also presents its own difficulties. For example, the Ingenuity 
knowledge base which is used in IPA includes associations in a wide range of tissue 
types and diseases. This is useful as a hypothesis generating tool as it may reveal 
new pathways of importance as yet unknown in the tissue of interest. However, it 
may also lead to apparent conflicting results thus complicating interpretation of data 
as seen in the downstream analysis in this study. MiR-429 and -181b-3p were 
associated with cellular mechanisms related to both increased and decreased risk of 
malignancy. This occurred in the same microarray and thus the same patient dataset. 
Therefore, one cannot conclude these results are due to differences in patients or 
array technique. It is difficult to elucidate which mechanisms might be relevant in the 
tissue type under study and so one may not be able to draw conclusions based on 
IPA alone. It is possible that larger microarray datasets with stronger statistical power 
would reduce the tendency to see conflicting outcomes in IPA. However, ultimately, 
clarification of the role of miRNAs/mRNAs in certain cell types and disease states 
would require functional cell based assays. This is described in further detail in future 





IPA of microarray data comparing both mRNA and miRNA expression in COPD 
endothelial cells provides further support to existing evidence that COPD and lung 
cancer are linked. Cancer was the most significant disease process associated with 
the mRNA microarray results and was in the top ten significant disease processes for 
both miRNA microarray results. This is supported by the fact that several related 
cancer mechanisms such as cell growth and proliferation and cell death and survival 
were also significantly altered in COPD providing possible underlying reasons why 
patients with COPD might be at an increased risk of cancer development. Further in 
depth analysis has also highlighted several networks and pathways such as 
‘Eicosanoid signalling’ which are altered in COPD and consist of multiple molecules 
associated with inflammation, angiogenesis and tumourigenesis suggesting that 
patients with COPD are at increased lung cancer risk.  
However, it is impossible to draw firm conclusions from this analysis as the 
downstream analysis in particular highlighted several significant processes which 
were associated with reduced malignancy risk. It is likely that these results reflect 
disease processes occurring in different tissue types and may not be relevant to 
HPECs in COPD. Certainly, known epidemiological studies would support increased 
malignancy in COPD rather than the contrary.(11) 
In conclusion therefore, it is necessary to validate the molecules contained in 
pathways that appear related to cancer risk in this study both quantitatively and 
functionally. This is beyond the scope of this thesis but such work would be useful to 
pursue once validation work on the miRNA and mRNA targets identified in chapter 3 
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is complete in order to understand the effect of these targets on pulmonary 





ISOLATION AND CULTURE OF HUMAN 





It is possible to extract human pulmonary endothelial cells (HPECs) from donated 
lung tissue. These cells can be cultured and used for cellular functional validation 
work. 
5.2 Aims of this chapter 
This chapter will detail the development of a technique to isolate HPECs from 
donated lung tissue. This was attempted in order to allow for studying the effects of 
altering a target of interest in HPECs rather than an alternative cell (such as Human 
Umbilical Vein Endothelial Cells (HUVECs)). The advantage of this is that alternative 
cell lines may not express the target of interest. The decision to extract HPECs was 
made as lung tissue is readily available from the Midlands Lung Tissue Consortium 
(section 2.1.1). It is possible to buy HPECs, but these cells are both expensive and 
can be difficult to grow (personal communication with R. Bicknell). Extracting and 
culturing HPECs from fresh tissue could potentially provide an easily accessible and 
economically viable source of HPECs. There would also be the possibility of isolating 
HPECs from normal and diseased (eg COPD) lung and comparing cell behaviours. 
5.3 Extraction of MLEC (mouse lung endothelial cells) 
Before an extraction of human HPECs was attempted extraction was performed 
using mouse lung tissue. This was performed under the supervision of Angel 
Armesilla at the University of Wolverhampton. This was performed according to the 
method in section 2.8. After negative selection the cells were reviewed every day by 
Dr Armesilla and the medium was changed every couple of days. Figure 5.1 




Figure 5.1: Appearance of mouse lung culture after negative selection: Colonies of 
endothelial cells were observed under the microscope. One of these colonies is 
highlighted at day one after negative selection. Only one MLEC extraction was 
performed and these images are representative of this extraction. Images were 








After five days, large endothelial colonies were visible under the microscope so 
positive selection of endothelial cells was performed in order to purify the culture 
further. After positive selection the cells were reviewed by Dr Armesilla daily and 
media was replaced every other day. The appearance of the cells and beads at day 
one after positive selection is in figure 5.2. Once the cells reached confluence the 
cells were split into two plates. After 15 days enough of the magnetic beads had 
disappeared to perform flow cytometry. 
To confirm that MLECs had been isolated flow cytometry was performed. The 
histogram for the control, CD31 and CD102 stained cells is shown in figure 5.3. The 
flow cytometry demonstrated that the MLECs positively stained for CD31 and CD102 
suggesting a pure endothelial isolate. (The negative selection was discarded and 
therefore flow cytometry was not performed on this.) 
5.4 Extraction of Human Pulmonary Endothelial Cells (HPECs) 
This method was initially based upon the MLEC extraction method in section 2.8 and 
the endothelial extraction method in section 2.3.2 (which was used to collect cells for 





Figure 5.2: Day one after positive selection for CD31 in mouse lung cell culture. 
Individual endothelial cells and small endothelial cell cultures can be seen. Magnetic 
beads are also visible. Only one MLEC extraction was performed and these images 
are representative of this extraction. Images were donated by the University of 




Figure 5.3: A histogram of flow cytometry performed on isolated MLECs. This was 
performed on the MLEC isolate from figures 5.1-2 (n=1). The blue histogram 
represents control cells (unstained), the orange histogram represents CD31 stained 
cells (75.4% positivity) and the pink histogram represents CD102 stained cells 
(93.4% positivity). As there is a shift in the histograms for CD31 and CD102 it shows 















5.4.1 Development of the extraction method 
Initial method (16.2.16): Method based on MLEC extraction using collagenase V 
for digestion 
This initial method is outlined in Appendix 4. There were large amounts of sticky 
partially digested tissue after collagenase digestion using this method. This made it 
very difficult to disaggregate cells after digestion. 
On day one the plate was reviewed under the microscope. Large amounts of 
erythrocytes were present and it was impossible to see any attached cells. Therefore, 
the media was removed and the plate was washed with DMEM-F12 with glutamine 
(11320033; Life Technologies (Gibco)) (10 ml) twice. 10 ml fresh MLEC/HPEC 
medium (section 2.8.1) was added to the plate, which was reviewed again under the 
microscope. Single cells were seen attached to the plate, but these were sparse. The 
cells were placed into the incubator again at 370C, 5% CO2 overnight. 
On day two small colonies of endothelial cells were seen (figure 5.4) in addition to 
multiple erythrocytes. The medium was changed to fresh MLEC/HPEC medium (10 
ml) and the cells were placed back into the incubator (370C, 5% CO2). 
The plate was later checked on day five. Unfortunately no colonies of endothelial 






   
 
Figure 5.4: Appearance of mixed lung cell culture on day two, extraction one 
(different areas of the same 10 cm plate). Multiple erythrocytes can be seen and 
attached cells are sparse. Small colonies of endothelial cells are seen and have been 
highlighted. Image taken with Leica microscope, objective: N PLAN 5x/0.12 PH0. 
Scale bar represents 1000μm. 
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Extraction 2 (3.3.16): Method with reduced volume of lung tissue, various 
digestion times and 6-well plates for culture 
After the failure of the first extraction attempts were made in order to improve the 
yield of cultured endothelial cells. Firstly, the volume of lung digested at each 
extraction was reduced to 1 cm3 in order to limit the development of large volumes of 
sticky tissue. It is likely that endothelial cells were trapped in this sticky tissue during 
attempt 1 and were therefore lost at the filtration stage. During this attempt four 
different time periods were used during the digestion phase in order to optimise 
digestion time: 30 minutes, 1 hour, 2 hours and 4 hours. These digestions were all 
performed using different pieces of the same lung. As the endothelial cells were 
sparse in attempt 1 a 6 well plate was used rather than a 10 cm plate for each 
digestion. Endothelial cells produce growth factors and therefore closer colonies of 
endothelial cells should encourage cell proliferation.(493) 
During the extraction attempt large amounts of sticky tissue occurred for the 
digestions at 30 minutes and 1 hour. Therefore, again, it was difficult to pass this 
through a 20 ml syringe to disaggregate the cells. There was no sticky tissue seen 
after the 2 and 4 hour digestions and these solutions passed easily in and out of a 20 
ml syringe. 
The cells from each digestion were reviewed on day one. Again, multiple 
erythrocytes occluded the view of attached cells. Therefore, the cells were washed 
with 4 ml of DMEM-F12 with glutamine (11320033; Life Technologies (Gibco)) prior 
to the addition of 5 ml MLEC/HPEC media (section 2.8.1) to each well. Very few 
attached cells were seen on any of the wells. However, the well from the 1 hour 
digestion had the most attached cells present. The cells were left in the incubator at 
370C, 5% CO2 before review on day 4.  
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On day 4 no viable cells were seen in the wells from the 30 minutes, 2 hour and 4 
hour digestions. Elongated individual cells were seen in the well from the 1 hour 
digestion. The media was replaced in the well from the 1 hour digestion only and the 
cells were incubated at 370C, 5% CO2. On day 10 no viable cells were seen and so 
the experiment was abandoned. It was concluded that 1 hour remained the optimal 
time for digestion.  
Extraction 3 (16.3.16): Method with altered means of cell disaggegation and 
removal of erythrocytes using bronchoalveolar lavage 
Due to the difficulty in passing the digested tissue in and out of a 20 ml syringe this 
step was removed from the protocol. However, to encourage cell disaggregation the 
digested tissue was passed in and out of a 10 ml pipette four times instead. 
As multiple erythrocytes were present in the cultures from extractions 1 and 2 it was 
postulated that these cells might be competing with endothelial cells for nutrients in 
the culture thereby limiting endothelial cell growth. Therefore, the culture method was 
repeated with an attempt to remove erythrocytes. A section of lung tissue was 
flushed with 0.9 % saline using a cannula and pressure bag (as in section 2.3.1) in 
an attempt to flush out the erythrocytes prior to digestion.  










Extraction 4 (16.3.16): Method with removal of erythrocytes using lymphoprep 
A second method of erythrocyte removal was attempted. After the lung had been 
digested and filtered the lung solution was overlaid on lymphoprep (Axis-Shield; 
1114545). This method is outlined in Appendix 4.  
The cells were reviewed on day one and multiple endothelial colonies were seen. 
These colonies were also seen on day two. Samples were reviewed on day 5. There 
had been a proliferation of the colonies (figure 5.5). 
The cells were reviewed again on day seven and appeared similar. Cells were frozen 
in 90 % fetal calf serum (Gibco; 10270106) and 10 % dimethyl sulfoxide (Sigma; 
D2650) (FCS/DMSO) at -800C. Cells were defrosted and replated weeks later but did 
not retain their endothelial appearance so the experiment was abandoned.  
Extraction 5 (16.3.16): Method with digestion using collagenase I 
As collagenase I (rather than V) was used in the MLEC extraction this was used 
during the digestion phase.  
The cells were reviewed on day one and multiple endothelial colonies were seen. On 
day two multiple small cells and clumps of cells were seen. Samples were reviewed 
on day 5. The collagenase I well continued to show clumps of cells (figure 5.6). 
In a similar fashion to extraction 4, on day 7 the cells were frozen and replated 
several weeks later but did not retain their endothelial appearance so the experiment 
was abandoned.  
Extraction 6 (16.3.16): Method with fibronectin 
Fibronectin was used to coat a well of a 6 well plate in an attempt to improve the 
number of adherent endothelial cells. 






Figure 5.5: Appearance of mixed lung cell culture on day five, extraction four. A: 
Image from extraction using lymphoprep. Primarily endothelial cells are seen with 
some clumps of other cells. B: Image from extraction using lymphoprep but higher 
magnification. (n=1) 
Images taken with Leica microscope: objective of A: N PLAN 5x/0.12 PH0, objective 
of B: C PLAN 10X/0.22 PH1 







Figure 5.6: Appearance of mixed lung cell culture on day five, extraction five. A: 
Image from extraction using collagenase I. Multiple small cells and clumps of cells 
are seen with possible endothelial cells. B: Image from extraction using collagenase I 
but higher magnification. (n=1) 
Images taken with Leica microscope: objective of A/C: N PLAN 5x/0.12 PH0, 
objective of B/D: C PLAN 10X/0.22 PH1 





Extraction 7 (12.4.16): Positive selection for endothelial cells attempted 
This method is outlined in Appendix 4. Four pieces of lung were digested and were 
plated on 4 wells of a 6 well plate.  
The cells were reviewed on day one and the four wells showed clusters of cells that 
were not obviously endothelial in nature.  
On day 3 one well was confluent with primarily endothelial like cells and was split into 
2 new wells. The second well showed primarily endothelial cells and was reaching 
confluence. The third well showed multiple endothelial colonies and the fourth well 
showed a few sparse single cells only.  
On day 6 the cells were reviewed again. All 5 wells showed primarily endothelial cells 
at near confluence. Therefore positive selection for endothelial cells was attempted. 
Positive selection of endothelial cells using mixed cell cultures from extraction 
7 
This method was based on the MLEC positive selection method in addition to 
positive selection performed when extracting HPECs for RNA isolation (section 
2.3.2). The full method of this initial attempt can be reviewed in Appendix 4. 
The cells were reviewed on day one after selection. There were adherent cells visible 
in addition to beads.  
The cells were next reviewed on day three. Each well showed a proliferation of cells. 
The cells from each well were removed after using 2x trypsin (section 2.9.2) and 
were replated on to 0.1% gelatin (section 2.8.1) coated 10 cm plates and left in the 
incubator at 370C, 5% CO2 overnight. The cells were reviewed on day four. 
Unfortunately the cells seen were very sparse and it was likely that cells had been 
lost during the removal via trypsin. Media was changed on day 6 and 10. By day 
fourteen the cells had an elongated appearance similar to fibroblasts. It is likely that 
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the endothelial cells had died and a few contaminating cells had overtaken the 
cultures. The experiment was then abandoned. 
Extraction 8 (12.5.16): Method with removal of erythrocytes using red cell lysis 
buffer 
Two samples of lung were processed during this extraction. One sample was 
processed according to the method in extraction 4. The other sample was split into 2 
digests: one digest was processed according to extraction 4. The second digest was 
performed using red cell lysis buffer (5830-100, Cambridge Biosciences). This was 
attempted to see if red cell lysis buffer provided a more efficient way at removing 
erythrocytes. The red cell lysis buffer method is outlined in Appendix 4.  
All wells were reviewed on day one and showed clusters of cells, which were not 
obviously endothelial in nature. There were fragments of cells visible in the well 
where red cell lysis buffer had been used. These cells were reviewed and the media 
was replaced every other day. Unfortunately none of these digests produced enough 
endothelial cells to attempt positive selection. The experiment was therefore 
abandoned. As there were large amounts of debris seen in the wells from the red cell 
lysis buffer this method was not attempted again. 
Extraction 9 (4.8.16): Method combining multiple lung digests 
This extraction was performed using the method from extraction 4. The tissue was 
divided into three prior to digestion and 3 separate digests were performed. At the 
end of the lymphoprep phase all 3 cell pellets were combined and resuspended into 
5 ml MLEC/HPEC media (section 2.8.1) and were plated into one well of a 0.1% 
gelatin (section 2.8.1) coated 6 well plate. This was performed in order to achieve a 
higher density of endothelial cells and to encourage endothelial cell growth.  
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On day one clusters of cells that were not obviously endothelial in nature were seen. 
On day four sparse endothelial cell clusters were seen and the media was changed. 
On day six the endothelial cell clusters were enlarging and the media was changed 
again. On day eight there were endothelial cell clusters, but also fibroblast like cells 
seen. The media was changed and cells were reviewed at day 12. At this point 
endothelial like cobblestone clusters were seen with areas of fibroblast like cells in 
sheets. Positive selection for endothelial cells was performed at this point. 
Positive selection of endothelial cells using mixed cell cultures from extraction 
9 – reduction in number of streptavidin beads and mixing of cells/beads using 
a wheel 
In an attempt to optimise this step two key changes were implemented. Firstly, the 
number of beads was reduced from the previous positive selection attempt as it was 
postulated that the addition of too many beads previously may have prevented some 
of the endothelial cells from being able to adhere to the gelatin coated plate. The 
number of beads used was chosen after reviewing existing literature on the 
extraction of pulmonary endothelial cells.(494) Secondly, to attempt better mixing of 
cells with Ulex-coated beads, the cells were removed from the culture plate and 
resuspended in bead solution. The cells/beads were then placed on a wheel in the 
cold room at 40C for 30 minutes to give the cells time to bind to the beads (rather 
than adding the beads to cells fixed on a plate). The mixing of the cells on the wheel 
should encourage the proper mixing of cells and beads. This method can be seen in 
detail in 2.9.2. 
The cells were reviewed on day one after positive selection. The majority of cells 
were present in the negative plate without beads and appeared to be elongated in 
sheets. There were scanty cells seen with beads on the positive plate. The cells were 
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reviewed on the following day and had similar appearances. The negative plate was 
confluent and was therefore split into 2 wells of a 6 well plate after removal with 
trypsin (section 2.9.2).  
On day three the positive plate showed only scanty cells. One of the negative plates 
was left alone, but the other plate had media replaced with DMEM-F12 with 
glutamine (11320033; Life Technologies (Gibco))/10% FCS (Gibco; 10270106) and 
penicillin/streptomycin (Gibco; 15140-122) (no growth factors). This was done in an 
attempt to see if any cells would start forming a cobblestone appearance in the 
absence of growth factors. This is because sometimes primary endothelial cell 
cultures can have a more elongated appearance in the presence of growth factors 
(personal communication with R. Bicknell).  
On day 6 the cells on the positive plate had started to proliferate and the media was 
changed. The cells on the negative plates both retained a fibroblast like appearance 
despite the removal of growth factors on one of these plates. The negative plates 
were therefore discarded. 
On day nine the cells on the positive plate had reached confluence. These cells did 
not have a typical cobblestone appearance of endothelial cells as the cells extracted 
by Hewett and Murray did.(330) The cells appeared more ‘spiky’ and elongated. The 
cells were removed using trypsin (section 2.9.2) and split into 3 wells of a 0.1% 
gelatin (section 2.8.1) coated 6 well plate.  
On day 10 the 3 wells appeared near confluence. The appearance of these cells can 
be seen in figure 5.7. 2 wells were removed using trypsin and frozen in FCS/DMSO 
(as in extraction 4) at -800C before being transferred to a liquid nitrogen freezer. The 
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third well was also removed using trypsin (section 2.9.2) and split into 3 wells of a 
0.1% gelatin coated 6 well plate.  
The cells were reviewed on day 14. The cells on the three wells appeared confluent 
and more fibroblast like. The media was replaced on two wells with MLEC/HPEC 
media (section 2.8.1). The media on the third well was replaced with media without 
growth factors (DMEM-F12/10% FCS and penicillin/streptomycin) to see if this would 
lead to the cells forming a more cobblestone like appearance.  
The cells were reviewed on day 16, but all three wells continued to have a fibroblast 
like appearance. The cells were removed using trypsin and were frozen at -800C in 
FCS/DMSO before being transferred to a liquid nitrogen freezer. 
5.4.2 Flow cytometry of positively selected lung cells 
To determine whether or not HPECs had been isolated in extraction 9 flow cytometry 
for CD31 (characteristic of endothelial cells) was performed according to section 
2.11.2. The following conditions were performed for both lung cells and HUVECs: 
x Unstained cells  
x Secondary antibody only (anti-mouse, FITC) 
x Secondary antibody and isotype antibody control (mouse IgG) 
x Test (CD31 antibody (mouse, anti-human) and secondary antibody) 
The lung cells (from the positive selection from extraction 9) and commercially bought 
HUVECs (Cellworks, ZHC-2102) were plated on to 0.1% gelatin (section 2.8.1) 
coated T25 (lung cells) and T75 (HUVECs) flasks 3 days prior to flow cytometry. The 
HUVECs were used as a positive control. Analysis of the flow cytometry performed 
using the software ‘FloJo’ can be seen in figures 5.8-5.11. In both HUVECs and lung 
cells the unstained cytogram was used initially and a gate was created by drawing a 
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plot around the main cell population (figures 5.8 and 5.10). The gates were used to 
limit results for the other cell conditions. Interestingly, the cytogram plots for the lung 
cells and HUVECs looked different from one another. This suggested that they 
represent two different types of cell populations and thus the lung cells were unlikely 
to be endothelial in nature. 
The histogram for the unstained cells was compared to the histograms for the other 
cell conditions (figures 5.9 and 5.11). The HUVECs stained for CD31 demonstrated a 
shift in the histogram (figure 5.9) suggesting that they stained positively for CD31 (as 
expected). Table 5.1 demonstrates that percentage positive cells was 95.9% in the 
CD31 stained group and median fluorescent intensity (MFI) was higher in this group 
in comparison to the control groups. However, there was no shift in the histogram for 
the lung cells stained for CD31. Table 5.2 demonstrates that percentage positive 
cells was 3.92% in the CD31 stained group and MFI was similar in this group in 
comparison to the control groups. This suggests that the lung cells did not stain for 





   
 
   
 
   
 
Figure 5.7: Appearance of lung cells on day 10 after positive selection using Ulex 
coated magnetic beads. These cells were positively selected from lung cells isolated 
in extraction 9. These wells consist of cells grown after one passage (on day 9) and 
were cultured in MLEC/HPEC media (section 2.8.1) on 0.1% gelatin (section 2.8.1) 
coated 6 well plates. All three wells were cultured in identical conditions and were 
passaged from the same original well of cells and are therefore replicates. Cells 
appear elongated and spiky. The multiple small dots visible are magnetic beads. 
A&B: Images from well 1. C&D: Images from well 2. E&F: Images from well 3. 
Images taken with Leica microscope: objective of A/C/E: N PLAN 5x/0.12 PH0, 
objective of B/D/F: C PLAN 10X/0.22 PH1. 








Figure 5.8: A cytogram plot from the program ‘FloJo’ for HUVECs: The dots represent 
individual cells. A gate has been drawn around the main cell population. N=1 
 
Figure 5.9: A histogram plot from flow cytometry performed on HUVECs: The plot 
compares unstained cells (green) to cells stained for secondary antibody only 
(orange), isotype control (red) and CD31 (blue). There is a shift in the CD31 stained 





Figure 5.10: A cytogram plot from the program ‘FloJo’ for lung cells: The dots 
represent individual cells. A gate has been drawn around the main cell population. 
The dots are distributed in a different way to the HUVEC dots and therefore suggest 
that this population of cells is different to HUVECs. N=1 
 
Figure 5.11: A histogram plot from flow cytometry performed on lung cells: The plot 
compares unstained cells (green) to cells stained for secondary antibody only 
(orange), isotype control (red) and CD31 (blue). There is no shift in the CD31 stained 
population indicating negative staining for the cell marker in question. N=1 
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HUVEC: CD31 95.9 % 8.26 
HUVEC: isotype 
control 
9.37 % 5.69 
HUVEC: secondary 
anyibody only 
8.86 % 6.02 
HUVEC: unstained 10.9 % 5.74 
 
This table outlines the four different HUVEC groups analysed by flow cytometry and 
the percentage positive of each group that fluoresced. The MFI for each group is also 
listed. HUVEC = Human Umbilical Vein Endothelial Cells. MFI = Median Fluorescent 
Intensity. N=1 
 





Lung cells: CD31 3.92 % 3.92 
Lung cells: isotype 
control 




3.18 % 4.1 
Lung cells: 
unstained 
4.26 % 4.03 
 
This table outlines the four different lung cell groups analysed by flow cytometry and 
the percentage positive of each group that fluoresced. The MFI for each group is also 










After several attempts we were not successful in reliably extracting and culturing 
HPECs from human lung tissue. Cellular appearances from some of the extractions 
do demonstrate endothelial-like appearances (figures 5.4 and 5.5). This might 
suggest that endothelial cells were successfully grown in culture, but these early 
endothelial colonies did not survive over time. As the initial digested lung is cultured 
as a mixture of cell types it is likely that this included contaminating cells such as 
fibroblasts. It is known that contamination of endothelial cell cultures with fibroblasts 
results in the death of endothelial cultures where the contaminating cells effectively 
take over the cell culture.(328) It is important to note that the classical HPEC 
extraction papers by Carley et al and Hewett and Murray removed the pleura from 
the lung they used in extractions whereas this was not performed in this study. (329, 
330) It is possible that mesothelial cell contamination could therefore have resulted in 
mesothelial cells overtaking early endothelial cell cultures in this study. Even though 
positive selection using Ulex-coated magnetic beads was used in extraction 9 to 
remove contaminating cells this selection may have occurred too late to obtain 
enough endothelial cells to achieve a successful culture. It is likely that the cells seen 
in figure 5.7 (after positive selection) were in fact derived from contaminating cells 
during positive selection rather than from cells that bound successfully to the Ulex 
beads. This hypothesis is supported by the fact that after positive selection only a few 
scanty cells were present in the positive selection culture whereas most cells were 
present in the negative selection culture (derived from cells that did not bind to the 
Ulex coated beads). Also, the morphology of the cells from the negative culture was 
similar to cells in the positive culture. Therefore, if the method was to be altered 
 
 260 
again, it would be sensible to remove the pleura prior to mincing and digesting the 
lung tissue to minimise mesothelial cell contamination. A change of media could also 
possibly help to minimise contaminating cells. It is possible to buy commercially 
made endothelial cell media in which one can add different growth factors.(495, 496) 
By using these sorts of media it would be possible to tailor make media to avoid 
growth factors that would encourage contaminating cell growth (such as fibroblast 
growth factor, FGF) and to use growth factors that would encourage primarily 
endothelial cell growth (such as vascular endothelial growth factor, VEGF). Perhaps 
by discouraging the growth of contaminating cells in this way larger amounts of 
endothelial cells would have been able to proliferate in the extractions above. Finally, 
another way of limiting the amount of contaminating cells in the culture would be to 
remove contaminating cells from the culture manually. This could be achieved by 
using a cell scraper followed by washing away the loose cells. However, in order to 
do this accurately one would have to remove contaminating cells under the 
microscope. This would therefore present a challenge unless performed under a 
microscope in a sterile tissue culture hood. Removing the cells outside of such a 
hood could easily result in infection. Alternatively, one could remove the endothelial 
colonies manually using cloning rings and replate the colonies on to new wells. This 
would also have to be performed under microscope however. 
A major impediment in the growth of HPECs was the low number of cells present in 
the initial isolate. As mentioned in the text, a large amount of sticky partially digested 
tissue was present after digestion with collagenase. It is very likely that this tissue 
may have consisted of endothelial cells. Therefore, when this tissue was filtered to 
achieve a single cell solution many of the lung endothelial cells would have been lost. 
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Indeed, this was not a problem during the MLEC extraction and one pair of mouse 
lungs provided enough MLECs to cover a whole 10 cm plate. However, several 
digestions of human lung tissue could not provide enough HPECs to successfully 
cover one well of a 6 well plate. To address this issue two methods were employed. 
Firstly, the cell digest was passed in and out of a 20 cm syringe via a needle in an 
attempt to disaggregate cells. However, the partially digested tissue made this 
impossible. Secondly, the digestion time was increased to 2 and 4 hours. Increasing 
the digestion time resulted in cell suspensions without partially digested tissue, but 
this resulted in poor cell yields presumably as a result of cellular damage. An 
alternative method to reduce the amount of partially digested tissue would be to use 
longer digestion times with a different enzyme such as neutral protease dispase. 
Dispase is more gentle on cell membranes so less likely to cause cell damage like 
collagenase at longer digestions and was used for over 16 hours in the extractions 
performed by Hewett and Murray.(330) A more thorough digest of tissue would 
hopefully reduce the amount of partially digested tissue and therefore reduce the 
number of endothelial cells removed at filtration. 
Another possible way to attempt to increase the yield of endothelial cells would be to 
perform positive selection earlier. During this study positive selection in extraction 9 
was performed after the initial cell cultures were approaching confluence. However, 
at this point other cell types were also visible. On day 6 after extraction 9 there were 
enlarging visible endothelial-like colonies. By day 8 fibroblast like cells were visible 
and positive selection was not performed until day 12. At this point the fibroblast like 
cells had formed sheets and were increasing in number. Perhaps, if the positive 
selection had been performed at day 6-8 the positive selection process may have 
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selected endothelial cells successfully. The total number of cells would have been 
fewer, but potentially the proportion of endothelial cells may have been higher 
increasing the final number of endothelial cells after positive selection. Other groups 
have used this approach with success. For example, Burg et al performed positive 
selection for HPECs after 5-7 days of mixed cell culture with the main purpose of 
preventing growth of contaminating cells.(338) 
It is possible that patient selection might also be important in increasing the yield of 
HPECs. Perhaps the MLEC extraction worked well as it was performed on a young 
mouse. In theory one might expect younger cells to proliferate more effectively than 
older cells. Unfortunately I only had access to lung tissue from older patients. The 
youngest patient in this part of the study was 57 years old. However, as nearly all 
lobectomies and pneumonectomies are performed for the investigation and treatment 
of lung cancer it is unlikely that many patients would be below the age of 50. Tissue 
not suitable for lung transplant could provide another source of lung tissue potentially 
from younger patients. However, tissue like this is available only very infrequently 
and is not available at predictable times limiting its use for HPECs needed on a 
regular basis. It might be supposed that the healthier the donated tissue is, the better 
the extracted HPECs might be at proliferation. Also, as tissue from patients with 
emphysema often has reduced pulmonary vasculature one might expect endothelial 
extractions from tissue from COPD patients to be poor.(205) However, extraction 4 
was performed using tissue from COPD lung and the initial cultures did have an 
endothelial like appearance (figure 5.5). Also, other groups have successfully grown 
HPECs from COPD lung.(336) Therefore, excluding patients with COPD from HPEC 
extraction attempts may not be a sensible strategy. One could also argue for the 
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extraction of HPECs from COPD and non-COPD lung which would allow the 
comparison of COPD and non-COPD HPECs in various functional work. Therefore, 
as yet, it is not clear which patients might provide lung tissue more amenable to 
HPEC extraction. Perhaps unknown genetic expression differences between patients 
might affect the success of HPEC isolation. However, this would be impossible to 
determine prior to every extraction and would be impractical. Other groups have also 
noticed that some HPEC extractions work better than others without obvious causes 
(Personal communication with Dr P Hewett.) 
Finally, it is possible that the position of the lung used for endothelial extraction could 
influence the success of HPEC extraction. Hewett and Murray discovered that 
peripheral lung tissue (less than 1 cm from the lung edge) appeared to produce 
greater yields of HPEC than more proximal pieces of lung tissue (Personal 
communication with Dr P Hewett.)(330) However, the use of distal tissue has not 
always been specified by other groups that have successfully extracted HPECs. 
(336, 338) Also, in any case, the tissue used in this study was generally derived from 
peripheral pieces of lung as far away from the tumour as possible. 
5.6 Conclusions 
In summary this chapter presents the results of multiple attempts at extracting 
HPECs from human lung tissue obtained at lobectomy/pneumonectomy. Despite 
initial success at extracting similar cells from mouse tissue no successful cultures of 
HPECs were obtained. The results presented suggest that HPECs initially grew in 
mixed cell cultures, but the growth of these cells was limited by the more rapid growth 
of contaminating cells. Methods to overcome this could include attempts to limit 
mesothelial cell contamination (such as dissection of the pleura prior to digestion) or 
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attempts to increase overall cell yield (such as longer digestion times with alternative 
enzymes such as dispase). It is clear that several alternative strategies could be 
employed in further extraction attempts and it would be useful to pursue these 






IDENTIFYING THE ROLE OF MICRORNA 





Increasing the expression of miR-181b-3p in endothelial cells will have effects on 
endothelial cell function that are relevant to the pathogenesis of COPD. 
6.2 Aims of this chapter 
This chapter outlines the functional work performed in human umbilical vein 
endothelial cells (HUVECs) to investigate the effect of miR-181b-3p on endothelial 
behaviour and function. Results for each assay performed will be outlined prior to a 
discussion and an overall conclusion for the chapter. 
6.3 The role of miR-181b-3p in angiogenesis 
To investigate whether or not miR-181b-3p influences endothelial function artificial 
mimics and inhibitors of miR-181b-3p were transfected into HUVECs and the altered 
expression of miR-181b-3p was confirmed using qPCR. Pooled HUVEC were 
purchased (Lonza) and used for all experiments in order to limit the effect of single 
nucleotide polymorphisms (SNPs) on endothelial function. HUVECs were grown and 
split in HUVEC media (section 2.11.3) and used at passage 3 or 4. 
HUVECs were chosen for cellular functional work primarily as attempted cultures of 
HPECs failed (chapter 5) and therefore a ready supply of HPECs was not available. 
HPECs can be purchased, but these are very expensive and previous attempts at 
culturing them successfully in the Bicknell laboratory had proven difficult. HUVECs 
are relatively cheap and easy to culture (personal communication with R. Bicknell) 






6.3.1 Optimisation of miR-181b-3p mimic into HUVECs 
An initial experiment was performed to transfect different concentrations of miR-
181b-3p mimic at the following concentrations: 1 nM, 5 nM and 10 nM (figure 6.1). 
Each condition was repeated in quadruplicate. The expression of miR-181b-3p in 
each sample was then assessed by qPCR. All concentrations of mimic were 
successful at significantly increasing the expression of miR-181-3p (p<0.001). 
However, tukey’s test demonstrated that the expression of miR-181b-3p was 
significantly increased in cells transfected with 10 nM concentration of mimic in 
comparison to 1 nM (p<0.001) and 5 nM (p=0.021). Thus, 10 nM was used for further 
experiments.  
To confirm that transfecting 10 nM miR-181b-3p mimic provided a stable increased 
level of miR-181b-3p expression in HUVECs three further experiments were 
performed confirming that miR-181b-3p expression was maintained up to three days 
after transfection (figure 6.2). Each experiment was repeated in quadruplicate. These 
experiments demonstrated that the expression of miR-181b-3p decreased over time 






Figure 6.1: Optimisation of miR-181b-3p mimic concentration. The figure shows the 
relative expression of miR-181b-3p in HUVECs transfected with miR-181b-3p mimic 
at 1 nM, 5 nM and 10 nM in comparison to negative siRNA (control). qPCR was used 
to determine the expression of miR-181b-3p in each group. RNU48 was used as the 
house-keeping small RNA to which the data was normalised. Expression of miR-
181b-3p in the mimic groups was normalised to that of the control group. The double 
delta Ct method was used to compare the expression levels. Expression was 
calculated from the delta Ct levels for miR-181b-3p expression in the mimic groups 
(n=4 per group) and the mean delta Ct for the control group (n=4). Figures represent 
mean fold changes; error bars being SEM fold change. 
A one-way ANOVA test was used to determine significant differences between mean 
delta Ct in all groups (p<0.001). Tukey’s test was used post-hoc to look for significant 
differences between the mean delta Ct in the control group and each concentration of 
mimic. The tukey’s test also demonstrated that miR-181b-3p expression was 
significantly higher in cells transfected with 10 nM mimic in comparison to 1 nM 
(p<0.001) and 5 nM (p=0.021) 




































Figure 6.2: Relative expression of miR-181b following mimic transfection at 10nM 
concentration. qPCR was used to determine the expression of miR-181b-3p in each 
group. RNU48 was used as the house-keeping small RNA to which the data was 
normalised. Expression of miR-181b-3p in the mimic groups was normalised to that 
of the control groups. The double delta Ct method was used to compare the 
expression levels.  
A: Mean relative expression of miR-181b-3p in HUVECs transfected with an artificial 
miR-181b-3p mimic 2 days post transfection. This represents the mean expression 
from 3 independent experiments. B: Mean relative expression of miR-181b-3p in 
HUVECs transfected with an artificial miR-181b-3p mimic 3 days post transfection. 
This represents the mean expression from 3 independent experiments.  
A t-test was used to determine significant differences between the mean relative 
expression in the mimic group and the control group. n=3 in each group 


























































6.3.2 Optimisation of miR-181b-3p inhibitor into HUVECs 
An initial experiment was performed to transfect different concentrations of miR-
181b-3p inhibitor at the following concentrations: 1 nM, 10 nM and 50 nM (figure 6.3). 
The expression of miR-181b-3p in each sample was then assessed by qPCR. Only 
the 10 nM concentration resulted in a reduction of miR-181b-3p expression although 
the effect was small (23.4% reduction). To confirm this effect the experiment was 
repeated using the 10 nM concentration of inhibitor only repeating all conditions in 
quadruplicate (figure 6.4). This demonstrated a 53.9% reduction in miR-181b-3p 
expression but did not reach statistical significance. 
In a similar way to miRNA mimic optimisation three further experiments were 
performed to confirm that inhibition of miR-181b-3p expression was maintained for 
three days after transfection (figure 6.5). Each experiment was repeated in 
quadruplicate. However, the miR-181b-3p was not successfully inhibited in any 
experiments. This is most likely because the background expression of miR-181b-3p 
was low in control cells (Ct values were primarily >35). Therefore, this suggests that 
miR-181b-3p expression could not be inhibited any further. MiR-181b-3p inhibitors 





Figure 6.3: Optimisation of miR-181b-3p inhibitor concentration. The figure shows the 
relative expression of miR-181b-3p in HUVECs transfected with miR-181b-3p 
inhibitor at 1 nM, 10 nM and 50 nM concentration in comparison to a negative 
inhibitor (control). qPCR was used to determine the expression of miR-181b-3p in 
each group. RNU48 was used as the house-keeping small RNA to which the data 
was normalised. Expression of miR-181b-3p in the inhibitor groups was normalised 
to that of the control group. The double delta Ct method was used to compare the 
expression levels. Expression was calculated from the delta Ct levels for miR-181b-
3p expression in the inhibitor groups (n=1 per group) and the control group (n=1). 


































Figure 6.4: Inhibition of miR-181b-3p using an inhibitor at 10 nM. The figure shows 
the relative expression of miR-181b-3p in HUVECs transfected with miR-181b-3p 
inhibitor and negative inhibitor (control). qPCR was used to determine the expression 
of miR-181b-3p in each group. RNU48 was used as the house-keeping small RNA to 
which the data was normalised. Expression of miR-181b-3p in the inhibitor group was 
normalised to that of the control group. The double delta Ct method was used to 
compare the expression levels. Expression was calculated from the delta Ct levels for 
miR-181b-3p expression in the inhibitor group (n=4) and the mean delta Ct for the 
control group (n=4). Figures represent mean fold changes; error bars being SEM fold 



























Figure 6.5: Relative expression of miR-181b following inhibitor transfection. qPCR 
was used to determine the expression of miR-181b-3p in each group. RNU48 was 
used as the house-keeping small RNA to which the data was normalised. Expression 
of miR-181b-3p in the inhibitor groups were normalised to that of the control groups. 
The double delta Ct method was used to compare the expression levels.  
A: Mean relative expression of miR-181b-3p in HUVECs transfected with an artificial 
inhibitor 2 days post transfection. This represents the mean expression from 3 
independent experiments. B: Mean relative expression of miR-181b-3p in HUVECs 
transfected with an artificial inhibitor 3 days post transfection. This represents the 
mean expression from 3 independent experiments.  
A t-test was used to determine significant differences between the mean relative 





















































6.3.3 The effect of miR-181b-3p overexpression on cell growth 
To determine whether or not miR-181-3p affects endothelial cell growth three 
separate experiments were performed. Briefly, HUVECs that had been transfected 
with miR-181b-3p mimic, negative siRNA, lipofectamine only or optimem only were 
plated into 3 wells (per condition) of 3 different 12 well plates. The number of cells 
per condition was counted 1-3 days post transfection (figure 6.6). There did not 
appear to be any difference in cell number in the miR-181b-3p, negative siRNA or 
lipofectamine conditions in any of the 3 experiments suggesting that miR-181b-3p 
overexpression does not have a significant effect on cell growth. However, cell 
number was significantly increased in the optimem only group which suggests that 
exposure to lipofectamine may impair cell growth.  
 
6.3.4 The effect of miR-181b-3p overexpression on the cell cycle  
To determine whether miR-181b-3p overexpression lead to any changes in the cell 
cycle, flow cytometry after propidium iodide staining was performed. HUVECs that 
had been transfected with miR-181b-3p mimic, negative siRNA, lipofectamine or 
optimem only were compared. This was performed in three separate experiments. 
Figure 6.7 demonstrates the proportion of cells in phases G1, S and G2 across all 
experiments. The proportion of cells in each phase did not differ between groups 
significantly suggesting that overexpression of miR-181b-3p did not alter the cell 
cycle. An example of the histogram plots of cell counts for cell cycle analysis from 




Figure 6.6: Cell growth assay. This figure shows the number of cells day 1, 2 and 3 
after transfection in cells transfected with miR-181b-3p mimic, negative siRNA, 
lipofectamine or optimem. Numbers represent the mean from three separate 
experiments. The Kruskal-Wallis test was used to determine significant differences 
between groups. N=3 in each group. Day 1; p = 0.046, day 2; p = 0.001, day 3; 
p<0.001. * = p <0.05, ** = p <0.01, *** = p <0.001 
 
 
Figure 6.7: Cell cycle analysis according to flow cytometry. The figure shows the 
proportion of cells in G1, S and G2 phases of the cell cycle in cells transfected with 
miR-181b-3p mimic, negative siRNA, lipofectamine or optimem. The values represent 
the mean from three separate experiments. 
A one-way ANOVA test was used to determine significant differences between 
groups. Tukey’s test was used post-hoc to look for significant differences between 


























































Figure 6.8: Histogram plots of cell counts for cell cycle analysis. This represents a  
typical histogram plot from one experiment. A = HUVECs transfected with 181b-3p 
mimic. B = HUVECs transfected with a negative siRNA. C = HUVECs transfected 
with lipofectamine only. D = HUVECs exposed to optimem only (no transfection). 
There was no significant difference in the proportion of cells in each phase of the cell 









6.3.5 The effect of miR-181b-3p overexpression on HUVEC tube formation  
To determine the effect of miR-181b-3p on HUVEC tube formation three separate 
matrigel assays were performed. HUVECs that had been transfected with miR-181b-
3p mimic, negative siRNA, lipofectamine only or optimem only were seeded on to 
matrigel and images were taken of each condition at 6, 12, 18 and 24 hours. The 
images were uploaded and analysed by the program ImageJ. Specifically, number of 
nodes, number of junctions, number of meshes and total mesh area were assessed 
in each experiment (figures 6.9-6.12). 
The four groups were significantly different in terms of number of nodes and number 
of junctions at each time point. A tukey’s test was performed post-hoc to compare 
individual groups which demonstrated that number of nodes and number of junctions 
were significantly reduced in HUVECs transfected with miR-181b-3p mimic compared 
to negative siRNA (p<0.001) at 6, 12 and 18 hours. The effect was lost at 24 hours. 
The four groups were significantly different in terms of number of meshes at 6, 12 
and 18 hours only, but were significantly different at all time points for total mesh 
area. A tukey’s test was performed post-hoc to compare individual groups which 
demonstrated that number of meshes and total mesh area were significantly reduced 
in HUVECs transfected with miR-181b-3p mimic compared to negative siRNA at 6 
(p<0.001) and 12 (p<0.05) hours. The effect on number of meshes and total mesh 
area was lost at 18 hours.  
Figure 6.13 demonstrates an example of images taken at 6, 12, 18 and 24 hours 
after HUVECs were added to matrigel in the miR-181b-3p mimic and negative siRNA 




Figure 6.9: Number of nodes formed by HUVECs imbedded in matrigel. The figure 
shows the mean number of nodes present 6, 12, 18 and 24 hours after HUVECs 
were seeded on matrigel. The numbers represent the mean from 3 separate 
experiments. An ANOVA test was used to look for significance between groups. *** = 
p <0.001 (ANOVA). Tukey’s test was used to compare groups which demonstrated 
that number of nodes was significantly reduced in the mimic group in comparison to 
the negative siRNA group at 6, 12 and 18 hours only (p<0.001 in all cases.) 
 
  
Figure 6.10: Number of junctions formed by HUVECs imbedded in matrigel. The 
figure shows the number of junctions present 6, 12, 18 and 24 hours after HUVECs 
were seeded on matrigel. The numbers represent the mean from 3 separate 
experiments. An ANOVA test was used to look for significance between groups. *** = 
p <0.001 (ANOVA). Tukey’s test was used to compare groups which demonstrated 
that number of junctions was significantly reduced in the mimic group in comparison 



























































Figure 6.11: Number of meshes formed by HUVECs imbedded in matrigel. The figure 
shows the number of meshes present 6, 12, 18 and 24 hours after HUVECs were 
seeded on matrigel. The numbers represent the mean from 3 separate experiments. 
An ANOVA test was used to look for significance between groups. *** = p<0.001 
(ANOVA). Tukey’s test was used to compare groups which demonstrated that 
number of meshes was significantly reduced in the mimic group in comparison to the 
negative siRNA group at 6 (p<0.001) and 12 (p=0.028) hours.  
 
   
Figure 6.12: Mesh area formed by HUVECs imbedded in matrigel. The figure shows 
the total mesh area at 6, 12, 18 and 24 hours after HUVECs were seeded on 
matrigel. The numbers represent the mean from 3 separate experiments. An ANOVA 
test was used to look for significance between groups (p<0.001 at 6-18 hours, 
p=0.004 at 24 hours). *** = p <0.001, ** = p<0.01 (ANOVA). Tukey’s test was used to 
compare groups which demonstrated that total mesh area was significantly reduced 
in the mimic group in comparison to the negative siRNA group at 6 (p<0.001) and 12 
































































Figure 6.13: An example of images from a matrigel experiment. A: HUVECs 
transfected with miR-181b-3p mimic. B: HUVECs transfected with negative siRNA. 
There is reduced tube formation seen in HUVECs transfected with the mimic. Scale 

















6.3.6 The effect of miR-181b-3p overexpression on HUVEC wound healing 
To assess the effect of miR-181b-3p overexpression on endothelial migration and 
wound healing three separate scratch wound experiments were performed. HUVECs 
that had been transfected with miR-181b-3p mimic, negative siRNA, lipofectamine 
only or optimem only were cultured in monolayers and a linear wound was created. 
The cultures were then imaged at 0, 6, 12, 18, 24 hours to determine the speed at 
which the wounds were closed. Each experiment was performed in triplicate. 
There was no significant difference between groups at 6, 18 and 24 hours although 
there was a trend for wound closure to be faster in the optimem only group (figure 
6.14). Wound closure was significantly different between groups at the 12 hour time 
point. A tukey’s test was performed post-hoc to compare results between groups 
which demonstrated that the optimem only group had a smaller percentage wound 
area remaining compared to the lipofectamine group (p=0.015). This was the only 
significant difference detected in the post-hoc analysis.  
As wound closure did not vary significantly between the miR-181b-3p mimic and 
negative siRNA groups these results suggest that miR-181b-3p does not have a 
significant effect on endothelial migration and wound closure. Figure 6.15 
demonstrates an example of images taken at 0, 6, 12, 18 and 24 hours after a 
scratch wound was completed in the miR-181b-3p mimic and negative siRNA 






Figure 6.14: Percentage wound area remaining during scratch wound assay. The 
average percentage wound remaining for each condition is recorded at 0, 6, 12, 18 
and 24 hours. The data represents the mean from three separate experiments. An 
ANOVA test was used to look for significance between groups. p=0.021 at 12 hours. 
* = p < 0.05 (ANOVA). A tukey’s test demonstrated that the optimem only group had 


















































Figure 6.15: An example of images from a scratch wound experiment. A: HUVECs 
transfected with miR-181b-3p mimic. B: HUVECs transfected with negative siRNA. 
The remaining wound area is highlighted. There was no significant difference 



























6.3.7 The effect of miR-181b-3p overexpression on HUVEC spheroid 
sprouting 
To determine how miR-181b-3p overexpression in HUVECs alters endothelial 
sprouting three spheroid assays were performed. In each experiment HUVECs 
transfected with miR-181b-3p mimic, negative siRNA, lipofectamine only or optimem 
were used to create spheroids. Confocal microscopy was used to image the 
spheroids. Five spheroids were imaged per condition. The images were uploaded 
into ImageJ and were analysed using the ‘Spheroid Analysis’ plugin developed at the 
University of Birmingham by Victoria Salisbury.(366)  
Number of sprouts, total sprout length and average sprout length were significantly 
different between groups (figures 6.16-18). Tukey’s tests were performed in post-hoc 
analyses for number of sprouts, total sprout length and average sprout length. These 
demonstrated that spheroids in the miR-181b-3p mimic group had reduced sprouting 
in comparison to the negative siRNA group suggesting that miR-181b-3p 
overexpression significantly reduced endothelial sprout formation. (Number of 
sprouts, p = 0.021; total sprout length, p = 0.003; average sprout length, p = 0.003.) 
An example of a typical endothelial spheroid formed from HUVECs transfected with 
miR-181b-3p mimic and negative siRNA can be seen in figure 6.19. Reduced 




Figure 6.16: Number of endothelial sprouts from spheroids. The figure shows the 
total number of endothelial sprouts for each condition. The numbers represent the 
mean from 3 separate experiments. An ANOVA test was used to determine 
significant differences between groups. *** = p <0.001 (ANOVA). A tukey’s test 
demonstrated that there was a reduced number of sprouts in the mimic group in 
comparison to the negative siRNA group (p=0.021). 
 
 
Figure 6.17: Total length of endothelial sprouts from spheroids. The figure shows the 
total endothelial sprout length for each condition. The numbers represent the mean 
from 3 separate experiments. An ANOVA test was used to determine significant 
differences between groups.  *** = p <0.001 (ANOVA). A tukey’s test demonstrated 
that there was a reduced total sprout length in the mimic group in comparison to the 



















































Figure 6.18: Average length of endothelial sprouts from spheroids. The figure shows 
the average endothelial sprout length for each condition. The numbers represent the 
mean from 3 separate experiments. An ANOVA test was used to determine 
significant differences between groups (p=0.003). ** = p <0.01 (ANOVA). A tukey’s 
test demonstrated that there was a reduced average sprout length in the mimic group 











































Figure 6.19: An example of an endothelial spheroid assay. A: Spheroid created from 
HUVECs transfected with miR-181b-3p. B: Spheroid created from HUVECs 
transfected with negative siRNA. There is reduced sprouting seen in the spheroid 
transfected with the miR-181b-3p mimic. Spheroids were imaged using a Zeiss 780 





6.3.8 Identification of miR-181b-3p targets 
As the above results suggest an inhibitory role for miR-181b-3p in angiogenesis an 
attempt was made to identify possible miR-181b-3p gene targets that could be 
responsible for this effect. Computer prediction programs were used in section 3.3.3 
to help to identify targets. Two predicted targets were identified in the top 100 list of 
targets that looked particularly promising: ELTD1 (adhesion G protein-coupled 
receptor L4) and IL8 (interleukin 8). These have both been previously associated with 
an upregulation of angiogenesis.(497, 498) Therefore, qPCR was performed to look 
for the expression of ELTD1 and IL8 in cells that has been transfected with miR-
181b-3p mimic (n=4) and compare this to expression in cells that had been 
transfected with a negative siRNA (n=4). Neither gene was significantly suppressed 
in the samples transfected with miR-181b-3p (figure 6.20). This suggests that either 
the target prediction was false and miR-181b-3p is acting through suppression of 
other genes, or miR-181b-3p targets ELTD1 and IL8 at a translational level. To 







Figure 6.20: Mean relative expression of ELDT1 and IL8 in cells transfected with 
miR-181b-3p mimic and negative siRNA. qPCR was used to determine the 
expression of each mRNA target in HUVECs transfected with miR-181b-3p mimic in 
comparison to HUVECs transfected with a negative siRNA (control). Flotillin 2 was 
used as the house-keeping gene to which the data was normalised. Expression of 
mRNA targets in HUVECs transfected with the mimic was normalised to that of 
HUVECs transfected with the negative siRNA. The double delta Ct method was used 
to compare the expression levels. The charts represent the mean expression from 
four separate experiments. A t-test was used to determine significant differences 
between the 2 groups. 






















































6.4.1 The evidence for miR-181b-3p’s involvement in angiogenesis 
In summary the results above suggest that miR-181b-3p overexpression significantly 
impairs tube formation and sprouting of endothelial cells in vitro. This does not 
appear to be through alteration of cell growth or changes to the cell cycle. Matrigel 
assays measure several angiogenic processes including adhesion, migration, cell 
alignment and formation of tubes.(499) The assay primarily assesses the 
differentiation stage of angiogenesis where cells form vessel sprouts.(500) This is 
supported by results from the spheroid assay in which endothelial sprouting was 
significantly reduced by miR-181b-3p overexpression. Therefore, the results of this 
study suggest that increased miR-181b-3p levels in endothelial cells impair 
angiogenesis. The spheroid assay possibly provides more conclusive evidence than 
the matrigel assay that this is the case. It is known that endothelial cells become 
undifferentiated in culture and therefore may function differently from cells in 
vivo.(501) However, when endothelial cells form spheroids the outer cells become 
differentiated and more closely resemble cells found in the vasculature.(502) They 
also produce capillary sprouts in collagen which have lumen and are lined by a 
flattened layer of endothelial cells rather like capillaries in vivo.(503) Therefore it is 
likely that spheroid assays more accurately reflect the process of angiogenesis. 
Consequently the results of the spheroid assay in this study strongly support the 
case for impaired angiogenesis in the context of miR-181b-3p overexpression. 
Wound closure however does not appear to be influenced by miR-181b-3p. This is 
unexpected due to the consistent reduction in tube formation and endothelial 
sprouting seen when miR-181b-3p is overexpressed. However, scratch wound 
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assays primarily assess cell migration and proliferation, but do not assess the same 
number of functions as the matrigel and spheroid assays.(504) Therefore, this could 
suggest that the reduction in angiogenesis is not primarily as a result of changes in 
cell migration; instead it could be due to cell alignment and endothelial sprout 
formation. The lack of change seen in cell proliferation in the scratch wound assay 
supports the cell growth experiments, which were non-significant between miR-181b-
3p overexpression and control siRNA groups. 
Development of the pulmonary vasculature appears to be key in the development of 
alveolar structures in the developing lung.(505) More recently it has also been 
postulated that the pulmonary microvascular circulation is important in maintenance 
of alveolar structures by producing factors termed ‘angiocrines’.(506) Preserving the 
lung vasculature could therefore promote growth and preserve the architecture of 
alveoli.(507) One possible angiocrine is retinoic acid. Retinoic acid stimulates tube 
formation in lung endothelial cells in vitro suggesting it enhances angiogenesis.(508) 
Patients with emphysema also have increased levels of CYP26A1 (an enzyme that 
degrades retinoic acid) in the endothelium.(508) This suggests that patients with 
emphysema may have reduced pulmonary endothelial retinoic acid levels. A 
reduction of retinoic acid could potentially result in dysregulated maintenance and 
repair of alveoli resulting in alveolar damage and emphysema. In support of this, 
murine models have demonstrated that retinoic acid can enhance lung growth both 
after pneumonectomy and in the setting of drug-induced disrupted alveolar 
development in adult mice and rats.(509, 510) These findings also suggest that the 
lung may have more intrinsic regenerative ability than previously thought further 
supporting the concept of lung regeneration as a treatment strategy for emphysema. 
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Retinoic acid agonists have been used in patients with alpha 1 antitrypsin deficiency 
and moderate-severe COPD (REPAIR trial). However, this trial did not demonstrate 
an improvement in lung density on CT scanning.(511) This could mean that retinoic 
acid is unlikely to improve COPD in human disease, but as the study was only carried 
out over one year and COPD progresses slowly, the study may simply have not been 
long enough to detect a treatment effect. The study also focused on patients with 
more severe disease and it is possible that too much tissue destruction existed in 
these patients to demonstrate an effect. Perhaps retinoic acid would have been more 
effective in patients with milder disease with more residual lung tissue. 
As previously discussed, there is little known information on miR-181b-3p’s function 
other than it appears to upregulate epithelial-mesenchymal transition in breast cancer 
cells.(380) However, some studies do support the results of this study as they show 
evidence for a reduction in angiogenesis secondary to miRNAs related to miR-181b-
3p. For example, miR-181b (the precursor of miR-181b-3p) is reduced in chick 
embryos when arsenic is added which is associated with a reduction in 
angiogenesis.(397) In mouse models, injection of glioma cells expressing miR-181b 
mixed with matrigel resulted in reduced angiogenic responses in the matrigel 
plugs.(512) This was not seen when the glioma cells expressed a negative control 
miRNA suggesting miR-181b was responsible for the reduced angiogenic 
response.(512) This effect appeared to be through the suppression of insulin-like 
growth factor 1 (IGF-1), a tyrosine kinase receptor that regulates multiple pathways 
including cell proliferation.(512) Results from one other study appear to conflict this 
however. As previously mentioned, one group identified that miR-181b was 
increased in retinoblastoma cells and enhanced angiogenesis through targeting 
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Programmed cell death-10 (PDCD10) and GATA binding protein 6 (GATA6).(392) 
There are no other studies looking at angiogenesis in relation to miR-181b-3p as yet 
and thus it is difficult to draw firm conclusions as a result of the evidence available. 
6.4.2 Limitations 
The main limitation of this study is the relatively small number of assays performed. 
Both the matrigel and scratch wound assay are relatively simple and test a restricted 
number of functions associated with angiogenesis. It has been previously argued that 
the tubes formed in matrigel assays do not have lumens typical of capillaries and 
therefore are limited in assessing angiogenesis function.(513) (Although this has 
been disputed by other groups who have identified such lumens under microscopy. 
(514)) Nevertheless, as the matrigel assay involves seeding endothelial cells on to a 
matrix only and does not involve input from other cell types it is unlikely to fully 
recreate the angiogenic process. This limitation has been partly assuaged by the use 
of the spheroid assay which produces capillary-like networks with lumen that more 
accurately reflect capillaries in vivo.(503) However, complex assays which include 
support from other cell types (co-culture assays) may be more accurate still.(515) 
Therefore, by limiting the assays performed to simple tests the degree of involvement 
of miR-181b-3p in angiogenesis function is not yet certain. However, due to time 
constraints it was not possible to perform co-cultures during the course of the study. 
These assays are considered in more depth in section 7.5.1. 
The other main limitation is that HUVECs were used for the functional work rather 
than HPECs. This was primarily due to the ease of availability of HUVECs in 
comparison to HPECs which proved difficult to isolate (chapter 5) and are expensive 
to purchase. It could therefore be argued that one cannot assume that HPECs would 
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behave in the same fashion if the level of miR-181b-3p expression in these cells was 
increased in the same manner as HUVECs. Indeed, studies have shown that 
although glycoprotein expression in different microvascular endothelial cells is similar 
between organ types there are key differences which, in theory, could influence cell 
function.(331, 332) If time permitted it would therefore have been prudent to repeat 
studies in HPECs. 
6.5 Conclusions 
 
In summary this chapter presents evidence that miR-181b-3p expression can be 
increased using transfection in HUVECs with success and without influencing the 
proportion of cells in each phase of the cell cycle or cell growth. Preliminary studies 
suggest that 181b-3p overexpression reduces tube formation and sprouting in 
HUVECs and could therefore limit angiogenesis. Previous results (chapter 3) 
demonstrate that miR-181b-3p is increased in HPECs in patients with COPD. An 
increase in miR-181b-3p in this setting could therefore impair HPEC function. This 
might be important in the development of emphysema as other work supports the 
notion that the lung vasculature is key in the structural maintenance of alveoli. 
Correcting miR-181b-3p expression levels could therefore be a possible route for 
treating emphysema by promoting support of alveolar structure and regeneration. 











7.1 Summary of project findings 
7.1.1 Key project findings 
This project has demonstrated that messenger RNA (mRNA) and microRNA (miRNA) 
expression in human pulmonary endothelial cells (HPECs) is significantly altered in 
patients with COPD. Four novel endothelial targets were also validated using qPCR 
as upregulated in COPD, one of which was also upregulated in lung cancer 
potentially providing a shared endothelial target between the two conditions. Pathway 
analysis further supported the hypothesis that COPD and lung cancer are related, as 
several pathways were upregulated in COPD with mechanistic links to lung cancer. 
For example, the transforming-growth factor-β (TGF-β) pathway that promotes 
epithelial-mesenchymal transition.(146) Finally, one endothelial target, miR-181b-3p, 
was also validated functionally using endothelial assays. Upregulation of miR-181b-
3p reduced tube formation and sprouting in endothelial cells suggesting that this 
miRNA suppresses angiogenesis. Upregulation of miR-181b-3p may thus contribute 
to the endothelial dysfunction seen in COPD.(218) HPECs are important in the 
structural maintenance of alveoli (506) and therefore upregulation of miR-181b-3p 
may lead to alveolar damage promoting the development of emphysema. 
This study has importance for two main reasons. Firstly, it is the only known study 
that has investigated miRNA and mRNA expression in HPECs in COPD and lung 
cancer. The majority of previous work in this area has used whole lung samples, 
which may miss signals from individual cell types. It is also difficult to attribute miRNA 
or mRNA expression findings to distinct cell types. Thus, the identified targets from 
this study are more likely to represent genuine endothelial targets as they were 
identified from this cell type alone. Secondly, this study is important, as it has 
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identified novel COPD targets. Current treatment for COPD manages symptoms only 
and does not alter the course of the disease.(17) Therefore, identification of new 
possible treatment targets is essential and miR-181b-3p may provide a new 
mechanism of treatment through alveolar regeneration and repair. 
7.1.2 Summary of the analysis of microRNA and messenger RNA 
expression in lung endothelium in COPD and lung cancer.  
The analysis was carried out by completing microarrays for both miRNA and mRNA 
expression in isolated pulmonary endothelial cells from patients with and without 
COPD. Where possible, lung tumour tissue was also collected to assess expression 
in lung cancer. Subsequent analysis using the program SAM (Significance Analysis 
of Microarrays) demonstrated significant differences in both miRNA and mRNA 
expression in patients with and without COPD. Fourteen endothelial targets were 
chosen for further validation with qPCR which resulted in the identification of four 
new targets: miR-23c, -181b-3p, -429 and LTA4H. MiR-429 was then validated as 
upregulated in lung cancer providing a possible shared target between the two 
conditions. 
All miRNA targets have little published data about them and are novel targets in the 
setting of COPD. However, LTA4H has been previously shown to be elevated in 
COPD and has potential roles in inflammation and transendothelial migration. (422)  
7.1.3 Summary of findings from Ingenuity Pathway Analysis  
Microarray results comparing COPD to non-COPD patients were uploaded into the 
program Ingenuity Pathway Analysis (IPA). This identified several disease 
associations with the results. Interestingly, cancer was the most significant disease 
process associated with the mRNA IPA results and the third most significant disease 
process associated with miRNA results. This further supports the hypothesis that 
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cancer and COPD are related. In addition, multiple cancer-related cellular 
mechanisms were dysregulated in COPD such as cell growth and proliferation 
providing evidence as to why the two conditions might be associated.  
To investigate the function of the targets identified above further in-depth pathway 
downstream analysis was performed. This linked targets to disease relevant 
pathways such as Eicosanoid signalling and the transforming growth factor-β 
pathway.  
7.1.4 Summary of findings from Human Pulmonary Endothelial Cell 
extractions. 
Multiple attempts at isolating HPECs from human lung tissue were performed using 
modifications of the isolation of endothelial cells technique for RNA extraction 
(section 2.3.2). This technique used the mincing of lung tissue and digestion by 
collagenase followed by filtration and plating of the cell solution. Purification of the 
HPEC extraction was attempted using Ulex europaeus agglutinin-1 coated magnetic 
beads. However, no modifications of this technique resulted in reliable enough 
cultures of HPECs to use said cells in endothelial functional work. This mainly 
appeared to result from rapid growth of contaminating cells that overcame the growth 
of HPECs. 
7.1.5 Summary of findings from functional studies investigating the role of 
miR-181b-3p in angiogenesis. 
Artificial miR-181b-3p mimics were transfected into HUVECs using lipofectamine. 
This resulted in the increased expression of miR-181b-3p over at least three days. 
Transfected cells were used in functional experiments to determine the effect of miR-
181b-3p overexpression on angiogenesis. Cell growth and the cell cycle did not 
seem to be altered by transfection. Matrigel studies showed reduced tube formation 
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in HUVECs transfected with miR-181b-3p mimics. Spheroid studies also showed 
reduced endothelial sprouting in these cells. These results suggest that miR-181b-3p 
overexpression impairs angiogenesis. Scratch wound adhesion was unaffected by 
the addition of a miR-181b-3p mimic. 
7.2 Possible mechanisms to explain miR-181b-3p’s role in angiogenesis 
 MiRNAs generally act to suppress target mRNAs either at the translational level or 
result in mRNA degradation.(516, 517) Therefore, it is likely that miR-181b-3p’s 
effects on angiogenesis are a result of target suppression of angiogenesis-related 
genes. MiR-181b-3p targets were searched for using two computer programs 
(TargetScan (368) and DIANA-Micro-T-CDS (369)). Two genes within the top 100 
targets have been previously related to angiogenesis: ELTD1 (adhesion G protein-
coupled receptor L4) and IL8 (interleukin 8). Both of these targets appear to 
upregulate angiogenesis.(497, 498) Consequently, it could be postulated that miR-
181b-3p overexpression in COPD results in a reduction in angiogenesis secondary to 
ELTD1 and IL8 suppression. To investigate this, a qPCR was performed to look for a 
reduction in ELTD1 and IL8 expression in HUVECs transfected with miR-181b-3p 
mimic (section 6.3.8). No reduction was seen suggesting that ELTD1 and IL8 were 
not true targets or miR-181b-3p inhibits the expression of ELTD1 and IL8 at a 
translational level. This could be investigated further using Western Blotting and 
confirmed with luciferfase reporter assays (section 7.5.2). If one looks further down 
the list of potential targets then other possible angiogenesis genes can also be 
identified. Firstly, vascular endothelial growth factor C (VEGFC) was on the predicted 
miR-181b-3p target list albeit at position 4050. VEGF is a key mediator in 
angiogenesis and it is possible that this may be a particularly relevant pathway to 
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explain miR-181b-3p’s function. Other possible targets that could possibly explain 
reduced tube formation secondary to miR-181b-3p overexpression include tubulin 
related genes such as TBCA (tubulin cofactor A) and TUBB1 (tubulin beta 1). Tubulin 
forms an important part of the cytoskeleton and thus disruption to tubulin related 
genes could impair endothelial tube formation. (518, 519)  
Further clues to miR-181b-3p’s function can be found in the IPA (chapter 4). MiR-181 
was associated with network 1 (figure 4.24) where it appears to directly inhibit 
EPHB1 (EPH receptor B1), a tyrosine kinase which has previously been associated 
with angiogenesis and neovascularization.(520) This, in addition with EPHB1’s 
associations with increased cell motility, could explain why miR-181b-3p results in 
reduced tube formation in matrigel studies.(521) Additionally, another member of this 
network, RHOA (ras homolog family member A, a GTPase), also contributes to cell 
motility by contributing to actin-myosin contractility.(522) This could also possibly help 
to explain the difference seen in endothelial tube formation and sprouting with miR-
181b-3p overexpression although miR-181 and RHOA are not directly linked in the 
network. 
Another network identified in figure 4.26 also contains miR-181. However, the miRNA 
is not linked to any targets in the network and so this particular figure does not help 
to shed light on miR-181 function per se. However, it may help to explain why miR-
181 is upregulated. In this network miR-181 appears to be directly activated by Smad 
2/3 which is a regulator of transcription.(481) Smad is known to be upregulated in 
COPD and appears to be associated with smoking.(483) Perhaps increased smoke 
exposure in COPD patients induces Smad which consequently results in miR-181b-
3p activation.  
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In summary, there are several pathways, which may be relevant in the context of 
miR-181-3p overexpression and angiogenesis. However, it would be necessary to 
validate these pathways first before any conclusions about miR-181b-3p’s function 
can be drawn. Without further exploration of miR-181b-3p’s functional pathways it 
would limit the use of this miRNA as a potential treatment target as it would be 
difficult to predict unwanted effects. 
7.3 The potential of miR-181b-3p as a treatment target 
Recently, miRNAs have been increasingly investigated as treatment targets. In fact, 
a miRNA inhibitor (Miravirsen) has been used successfully in phase 2 trials in the 
treatment of Hepatitis C.(523) This inhibitor binds to miR-122 to form a stable 
heteroduplex thus impairing its function.(523) MiR-122 is required for the propagation 
of the Hepatitis C virus and Miravirsen successfully reduced Hepatitis C titres in a 
phase 2 trial. (523) There are no miRNA treatment studies in COPD as yet, but 
animal models do provide some evidence that miRNA based therapy may be of use 
in pulmonary disease. For example, in a lung cancer mouse model systemic delivery 
of a miR-34a mimic led to a reduction in tumour area.(524)  
As technology is already in place to develop therapeutic miRNA inhibitors it is 
possible that such an inhibitor could be developed for miR-181b-3p, which could be 
trialled in animal models in the first instance. However, there are considerations that 
would need to be taken into account before employing such a strategy. For example, 
COPD is an umbrella term for multiple clinical phenotypes. It has already been 
discussed (section 1.4.1) that the endothelium appears to behave differently in the 
settings of chronic bronchitis and emphysema. (210, 211) Therefore, it is possible 
that a drug that inhibits miR-181b-3p and enhances angiogenesis in the context of 
 
 302 
emphysema would not be appropriate to use in patients with chronic bronchitis with 
increased VEGF expression. This leads to another consideration: targeting of 
therapy. It is conceivable that inhibition of miR-181b-3p might have undesirable 
effects on other pulmonary cell types. To minimise this would require consideration of 
which route (local versus systemic) and method (i.e. what vector) would be most 
appropriate.(525) This may be particularly difficult in endothelial cells as a systemic 
delivery would most likely be required. MiRNAs can also target multiple mRNAs 
involved in many different cellular pathways; the computer prediction programs 
predicted thousands of targets for miR-181b-3p. Therefore, as well as unwanted 
effects in other cell types, it is quite possible that miR-181b-3p inhibition could also 
have unwanted effects in endothelial cells too. Consequently, a thorough 
investigation of miR-181b-3p and its targets would be warranted before developing 
drugs to inhibit the miRNA. Finally, it is unlikely that miR-181b-3p will be an effective 
target to treat emphysema on its own. COPD is a complex disease involving multiple 
cells and inflammatory pathways and several miRNAs have previously been 
identified as being up or down regulated in COPD.(525) Hence, to be successful in 
treating COPD, investigating and targeting multiple abnormal miRNAs would 
probably be the treatment strategy most likely to succeed. 
To summarize, miRNAs present new possible treatment targets and miRNA inhibitors 
have been used in previous phase 2 human trials suggesting that targeting miR-
181b-3p may be a valid strategy in COPD. However, as miRNAs have varied targets 
and COPD has a heterogeneous nature, miR-181b-3p’s function needs to be 





This study has identified significant differences in both miRNA and mRNA expression 
in human pulmonary endothelial cells (HPECs) between patients with and without 
COPD. Fourteen potential targets known to be expressed in endothelial tissue were 
assessed further, four of which were validated by qPCR. One target, miR-429, was 
also upregulated in lung cancer HPECs. Another target, miR-181b-3p, has been 
validated functionally and appears to reduce endothelial tube formation and sprouting 
suggesting an inhibitory role in angiogenesis. 
Previous work suggests that there is an abnormal amount of endothelial tissue in 
COPD which behaves in an atypical fashion.(2) Furthermore, there is evidence that 
vasculature has an important supportive role in pulmonary tissue promoting the 
growth and preserving the structure of the alveoli.(507) Faulty pulmonary vascular 
tissue could therefore result in the dysregulation of alveolar maintenance and repair 
resulting in alveolar damage and emphysema.(508) Consequently, targeting and 
normalizing the levels of the aforementioned endothelial targets could provide a new 
mechanism of treatment for COPD which is focused on repair and regeneration of 
lung tissue. 
Patients with COPD are at an increased risk of lung cancer despite adjusting for 
smoking history.(16) Thus, the identification of miR-429 as a target increased in both 
COPD and lung cancer provides an exciting new potential shared target between the 
two conditions. This target needs to be functionally validated but targeting and 
modifying this miRNA could provide a new treatment route in both conditions. In 
 
 304 
COPD patients targeting miR-429 may perhaps offer a possibility of treating an at risk 
patient group before the development of lung cancer. 
7.4.1 Reflections on the study hypothesis 
This study was undertaken to explore the hypothesis that lung cancer and COPD 
might have a common pathogenesis. The endothelium plays an important role in 
transendothelial migration (TEM), the process by which inflammatory cells such as 
the neutrophil cross the endothelial barrier into the lung.(231) As inflammation is also 
associated with cancer, it is possible that dysregulation of the endothelium resulting 
in upregulation of TEM and inflammation could promote the development of cancer in 
the COPD lung.(147) This study supports that miRNA and mRNA expression is 
significantly altered in COPD. The fact that one of the identified endothelial targets in 
this study (miR-181b-3p) alters endothelial function implies that the miRNA and 
mRNA changes seen in COPD pulmonary endothelium may have functional effects. 
MiR-429, another identified target, was upregulated in COPD and upregulated to a 
further extent in lung cancer. This suggests that changes in the COPD pulmonary 
endothelium might represent a pre-malignant state that can be targeted.  
However, the functional studies from chapter 6 indicate that miR-181b-3p reduces 
angiogenesis. This could potentially result in emphysema (through lack of support of 
alveolar epithelial cells) (507) but does not fit with current knowledge about lung 
cancer in which angiogenesis is upregulated.(240) Therefore, miR-181b-3p is 
unlikely to represent a shared endothelial target. As miR-429 is upregulated in both 
COPD and lung cancer it is a more likely shared target but further work would need 
to be done to validate miR-429 before this hypothesis could be proven. For example, 
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transendothelial migration studies (section 7.5.4) would be necessary to support the 
hypothesis that miR-429 would increase TEM (and consequently inflammation 
increasing cancer risk). In conclusion therefore, this work supports the theory that the 
pulmonary endothelium behaves in a dysfunctional manner in COPD and has 
identified potential targets that could contribute to this. However, a shared 
COPD/lung cancer target has not been functionally validated in this study. Thus, 
further work (section 7.5) would be required to fully explore the hypothesis of this 
thesis (section 1.7). In particular, transendothelial migration studies are required to 
determine whether or not the identified targets influence TEM and inflammation seen 
in COPD, which could predispose the lung to malignant changes.  
7.5 Future work 
Identified future work can be divided into four sections. Firstly, the further 
investigation of RNA targets identified in this study using more complex endothelial 
functional assays. Secondly, the identification of miRNA targets to recognize 
potential treatment pathways. Thirdly, transendothelial assays to investigate the role 
of identified targets in the interaction of endothelial and inflammatory cells. Lastly, the 
development of drugs and in vitro and in vivo investigation of treating RNA targets. 
7.5.1 Endothelial functional assays 
MiR-181b-3p 
In the first instance it would be useful to further investigate miR-181b-3p’s effects on 
angiogenesis by means of more complex angiogenesis assays, such as co-culture 
assays. These assays co-culture endothelial cells with other human cells in a matrix. 
The main role of supportive cells in these assays is to secrete extracellular matrix and 
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growth factors (526) resulting in endothelial cells forming anastomosing tubules over 
the course of 1-2 weeks.(527) Matrigel assays look at cell-cell assembly rather than 
true endothelial migration and sprouting angiogenesis, hence this assay is more 
reflective of the in vivo situation.(526) MiR-181b-3p appears to reduce endothelial tube 
formation, thus it would be interesting to see whether or not angiogenesis is reduced in 
this assay. 
Another co-culture of interest uses endothelial cells with pulmonary epithelial cells of 
bronchial or alveolar origin.(528) The epithelial cells start to form bronchiolar or 
alveolar-like structures in vitro depending on their cell of origin.(528) These cultures 
have primarily been used to look at epithelial cell development, but it would be 
intriguing to see whether or not alteration of the supporting endothelial cells with a miR-
181b-3p mimic would result in alteration of epithelial cell structures.(528) As current 
evidence suggests that pulmonary vasculature is key in the development and 
maintenance of lung tissue one might expect to see malformation of epithelial 
structures in these assays.(505, 506) 
MiR-429, miR-23c and LTA4H 
It would be ideal to perform similar functional assays (matrigel, scratch wound spheroid 
and co-culture assays) with these other three validated targets. The miRNA targets 
could be investigated in an identical manner to miR-181b-3p using commercially 
bought miRNA mimics or inhibitors transfected into endothelial cells using 
lipofectamine. Overexpression of LTA4H could be achieved using lentivirus 
transfection.(365) Underexpression could be performed in a similar fashion to the 
miRNA work using commercially available siRNA.(304) 
Overexpression/underexpression would require confirmation at the RNA level using 
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quantitative PCR (qPCR) and, in the case of LTA4H, at the protein level using Western 
Blot analysis. 
7.5.2 MiRNA target identification 
MiRNAs function by targeting and (usually) suppressing the function of mRNAs.(368) 
Therefore, after identifying miRNAs that appear to have a role in endothelial function 
the next critical step would be to identify which mRNAs are being targeted in order to 
have these effects. The easiest way to do this is via computer prediction programs 
such TargetScan discussed in Chapter 3.(368) However, these programs all have 
different algorithms producing different results and can produce several false 
positives.(529) Therefore, it is necessary to confirm computer prediction results in the 
laboratory setting before one can confidently identify a miRNA target. 
One way of looking for miRNA targets would be to perform gene expression analysis 
(such as with a microarray, Chapter 3) in endothelium in which the miRNA had been 
over-expressed. This technique has been used successfully to identify miRNA 
targets in other cell types.(516) The results of this gene expression analysis could be 
compared to similar results from endothelium transfected with a negative control 
siRNA (short inhibitory RNA). Genes that were significantly downregulated could 
likely be targets of the miRNA. However, there are two limitations to this approach. 
Firstly, miRNAs can regulate transcriptional levels of their targets, detectable by 
microarray screening. However, miRNAs often work by translational blocking and 
therefore this type of targeting would not be visible by microarray screening.(517) 
Secondly, this approach identifies both indirect and direct mRNA targets and cannot 
identify the miRNA binding sites.(530) Therefore, although this approach would 
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support findings from computer prediction programs the results would still need to be 
validated in some way. 
One example of a laboratory method able to confirm mRNA-miRNA binding is 
through use of a luciferase-reporter assay. This technique involves the insertion of 
mRNA target sequences into a firefly luciferase reporter vector, which is inserted into 
a cell.(531) A miRNA is then transfected into the cell and, if the miRNA binds to the 
putative mRNA sequence, there is a reduction in luciferase activity.(531) This is a 
useful way of confirming specific mRNA-miRNA interactions, and could validate 
potential targets identified in computer predictions or via gene expression screening. 
However, this method cannot identify multiple targets at once and is labour intensive. 
In order to overcome difficulties with luciferase-reporter assays immunoprecipitation 
methods have been developed. These involve immunoprecipitation of the RNA-
Inhibiting-Silencing-Complex (RISC) in which miRNAs bind to mRNA.(532) It is then 
possible to identify the targeted mRNAs using microarray analysis. In more recent 
years this technique has been further advanced by stabilizing the mRNA-miRNA 
interactions initially using crosslinking with ultraviolet radiation (high-throughput 
sequencing of RNA isolated by crosslinking immunoprecipitation; HITS-CLIP).(23) 
Ultraviolet cross-linking can also be further stabilized by incubating photoactivatable 
nucleosides with cells in culture (photoactivatable-ribonucleoside-enhanced 
crosslinking and immunoprecipitation; PAR-CLIP).(533) These techniques allow the 
researcher to accurately look for mRNA-miRNA interactions on a large scale. 
Unfortunately, the techniques also require specialist equipment and are far more 
costly in comparison to simpler reporter assays, which limit them for wide range use. 
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Another technique for the potential to identify multiple miRNA targets at once utilizes 
streptavidin beads in a similar fashion to the pulmonary endothelial cell extraction in 
section 2.3.2.(534) MiRNA is biotinylated and miRNA/mRNA duplexes are captured 
(after cell lysis) using streptavidin beads.(534) mRNA targets can then be identified 
by microarray analysis.(534) This method is advantageous has it does not require 
irradiation prior to cell analysis. However, in a similar manner to immunoprecipitation 
technologies microarray is required which drastically increases cost in comparison to 
reporter methods. 
Finally, proteomic techniques have been developed to identify miRNA targets such 
as SILAC (stable isotope labelling with amino acids in cell culture).(535) These help 
to screen for changes in protein expression in relation to introduction of a 
miRNA.(535) These methods have the advantage that they look at protein rather 
than gene expression and therefore identify expression changes post 
translation.(535) However, currently their depth of coverage is not as great as gene 
expression approaches which would result in missing potential targets.(536) These 
approaches may also identify indirect targets and therefore further validation with a 
luciferase reporter assay would be necessary. 
7.5.3 Immunohistochemistry 
After identification of miRNA targets a way of validating these in humans on the 
protein level would be to use immunohistochemistry on formalin fixed paraffin 
embedded sections. By staining both healthy lung and COPD lung sections one 
could identify whether or not the protein staining for the targets varied between 
COPD and non-COPD. It would also be possible to use endothelial markers (such as 
PECAM-1) to identify target protein expression in lung endothelium.(363) 
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7.5.4 Neutrophil Transendothelial Migration studies 
As previously discussed, transendothelial migration (TEM) may be a way that the 
endothelium influences the development of COPD due to the fact that neutrophils 
play an important role in the inflammatory response in COPD.(54) In order to reach 
the lung tissue neutrophils must bind to, and migrate through, the endothelium.(188) 
Therefore, to fully investigate the role of the above mentioned targets in COPD it 
would be necessary to perform TEM assays after overexpression/underexpression of 
miRNAs or mRNAs of interest in endothelial cells (as above). The altered 
endothelium could then be used in two types of co-culture assay, after isolation of 
neutrophils from blood using density gradient centrifugation with Percoll.(537) Firstly, 
static co-cultures could be used to monitor neutrophil interaction with cultured 
endothelium. Static co-cultures involve adding isolated neutrophils to the surface of a 
confluent endothelial culture.(538) Phase-contrast video-microscopy is then used to 
identify the proportion of neutrophils that have successfully transmigrated across the 
endothelial layer.(538) These assays would give an idea of whether or not the above 
targets affect TEM. However, in order to monitor TEM in real time flow co-cultures 
would be required. This requires mounting microslides containing confluent 
endothelium on a phase-contrast, video microscope in a Perspex chamber.(539) 
Isolated neutrophils are then drawn through the microslides using a syringe 
pump.(539) A video recording can be performed of neutrophil transmigration across 
the HPEC layer.(539) By comparing the results of these assays to the same assays 
using endothelium exposed to negative siRNA one can identify the influence of the 
targets on TEM. I have been successful in gaining grant funding to carry out this work 
from the British Lung Foundation (ERN_17-0008). 
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7.5.5 In vitro drug response 
After identifying functional changes in endothelium with the alteration of a target of 
interest it would be necessary to identify how treatment of these alterations affects 
endothelial function. For example, there are already drugs that target LTA4H (section 
3.5.2) such as 4MDM (which selectively increases LTA4H aminopeptidase activity) or 
ARM1 (a selective LTA4H hydrolase inhibitor).(423, 425) One could perform similar 
endothelial functional studies to above with increased endothelial LTA4H expression 
with and without these drugs in order to identify whether or not these medications 
could target the effects of increased LTA4H on endothelial cells. It may also be 
interesting to identify drug responses to airway cells on an ‘airway-on-a-chip’ co-culture 
in vitro. These co-cultures consist of airway epithelium with supportive endothelium 
that experiences fluid flow (540) and allow measurement of inflammatory markers in 
response to drug treatments in the co-culture. If 4MDM or ARM1 resulted in reduced 
inflammation on the airway-on-a-chip this may suggest that targeting LTA4H would be 
an effective strategy to reduce pulmonary inflammation in COPD. 
As the other validated RNAs are all miRNAs and therefore likely have multiple mRNA 
targets they are less likely to be useful as drug targets. This is a result of an increased 
chance of unwanted side effects. Therefore, it would be more useful to identify possible 
drug targets from identified miRNA targets rather than using the miRNAs themselves. 
7.5.6 In vivo drug response 
In a similar way to above, treatment of LTA4H/miRNA targets could be tested in animal 
models of COPD. It is possible to induce emphysema in mice using chronic smoke 
exposure.(423) This would provide an ideal model to test whether or not treatment of 
the targets influences COPD development. Advantages of using mouse models 
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include their relatively low cost and the large availability of gene sequences and 
antibodies.(541) It is also possible to produce genetically modified mice to investigate 
the role of certain genes in COPD.(541) However, there are key differences between 
mouse and human pulmonary anatomy, which should be taken into account when 
interpreting mouse model results. For example, mice have fewer submucosal glands, 
less airway branching and do not have respiratory bronchioles.(542) This means 
caution needs to be applied when using these models as small airway remodeling and 
increased mucus production are important in COPD pathogenesis.(543) Smoke 
induced models of COPD also induce relatively mild disease (GOLD stage I/II) rather 
than severe COPD.(544) This suggests that effective interventions seen in models 
may not be effective in more severe cases of COPD in humans. 
7.5.7 Macrophages 
Finally, the macrophage targets were not followed up in this thesis. This would be a 
larger undertaking, involving all the steps included in chapters 3,4 and 6, plus elements 
analogous to that described here for the endothelium (future work section). One of the 
miRNAs associated with COPD appears to target iron regulation genes, which we 
have recently shown to be relevant to malignancy (545), and aligns to genetic 
associations of COPD (546, 547) hence this pathway might be of particular interest for 
studies of cancer-COPD shared pathogenesis. This is likely to be the subject of further 
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CAMP Cathelicidin Antimicrobial Peptide 
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CCNA2 Cyclin A2 
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MME Membrane metalloendopeptidase 
NLRP12 NLR family pyrin domain containing 
12 
PIP5K1B Phosphatidylinositol-4-phosphate 5-
kinase type 1 beta 
PTGS1 Prostaglandin-endoperoxide synthase 
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S100A7 S100 calcium binding protein A7 
SYK Spleen associated tyrosine kinase 
TGM6 Transglutaminase 6 
TP53 Tumour protein 53 
2014 
mRNA 
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AQP3 Aquaporin 3 
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TACR1 Tachykinin receptor 1 
TP53 Tumour protein 53 
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of fatty acid 
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SYK Spleen associated tyrosine kinase 
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TP53 Tumour protein 53 
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ABCG5 ATP binding cassette subfamily G 
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family member 3 
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mitochondrial 
GPAT2 Glycerol-3-phosphate acyltransferase 
2, mitochondrial 
HPGDS Haematopoietic prostaglandin D 
synthase 
IGF1 Insulin like growth factor 1 
INS Insulin 




LTA4H Leukotriene A4 hydrolase 
MC5R Melanocortin 5 receptor 
P2RX1 Purinergic receptor P2X 1 
PIP5K1B Phosphatidylinositol-4-phosphate 5-
kinase type 1 beta [Homo sapiens 
PLA2G2A Phospholipase A2 group IIA 
PLA2G4F Phospholipase A2 group IVF 
PNPLA3 Patatin like phospholipase domain 
containing 3 
PTGS1 Prostaglandin-endoperoxide synthase 
1 
RGN Regucalcin 
RLBP1 Retinaldehyde binding protein 1 
SCD5 Stearoyl-CoA desaturase 5 
SLC22A2 Solute carrier family 22 member 2 
SYK Spleen associated tyrosine kinase 
TACR1 Tachykinin receptor 1 
TIRAP TIR domain containing adaptor protein 
TP53 Tumour protein 53 
2015 
miRNA 
4.24: Network 1 DICER1 Dicer 1, ribonuclease III 
EPHB1 EPH receptor B1 
FOS Fos proto-oncogene, AP-1 
transcription factor subunit 
HMGCR 3-hydroxy-3-methylglutaryl-coenzyme 
A reductase 
KDR Kinase insert domain receptor 
KRBOX4 KRAB box domain containing 4 
 
 378 
OGT O-linked N-acetylglucosamine 
(GlcNAc) transferase 
PRDX6 Peroxiredoxin 6 
PRKCA Protein kinase C alpha 
PRKG1 Protein kinase, cGMP-dependent, 
type I 
REL REL proto-oncogene, NF-kB subunit 
RHOA Ras homolog family member A  
SCN11A Sodium voltage-gated channel alpha 
subunit 11 
SLC35E2B Solute carrier family 35 member E2B 
SUFU SUFU negative regulator of hedgehog 
signaling 
THAP3 THAP domain containing 3 
ZNF385B Zinc finger protein 385B 
Figure 4.25: 
Network 2 
DYDC2 DPY30 domain containing 2 
EI24 EI24, autophagy associated 
transmembrane protein 
EPOR Erythropoietin receptor 
FGF2 Fibroblast growth factor 2 
GCC1 GRIP and coiled-coil domain 
containing 1 
GUF1 GUF1 homolog, GTPase 
HBEGF Heparin binding EGF like growth 
factor 
MSX2 MSH homeobox 2 
NCL Nucleolin 
NR3C1 Nuclear receptor subfamily 3 group C 
member 1 
PDGFRA Platelet derived growth factor receptor 
alpha 
RB1 RB transcriptional corepressor 1 
RPS15 Ribosomal protein S15 
SEPP1 Selenoprotein P 
TGFB2 Transforming growth factor beta 2 





Akt AKT serine/threonine kinase 1 
Cg Cathepsin G 
Creb cAMP responsive element binding 
protein 
FSH Bromodomain containing 2 
MAP2K 1/2 Mitogen-activated protein kinase 1/2 
Ras KRAS proto-oncogene, GTPase 






Basic transcription factor 3 like 4 
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C11orf95 Chromosome 11 open reading frame 
95 
CCND2 Cyclin D2 
CCDC30 Coiled-coil domain containing 30 
CGNL1 Cingulin like 1 
EIF2S1 Eukaryotic translation initiation factor 
2 subunit alpha 
FAM149B1 Family with sequence similarity 149 
member B1 
IMPACT Impact RWD domain protein 
JAKMIP3 Janus kinase and microtubule 
interacting protein 3 
OR2W5 Olfactory receptor family 2 subfamily 
W member 5 
OGFOD3 2-oxoglutarate and iron dependent 
oxygenase domain containing 3 
NDRG1 N-myc downstream regulated 1 
PEX7 Peroxisomal biogenesis factor 7 
PTER Phosphotriesterase related 
RAB37 RAB37, member RAS oncogene 
family 
RAVER2 Ribonucleoprotein, PTB binding 2 
2016 mRNA Retina and anterior neural fold 
homeobox 
SSTR1 Somatostatin receptor 1 




ARMC8 Armadillo repeat containing 8 
CBX5 Chromobox 5 
CUL3 Cullin 3 
EGLN3 Egl-9 family hypoxia inducible factor 3 
ERAL1 Era like 12S mitochondrial rRNA 
chaperone 1 
HOOK1 Hook microtubule tethering protein 1 
HS3ST1 Heparan sulfate (glucosamine) 3-O-
sulfotransferase 1 
HS3ST2 Heparan sulfate (glucosamine) 3-O-
sulfotransferase 2 
IPO8 Importin 8 
KCTD16 Potassium channel tetramerization 
domain containing 16 
KIRREL3 Kirre like nephrin family adhesion 
molecule 3 
KLF9 Kruppel like factor 9 
KLHL10 Kelch like family member 10 
NACC1 Nucleus accumbens associated 1 
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PALM2 Paralemmin 2 
PLPPR4 Phospholipid phosphatase related 4 
SLC45A3 Solute carrier family 45 member 3  
TLL2 Tolloid like 2 
TMEM178A Transmembrane protein 178A 
TMIGD3 Transmembrane and immunoglobulin 
domain containing 3 
TMPO Thymopoietin 
VASH2 Vasohibin 2 
WDFY4 WDFY family member 4 
WDR91 WD repeat domain 91 
ZNF236 Zinc finger protein 236 
ZNF585B Zinc finger protein 585B 











Anaphase promoting complex 
ASTN2 Astrotactin 2 
CCDC80 Coiled-coil domain containing 80 
CCNA2 Cyclin A2 
CCNB1 Cyclin B1 
Cdc2 Cyclin dependent kinase 1 
CEP55 Centrosomal protein 55 
CHEK2 Checkpoint kinase 2 
DLGAP5 DLG associated protein 5 
E2f E2F transcription factor 
E2F1 E2F transcription factor 1 
GEN1 GEN1, Holliday junction 5' flap 
endonuclease 
GINS2 GINS complex subunit 2 
GSTA4 Glutathione S-transferase alpha 4 
LRRC3 Leucine rich repeat containing 3 
LTA4H Leukotriene A4 Hydrolase  
MBTPS2 Membrane bound transcription factor 
peptidase, site 2 
PAX2 Paired box 2 
PHF21B PHD finger protein 21B 
PLPPR4 Phospholipid phosphatase related 4 
PTPRU Protein tyrosine phosphatase, 
receptor type U 
RASSF2 Ras association domain family 
member 2 
Rb RB transcriptional corepressor  




THBS2 Thrombospondin 2 
TP53 Tumour Protein 53 
TWIST2 Twist family bHLH transcription factor 
2 





12-HETE 12-Hydroxyeicosatetraenoic acid 
15-S-HETE 15-S-Hydroxyeicosatetraenoic acid 
ALOX5 Arachidonate 5-lipoxygenase 
ALOX5AP Arachidonate 5-lipoxygenase 
activating protein 
ALOX12 Arachidonate 12-lipoxygenase, 12S 
type 
ALOX15 Arachidonate 15-lipoxygenase 
CYSLTR Cysteinyl leukotriene receptor 
DPEP Dipeptidase 
GGT1 Gamma-glutamyltransferase 
LTB4R Leukotriene B4 Receptor 
LTA4H Leukotriene A4 Hydrolase 
LTA4R Leukotriene A4 Receptor 
LTC4S Leukotriene C4 synthase 
PGD2 Prostaglandin D2 
PGDS Prostaglandin D2 synthase 
PGE2 Prostaglandin E2 
PGES Prostaglandin E2 synthase 
PGF2a Prostaglandin F2a 
PGFS Prostaglandin F synthase 
PGH2 Prostaglandin H2 
PGI2 Prostaglandin I2 
PGIS Prostaglandin I synthase 
PLA2 Phospholipase A2 
PTGDR Prostaglandin D2 receptor 
PTGER1 Prostaglandin E receptor 1 
PTGER2 Prostaglandin E receptor 2 
PTGER3 Prostaglandin E receptor 3 
PTGER4 Prostaglandin E receptor 4 
PTGFR Prostaglandin F receptor 
PTGIR Prostaglandin I receptor 
PTGS Prostaglandin G synthase 
TBXA2R Thromboxane A2 receptor 
TXS Thromboxane A synthase 1 
 
This table lists gene names included in various figures in chapter 4. The table lists 
the IPA involved, the figure, gene symbols and gene names included in each figure.
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The table lists the disease or function significantly altered in COPD, the direction it is altered in and the genes involved in the 
disease/function. The p-value of overlap is used to determine significance between groups with a cut-off of <0.05.  
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The table lists the disease or function significantly altered in COPD, the direction it is altered in and the genes involved in the 


























Genes of interest identified in the IPA network analysis. 
Gene Microarray Network Expression 
level 
Gene functions COPD 
associations 



























































1 Down Regulates gene 
transcription and 
the DNA damage 
response. 


































































































































2 Down Deubiquitinase 
enzyme 





1 Up Regulates 
transcription 
Increased in 
COPD related to 
















1 Up Major growth 









































7 Down Regulates protein 
synthesis 










7 Down Regulates mRNA 
translation 












7 Down Regulates mRNA 
translation 





















































2014 mRNA 4 Up Promotes 
transcription of 
genes including 
the NF-κB pathway 
and cell 
proliferation. 
 Bladder cancer, 
Breast cancer, 
Colorectal cancer, 








The table lists each gene, the microarray analysis it was identified in, whether it was up or downregulated in COPD, its function and 


















Up (predicted) Receptor for cysteinylated 
leukotrienes. Signalling 
via CYSLTR is associated 
with bronchoconstriction 
and eosinophilia. 
Increased levels in 
bronchial cells in 
COPD. Increased in 
exacerbations. 
Associated with 
emphysema in animal 
models. 




Up Converts LTA4 to LTB4. 
Degrades proline-glycine-
proline. 
Increased in sputum. Chronic lymphcytic 
leukaemia, Lung 
lepidic carcinoma in 







Up (predicted) Negatively regulates 
adipocyte differentiation. 
Binds to LTB4 
(chemoattractant). Leads 
to allergen-mediated CD8 










cancer, Lung cancer 





LXA4R (Lipoxin A4 
receptor) 
Up (predicted) Reduces neutrophil 
activation. Anti-apoptotic. 
Promotes homing of 
EPCs. Resolves 
inflammation. 
Reduced in COPD 














Up Arachidonic acid 
production from 
phospholipids. 













Up (predicted) Activation results in 
cytokine release and 
macrophage migration. 
Increases migratory 
capacity and survival of 
neutrophils in vitro. 
Increased neutrophils 












Up Synthesises PGD2. 
Urinary biomarker for 
lupus nephritis. Increased 
levels in preterm births. 
Associated with coronary 
vasoconstriction. Induces 
apoptosis and prevents 
cell cycle progression. 
Increased levels in 
moderate vs mild 
COPD. Increased 
PGD2 levels in BAL 
from COPD patients. 












Up (predicted) Increases cell migration 
and adhesion in 
hepatocellular carcinoma 
and oral cancer. Reduces 
metastases in breast 
cancer. Enhances MMP2 
expression. Induces IL-8 





















Up (predicted) Reduces fibroblast 
proliferation. Increases 




Increases cell invasion 
and migration. Induces IL-
8. 
Increased levels in 
COPD fibroblasts 
resulting in increased 






















and invasion. Myometrial 
contraction. 




Colon cancer, Gastric 
cancer, Lung cancer, 
Oral cancer, Prostate 






Up (predicted) Increases the production 
of IL-6, IL-8, M-CSF and 
VEGF. Increases IL-23 




PGE2 (positive feedback). 
Reduces TEM in HPEC. 
Involved in the cellular 
response to oxidative 
stress. Inhibits platelet 







cancer, Head and 
neck cancer, Lung 
cancer, Melanoma, 
Prostate cancer, 














Up (predicted) Increases angiogenesis. 
PTGI binds to PPARγ 
(protective in lung 
cancer). 
Reduction seen in 
pulmonary endothelial 
cells in emphysema. 






Up (predicted) Induces 
bronchoconstriction and 
airway plasma exudation. 




Previous TEM in 
endothelium 
Bronchoconstriction Breast cancer, Lung 






Up Production of 
prostaglandin H2 from 
arachidonic acid 
Higher levels in 
fibroblasts cultured 














variants associated with 




induced by smoke. 
Astrocytoma, Breast 












Converts PGH2 to TXA2. 
TXA2 is a vasoconstrictor 
that promotes platelet 
aggregation and is 
important in 
angiogenesis. Inhibition 
leads to lung cancer cell 
apoptosis. 




The table lists each gene, whether it was up or downregulated in COPD, its function and COPD or cancer associations.  
LTA4 = Leukotriene A4, LTB4 = Leukotriene B4, EPCs = Endothelial Progenitor Cells, BAL = Bronchoalveolar lavage, PGD2 = 
Prostaglandin D2, FEV1 = Forced Expiratory Volume in 1 second, MMP2 = Matrix Metalloproteinase 2, IL = Interleukin, NF-Κb = 
Nuclear factor kappa-light-chain-enhancer of Activated B cells, HIF-1α = Hypoxia Inducible Factor 1α, VEGF = Vascular Endothelial 
Growth Factor, M-CSF = Macrophage Colony Stimulating Factor, Th17 = T helper 17 cells, PPARγ = Peroxisome Proliferator 
Activated Receptor Gamma, TEM= Tumour Endothelial Marker, COX-2 = Cyclo-oxygenase 2, PGH2 = Prostaglandin H2, TXA2 = 
Thromboxane A2 




